[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 100 of about 785
1. Camacho CP, Latini FR, Oler G, Hojaij FC, Maciel RM, Riggins GJ, Cerutti JM: Down-regulation of NR4A1 in follicular thyroid carcinomas is restored following lithium treatment. Clin Endocrinol (Oxf); 2009 Mar;70(3):475-83
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • INTRODUCTION: The identification of follicular thyroid adenoma-associated transcripts will lead to a better understanding of the events involved in pathogenesis and progression of follicular tumours.
  • Using Serial Analysis of Gene Expression, we identified five genes that are absent in a malignant follicular thyroid carcinoma (FTC) library, but expressed in follicular adenoma (FTA) and normal thyroid libraries.

  • MedlinePlus Health Information. consumer health - Thyroid Cancer.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. LITHIUM COMPOUNDS .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Proc Natl Acad Sci U S A. 2001 Dec 18;98(26):15044-9 [11752453.001]
  • [Cites] J Biol Chem. 2001 Jul 13;276(28):26180-8 [11337498.001]
  • [Cites] Br J Cancer. 2002 Mar 18;86(6):917-23 [11953824.001]
  • [Cites] J Clin Endocrinol Metab. 2002 Aug;87(8):3947-52 [12161538.001]
  • [Cites] Am J Surg Pathol. 2002 Aug;26(8):1016-23 [12170088.001]
  • [Cites] Proc Natl Acad Sci U S A. 2002 Aug 20;99(17):11287-92 [12119410.001]
  • [Cites] Carcinogenesis. 2002 Oct;23(10):1583-92 [12376465.001]
  • [Cites] Biochem J. 2002 Nov 1;367(Pt 3):723-8 [12153396.001]
  • [Cites] J Clin Endocrinol Metab. 2003 Jan;88(1):354-7 [12519876.001]
  • [Cites] Mol Genet Metab. 2003 Jan;78(1):74-8 [12559851.001]
  • [Cites] Mol Endocrinol. 2003 Mar;17(3):450-9 [12554771.001]
  • [Cites] Cancer Res. 2003 Apr 1;63(7):1454-7 [12670889.001]
  • [Cites] Eur J Endocrinol. 2003 May;148(5):505-13 [12720532.001]
  • [Cites] J Clin Endocrinol Metab. 2003 May;88(5):2318-26 [12727991.001]
  • [Cites] Biochim Biophys Acta. 2003 Jun 5;1653(1):1-24 [12781368.001]
  • [Cites] Oncogene. 2003 Jul 17;22(29):4578-80 [12881714.001]
  • [Cites] Thyroid. 2003 Jun;13(6):537-45 [12930597.001]
  • [Cites] J Endocrinol Invest. 2003 Jun;26(6):516-21 [12952364.001]
  • [Cites] Cell. 2004 Feb 20;116(4):527-40 [14980220.001]
  • [Cites] J Clin Invest. 2004 Apr;113(8):1234-42 [15085203.001]
  • [Cites] Clin Endocrinol (Oxf). 2004 Aug;61(2):280-2 [15272927.001]
  • [Cites] J Clin Invest. 1972 Oct;51(10):2746-56 [4115707.001]
  • [Cites] Ann Endocrinol (Paris). 1974 May-Jun;35(3):281-2 [4463794.001]
  • [Cites] Proc Natl Acad Sci U S A. 1988 Nov;85(22):8444-8 [3186734.001]
  • [Cites] Virchows Arch B Cell Pathol Incl Mol Pathol. 1989;57(3):167-74 [2570483.001]
  • [Cites] J Clin Endocrinol Metab. 1993 Oct;77(4):996-1004 [8408476.001]
  • [Cites] Nature. 1994 Jan 20;367(6460):277-81 [8121493.001]
  • [Cites] Oncogene. 1995 Sep 21;11(6):1207-10 [7566982.001]
  • [Cites] Proc Natl Acad Sci U S A. 1996 May 28;93(11):5533-8 [8643610.001]
  • [Cites] Curr Biol. 1996 Dec 1;6(12):1664-8 [8994831.001]
  • [Cites] Mol Cell Biol. 1998 Aug;18(8):4719-31 [9671482.001]
  • [Cites] J Clin Endocrinol Metab. 1999 Mar;84(3):912-6 [10084570.001]
  • [Cites] Nature. 1999 Apr 1;398(6726):422-6 [10201372.001]
  • [Cites] Thyroid. 2005 Mar;15(3):210-21 [15785240.001]
  • [Cites] J Clin Invest. 2005 Apr;115(4):1068-81 [15761501.001]
  • [Cites] J Biol Chem. 2005 Jul 1;280(26):24903-14 [15871945.001]
  • [Cites] Eur J Endocrinol. 2005 Dec;153(6):929-38 [16322400.001]
  • [Cites] Thyroid. 2006 Feb;16(2):109-42 [16420177.001]
  • [Cites] JAMA. 2006 May 10;295(18):2164-7 [16684987.001]
  • [Cites] Eur J Endocrinol. 2006 Jun;154(6):787-803 [16728537.001]
  • [Cites] Clin Cancer Res. 2006 Jun 1;12(11 Pt 1):3311-8 [16740752.001]
  • [Cites] Br Med J. 1968 Sep 21;3(5620):710-3 [17016877.001]
  • [Cites] Cell Biol Toxicol. 2007 Mar;23(2):83-90 [17103031.001]
  • [Cites] Surgery. 2007 Feb;141(2):161-5; discussion 165 [17263970.001]
  • [Cites] Mol Cancer Ther. 2007 Mar;6(3):1151-8 [17363508.001]
  • [Cites] Nat Med. 2007 Jun;13(6):730-5 [17515897.001]
  • [Cites] Cancer Res. 2007 Aug 15;67(16):7885-92 [17699795.001]
  • [Cites] Cancer Res. 2007 Sep 1;67(17):8113-20 [17804723.001]
  • [Cites] Genes Cells. 2008 May;13(5):411-9 [18429814.001]
  • [Cites] J Cancer Res Clin Oncol. 2008 Jul;134(7):803-12 [18202854.001]
  • [Cites] Endocr Relat Cancer. 2008 Sep;15(3):787-99 [18559958.001]
  • [Cites] Science. 2000 Aug 18;289(5482):1159-64 [10947977.001]
  • [Cites] Science. 2000 Aug 25;289(5483):1357-60 [10958784.001]
  • [Cites] Proc Natl Acad Sci U S A. 2001 Mar 27;98(7):3690-4 [11274386.001]
  • [Cites] Physiol Rev. 2001 Jul;81(3):1269-304 [11427696.001]
  • [Cites] J Biol Chem. 2002 Feb 22;277(8):6118-23 [11751871.001]
  • (PMID = 18727708.001).
  • [ISSN] 1365-2265
  • [Journal-full-title] Clinical endocrinology
  • [ISO-abbreviation] Clin. Endocrinol. (Oxf)
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / R21 CA113461-01A1; United States / NCI NIH HHS / CA / CA113461-01A1; United States / NCI NIH HHS / CA / CA113461; United States / NCI NIH HHS / CA / R21 CA113461; United States / NCI NIH HHS / CA / R33 CA113461
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / CCND1 protein, human; 0 / DNA-Binding Proteins; 0 / FOSB protein, human; 0 / Lithium Compounds; 0 / NR4A1 protein, human; 0 / Nuclear Receptor Subfamily 4, Group A, Member 1; 0 / Proto-Oncogene Proteins c-fos; 0 / Receptors, Steroid; 0 / Wnt Proteins; 136601-57-5 / Cyclin D1
  • [Other-IDs] NLM/ NIHMS93432; NLM/ PMC2742303
  •  go-up   go-down


2. Mihai R, Borley N: Transanal endoscopic microsurgery--impact on the practice of a colorectal surgeon in a district general hospital. Ann R Coll Surg Engl; 2005 Nov;87(6):432-6
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [MeSH-major] Adenocarcinoma / surgery. Adenoma / surgery. Colorectal Neoplasms / surgery. Microsurgery / methods. Proctoscopy / methods

  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16263010.001).
  • [ISSN] 1478-7083
  • [Journal-full-title] Annals of the Royal College of Surgeons of England
  • [ISO-abbreviation] Ann R Coll Surg Engl
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC1964132
  •  go-up   go-down


3. Favia G, Iacobone M, Zanella S, Ciarleglio FA: Management of invasive and advanced thyroid cancer. Minerva Endocrinol; 2009 Mar;34(1):37-55
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [MeSH-minor] Adenocarcinoma, Follicular / pathology. Adenocarcinoma, Follicular / secondary. Adenocarcinoma, Follicular / therapy. Adenoma, Oxyphilic / surgery. Carcinoma / radiotherapy. Carcinoma / secondary. Carcinoma / surgery. Carcinoma, Medullary / surgery. Carcinoma, Papillary / pathology. Carcinoma, Papillary / secondary. Carcinoma, Papillary / therapy. Child. Combined Modality Therapy. Female. Humans. Iodine Radioisotopes / therapeutic use. Larynx / pathology. Lymphatic Metastasis. Neck Muscles / pathology. Neoplasm Invasiveness. Neoplasm Staging. Palliative Care. Prognosis. Recurrent Laryngeal Nerve / pathology. Thyroidectomy. Trachea / pathology

  • Genetic Alliance. consumer health - Thyroid Cancer.
  • MedlinePlus Health Information. consumer health - Thyroid Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19209127.001).
  • [ISSN] 0391-1977
  • [Journal-full-title] Minerva endocrinologica
  • [ISO-abbreviation] Minerva Endocrinol.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Italy
  • [Chemical-registry-number] 0 / Iodine Radioisotopes
  • [Number-of-references] 174
  •  go-up   go-down


Advertisement
4. Tischoff I, Tannapfel A: Barrett's esophagus: can biomarkers predict progression to malignancy? Expert Rev Gastroenterol Hepatol; 2008 Oct;2(5):653-63
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Barrett's esophagus (BE) is one of the most common premalignant lesions and can progress to esophageal adenocarcinoma.
  • Similar to the adenoma-carcinoma sequence of colorectal carcinomas, esophageal adenocarcinoma develops through progression from BE to low- and high-grade dysplasia, then to adenocarcinoma with accumulation of genetic and epigenetic abnormalities.
  • Dysplasia is the most predictive marker for risk of esophageal adenocarcinoma, whereas endoscopic and histological diagnoses are still the gold standard for surveillance of patients with BE.
  • Several studies have identified candidate biomarkers that may have predictive value and may serve as additional factors for the risk assessment of esophageal adenocarcinoma.
  • This review discusses the role of biomarkers in the progression from BE to adenocarcinoma, focusing on clinical and molecular markers.
  • [MeSH-minor] Adenocarcinoma / genetics. Adenocarcinoma / metabolism. Disease Progression. Humans. Predictive Value of Tests

  • Genetic Alliance. consumer health - Barrett's Esophagus.
  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19072343.001).
  • [ISSN] 1747-4132
  • [Journal-full-title] Expert review of gastroenterology & hepatology
  • [ISO-abbreviation] Expert Rev Gastroenterol Hepatol
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Biomarkers, Tumor
  • [Number-of-references] 97
  •  go-up   go-down


5. Wang Y, Hou P, Yu H, Wang W, Ji M, Zhao S, Yan S, Sun X, Liu D, Shi B, Zhu G, Condouris S, Xing M: High prevalence and mutual exclusivity of genetic alterations in the phosphatidylinositol-3-kinase/akt pathway in thyroid tumors. J Clin Endocrinol Metab; 2007 Jun;92(6):2387-90
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • DESIGN: We used real-time quantitative PCR for the analysis of PIK3CA copy gain and direct DNA sequencing for the detection of PIK3CA, RAS, and PTEN mutations on genomic DNA isolated from 234 thyroid tumors, including 31 follicular thyroid cancer (FTC), 141 papillary thyroid cancer (PTC), and 62 follicular thyroid adenoma (FTA).
  • [MeSH-major] Adenocarcinoma, Follicular / genetics. Carcinoma, Papillary / genetics. Phosphatidylinositol 3-Kinases / genetics. Phosphatidylinositol 3-Kinases / metabolism. Proto-Oncogene Proteins c-akt / metabolism. Thyroid Neoplasms / genetics

  • MedlinePlus Health Information. consumer health - Thyroid Cancer.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17426084.001).
  • [ISSN] 0021-972X
  • [Journal-full-title] The Journal of clinical endocrinology and metabolism
  • [ISO-abbreviation] J. Clin. Endocrinol. Metab.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] EC 2.7.1.- / Phosphatidylinositol 3-Kinases; EC 2.7.1.137 / PIK3CA protein, human; EC 2.7.11.1 / Proto-Oncogene Proteins c-akt; EC 3.1.3.48 / PTEN protein, human; EC 3.1.3.67 / PTEN Phosphohydrolase; EC 3.6.5.2 / ras Proteins
  •  go-up   go-down


6. Nishikawa A, Imazawa T, Kuroiwa Y, Kitamura Y, Kanki K, Ishii Y, Umemura T, Hirose M: Induction of colon tumors in C57BL/6J mice fed MeIQx, IQ, or PhIP followed by dextran sulfate sodium treatment. Toxicol Sci; 2005 Apr;84(2):243-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • After 20 weeks, colon tumors including adenocarcinomas were found at incidences of 22%, 24%, and 45% in the groups receiving MeIQx, IQ, and PhIP, respectively, which were significantly (p < 0.05 or 0.01) different from the DSS alone value (0%).
  • [MeSH-major] Adenocarcinoma / chemically induced. Adenoma / chemically induced. Carcinogens / toxicity. Colonic Neoplasms / chemically induced. Dextran Sulfate / toxicity. Imidazoles / toxicity

  • Hazardous Substances Data Bank. 2-Amino-1-methyl-6-phenylimidazo[4,5-b]pyridine .
  • Hazardous Substances Data Bank. 2-AMINO-3-METHYLIMIDAZO(4,5-f)QUINOLINE .
  • Hazardous Substances Data Bank. 2-Amino-3,8-dimethylimidazo[4,5-f]quinoxaline .
  • Mouse Genome Informatics (MGI). Mouse Genome Informatics (MGI) .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15635146.001).
  • [ISSN] 1096-6080
  • [Journal-full-title] Toxicological sciences : an official journal of the Society of Toxicology
  • [ISO-abbreviation] Toxicol. Sci.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Carcinogens; 0 / Imidazoles; 0 / Quinolines; 0 / Quinoxalines; 76180-96-6 / 2-amino-3-methylimidazo(4,5-f)quinoline; 77500-04-0 / 2-amino-3,8-dimethylimidazo(4,5-f)quinoxaline; 9042-14-2 / Dextran Sulfate; 909C6UN66T / 2-amino-1-methyl-6-phenylimidazo(4,5-b)pyridine
  •  go-up   go-down


7. Miyamoto T, Hagari Y, Inoue S, Watanabe T, Yoshino T: Axillary apocrine carcinoma with benign apocrine tumours: a case report involving a pathological and immunohistochemical study and review of the literature. J Clin Pathol; 2005 Jul;58(7):757-61
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The immunohistochemical results support the notion that apocrine hyperplasia is a precursor of cancer and that apocrine carcinoma, adenoma, and hyperplasia may be successive steps in the linear progression to carcinoma.
  • [MeSH-major] Adenocarcinoma, Papillary / pathology. Apocrine Glands / pathology. Precancerous Conditions / pathology. Sweat Gland Neoplasms / pathology
  • [MeSH-minor] Adenoma, Sweat Gland / pathology. Aged. Aged, 80 and over. Axilla. Humans. Hyperplasia. Male

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Am J Clin Oncol. 1999 Apr;22(2):131-5 [10199445.001]
  • [Cites] J Dermatol. 1997 Aug;24(8):535-8 [9301148.001]
  • [Cites] Pathol Res Pract. 2001;197(6):419-25 [11432669.001]
  • [Cites] Pathol Int. 2002 Feb;52(2):169-73 [11940224.001]
  • [Cites] J Pathol. 2002 Dec;198(4):458-67 [12434415.001]
  • [Cites] J Pathol. 2003 Jan;199(1):1-3 [12474219.001]
  • [Cites] J Dermatol. 2003 Jan;30(1):72-5 [12598714.001]
  • [Cites] Histopathology. 1989 Apr;14(4):409-16 [2544501.001]
  • [Cites] Acta Pathol Jpn. 1990 Jun;40(6):431-4 [2203231.001]
  • [Cites] Am J Surg Pathol. 1990 Oct;14(10):939-47 [1698341.001]
  • [Cites] Acta Pathol Jpn. 1991 Dec;41(12):927-32 [1785351.001]
  • [Cites] Virchows Arch A Pathol Anat Histopathol. 1992;421(4):323-30 [1384227.001]
  • [Cites] Cancer. 1993 Jan 15;71(2):375-81 [7678545.001]
  • [Cites] Am J Surg Pathol. 1994 Aug;18(8):832-6 [8037297.001]
  • [Cites] Am J Dermatopathol. 2001 Feb;23(1):50-7 [11176053.001]
  • (PMID = 15976347.001).
  • [ISSN] 0021-9746
  • [Journal-full-title] Journal of clinical pathology
  • [ISO-abbreviation] J. Clin. Pathol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] England
  • [Number-of-references] 18
  • [Other-IDs] NLM/ PMC1770727
  •  go-up   go-down


8. Javeri K, Williams TR, Bonnett JW: An overview of the method, application, and various findings of computed tomographic colonography in patients after incomplete colonoscopy. Curr Probl Diagn Radiol; 2010 Nov-Dec;39(6):262-74
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [MeSH-minor] Adenocarcinoma / radiography. Adenoma / radiography. Colitis / radiography. Colonic Polyps / pathology. Colonic Polyps / surgery. Humans. Hyperplasia. Image Processing, Computer-Assisted. Lipoma / radiography. Patient Acceptance of Health Care

  • MedlinePlus Health Information. consumer health - Colonoscopy.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright © 2010 Mosby, Inc. All rights reserved.
  • (PMID = 20875613.001).
  • [ISSN] 1535-6302
  • [Journal-full-title] Current problems in diagnostic radiology
  • [ISO-abbreviation] Curr Probl Diagn Radiol
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  •  go-up   go-down


9. Wang Y, Li Y, Zhang WY, Xia QJ, Li HG, Wang R, Yang L, Sun XF, Zhou ZG: mRNA expression of minichromosome maintenance 2 in colonic adenoma and adenocarcinoma. Eur J Cancer Prev; 2009 Feb;18(1):40-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] mRNA expression of minichromosome maintenance 2 in colonic adenoma and adenocarcinoma.
  • Here, we aimed to evaluate the possible value of a proliferation marker, minichromosome maintenance 2 (MCM2), in the early diagnosis of colorectal cancer, by analyzing the difference in MCM2 expression among normal mucosa, adenoma, and adenocarcinoma, and investigating the relationship of MCM2 expression in adenomas with clinicopathologic variables.
  • Using immunohistochemistry and real-time reverse transcription-PCR, we observed that the expression of MCM2 protein was present on basal third to half of colonic crypts in normal mucosa, whereas throughout the epithelium in adenomas and adenocarcinomas, the expression of MCM2 mRNA in adenocarcinomas was significantly higher than in adenomas (P=0.001), whereas the difference between adenoma and normal mucosa was not significant (P=0.184); we also found that the expression of MCM2 mRNA tended to be increased in the adenomas with high-grade dysplasia, or in older patients, respectively, compared with those with low-grade dysplasia, and younger patients.
  • [MeSH-major] Adenocarcinoma / genetics. Adenoma / genetics. Cell Cycle Proteins / genetics. Colonic Neoplasms / genetics. Nuclear Proteins / genetics

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19077563.001).
  • [ISSN] 1473-5709
  • [Journal-full-title] European journal of cancer prevention : the official journal of the European Cancer Prevention Organisation (ECP)
  • [ISO-abbreviation] Eur. J. Cancer Prev.
  • [Language] eng
  • [Publication-type] Comparative Study; Evaluation Studies; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Cell Cycle Proteins; 0 / Nuclear Proteins; 0 / RNA, Messenger; EC 3.6.4.12 / MCM2 protein, human; EC 3.6.4.12 / Minichromosome Maintenance Complex Component 2
  •  go-up   go-down


10. Clerici T, Kolb W, Beutner U, Bareck E, Dotzenrath C, Kull C, Niederle B, German Association of Endocrine Surgeons: Diagnosis and treatment of small follicular thyroid carcinomas. Br J Surg; 2010 Jun;97(6):839-44
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Most initial diagnoses had to be revised because of incorrect size assessment or incorrect diagnosis (benign adenoma, papillary thyroid carcinoma (PTC), follicular variant of PTC).
  • [MeSH-major] Adenocarcinoma, Follicular / pathology. Thyroid Neoplasms / pathology. Thyroid Neoplasms / surgery

  • MedlinePlus Health Information. consumer health - Thyroid Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20473996.001).
  • [ISSN] 1365-2168
  • [Journal-full-title] The British journal of surgery
  • [ISO-abbreviation] Br J Surg
  • [Language] eng
  • [Publication-type] Journal Article; Multicenter Study
  • [Publication-country] England
  • [Investigator] Kaserer K; Perren A; Schmid KW; Köberle-Wührer R; Wenzl E; Asari R; Klinge U; Müller G; Kroell KP; Blankenburg C; Voss H; Cupisti K; Witte J; Knoefel WT; Simon D; Lienenlüke RH; Vorländer C; Wacha H; Schabram J; Lorenz K; Dralle H; Wojciechowski B; Kussmann J; Weber Y; Schürmann G; Goretzki PE; Ulitzer H; Eberle A; Mayer M; Stabenow R; Stegmaier C; Bühlmann R; Schlumpf R; Triponez F; Ess SM
  •  go-up   go-down


11. Niederhagen M, Zengel P, Ihrler S: [Secondary high-malignant transformation of a low-malignant epithelial-myoepithelial carcinoma]. Pathologe; 2009 Nov;30(6):461-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • In the eight published cases so far, the high-malignant component was reported to be either adenocarcinoma or undifferentiated carcinoma or was otherwise not specified.
  • We discuss interesting parallels to the pathogenesis of secondary transformation of carcinoma ex pleomorphic adenoma.

  • Genetic Alliance. consumer health - Epithelial-Myoepithelial Carcinoma.
  • Genetic Alliance. consumer health - Myoepithelial carcinoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Otolaryngol Head Neck Surg. 1988 Feb;98(2):155-61 [3128758.001]
  • [Cites] Am J Surg Pathol. 2000 Mar;24(3):469-71 [10716163.001]
  • [Cites] Am J Surg Pathol. 2000 Oct;24(10):1439-40 [11023111.001]
  • [Cites] Histopathology. 2002 Sep;41(3):250-9 [12207787.001]
  • [Cites] Cancer. 1971 Aug;28(2):461-6 [5566365.001]
  • [Cites] Virchows Arch. 1999 Apr;434(4):291-9 [10335939.001]
  • [Cites] Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2008 Jul;106(1):85-91 [18417380.001]
  • [Cites] Virchows Arch A Pathol Pathol Anat. 1972;356(1):16-31 [4340536.001]
  • [Cites] Pathologe. 2009 Nov;30(6):446-56 [19844715.001]
  • [Cites] Hum Pathol. 2003 Oct;34(10):1068-72 [14608545.001]
  • [Cites] Am J Surg Pathol. 1999 Apr;23(4):465-72 [10199477.001]
  • [Cites] Am J Surg Pathol. 2007 Jan;31(1):44-57 [17197918.001]
  • (PMID = 19823828.001).
  • [ISSN] 1432-1963
  • [Journal-full-title] Der Pathologe
  • [ISO-abbreviation] Pathologe
  • [Language] ger
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Biomarkers, Tumor
  •  go-up   go-down


12. Letsas KP, Vartholomatos G, Tsepi C, Tsatsoulis A, Frangou-Lazaridis M: Fine-needle aspiration biopsy-RT-PCR expression analysis of prothymosin alpha and parathymosin in thyroid: novel proliferation markers? Neoplasma; 2007;54(1):57-62
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • A semi-quantitative RT-PCR assay was developed to determine prothymosin alpha and parathymosin mRNA expression patterns in thyroid follicular cells obtained from the fine-needle aspiration biopsy specimens of patients diagnosed with simple nodular goitre, follicular adenoma, papillary and follicular well-differentiated carcinomas.
  • Prothymosin alpha and parathymosin mRNA levels were found significantly elevated in well-differentiated carcinomas in relation to adenomas (p<0.05) and goitres (p<0.05), an event possibly linked to the proliferation activity of thyroid follicular cells.
  • [MeSH-minor] Adenocarcinoma, Follicular / genetics. Adenocarcinoma, Follicular / pathology. Adult. Aged. Biomarkers / analysis. Biopsy, Fine-Needle / methods. Carcinoma, Papillary / genetics. Carcinoma, Papillary / pathology. Cell Proliferation. Diagnosis, Differential. Female. Humans. Male. Middle Aged. RNA, Messenger / genetics. RNA, Messenger / metabolism. Reproducibility of Results. Reverse Transcriptase Polymerase Chain Reaction / methods. Thyroid Nodule / genetics. Thyroid Nodule / pathology

  • MedlinePlus Health Information. consumer health - Thyroid Cancer.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17203893.001).
  • [ISSN] 0028-2685
  • [Journal-full-title] Neoplasma
  • [ISO-abbreviation] Neoplasma
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Slovakia
  • [Chemical-registry-number] 0 / Biomarkers; 0 / Protein Precursors; 0 / RNA, Messenger; 0 / prothymosin alpha; 61512-21-8 / Thymosin; 95328-48-6 / parathymosin alpha
  •  go-up   go-down


13. Albores-Saavedra J, Keenportz B, Bejarano PA, Alexander AA, Henson DE: Adenomyomatous hyperplasia of the gallbladder with perineural invasion: revisited. Am J Surg Pathol; 2007 Oct;31(10):1598-604
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The original pathologic diagnosis of adenocarcinoma was made in 5 patients and of "adenoma malignum" in one.
  • The pseudoinvasive pattern of the RASs, reactive epithelial atypia, and the perineural and intraneural invasion probably contributed to the erroneous diagnosis of adenocarcinoma or "adenoma malignum."
  • [MeSH-minor] Adenocarcinoma / diagnosis. Aged. Aged, 80 and over. Cholelithiasis / pathology. Cholelithiasis / surgery. Diagnosis, Differential. Female. Humans. Hyperplasia. Male. Middle Aged. Muscle, Smooth. Reoperation

  • MedlinePlus Health Information. consumer health - Gallbladder Diseases.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17895763.001).
  • [ISSN] 0147-5185
  • [Journal-full-title] The American journal of surgical pathology
  • [ISO-abbreviation] Am. J. Surg. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


14. Bozza F, Vigili MG, Ruscito P, Marzetti A, Marzetti F: Surgical management of parapharyngeal space tumours: results of 10-year follow-up. Acta Otorhinolaryngol Ital; 2009 Feb;29(1):10-5
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Different surgical approaches were used: transcervical-transmandibular in 5 cases (41.6%); transparotid-transcervical in 4 patients (33.4%); transoral in 2 patients (16.6%) with a small pleomorphic adenoma of the deep lobe of parotid, and in the last case (8.4%), transcervical surgery was performed for papillary thyroid carcinoma metastasis.
  • One patient with a recurrent parotid gland adenocarcinoma died of distant metastasis 4 years after parapharyngeal space surgery.

  • MedlinePlus Health Information. consumer health - Head and Neck Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Otolaryngol Head Neck Surg. 1999 Nov;121(5):539-42 [10547466.001]
  • [Cites] Otolaryngol Head Neck Surg. 2007 Mar;136(3):411-4 [17321869.001]
  • [Cites] Ann Otol Rhinol Laryngol. 2001 Dec;110(12):1093-8 [11768696.001]
  • [Cites] Laryngoscope. 2003 Nov;113(11):1893-7 [14603042.001]
  • [Cites] Head Neck. 2004 Feb;26(2):190-6 [14762889.001]
  • [Cites] Head Neck Surg. 1981 May-Jun;3(5):371-8 [6263826.001]
  • [Cites] J R Coll Surg Edinb. 1989 Apr;34(2):111-2 [2724211.001]
  • [Cites] Laryngoscope. 1990 Jun;100(6):583-9 [2348735.001]
  • [Cites] Laryngoscope. 1994 May;104(5 Pt 2 Suppl 63):1-28 [8189998.001]
  • [Cites] Otolaryngol Head Neck Surg. 2005 Mar;132(3):401-6 [15746851.001]
  • [Cites] Otolaryngol Head Neck Surg. 2005 Apr;132(4):587-91 [15806051.001]
  • [Cites] Head Neck. 2005 Aug;27(8):669-75 [15880689.001]
  • [Cites] Otolaryngol Head Neck Surg. 2005 Sep;133(3):319-22 [16143173.001]
  • [Cites] Clin Otolaryngol. 2005 Aug;30(4):364-7 [16209682.001]
  • [Cites] J Coll Physicians Surg Pak. 2006 Jan;16(1):7-10 [16441979.001]
  • [Cites] J Exp Clin Cancer Res. 2001 Sep;20(3):439-41 [11718226.001]
  • (PMID = 19609376.001).
  • [ISSN] 1827-675X
  • [Journal-full-title] Acta otorhinolaryngologica Italica : organo ufficiale della Società italiana di otorinolaringologia e chirurgia cervico-facciale
  • [ISO-abbreviation] Acta Otorhinolaryngol Ital
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Italy
  • [Other-IDs] NLM/ PMC2689563
  • [Keywords] NOTNLM ; Mandibulotomy / Parapharyngeal space / Parapharyngeal tumour / Parotid / Pleomorphic adenoma / Surgical approach
  •  go-up   go-down


15. Allon I, Vered M, Buchner A, Dayan D: Stromal differences in salivary gland tumors of a common histopathogenesis but with different biological behavior: a study with picrosirius red and polarizing microscopy. Acta Histochem; 2006;108(4):259-64
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Salivary gland neoplasms - pleomorphic adenoma, polymorphous low-grade adenocarcinoma, and adenoid cystic carcinoma - share a common histogenetic trait, but differ markedly in their biological properties.
  • Thick fibers showed a different distribution in polymorphous low-grade adenocarcinoma and adenoid cystic carcinoma (approximately 50% green-yellow) compared to pleomorphic adenoma and mucous extravasation phenomenon (approximately 13% green-yellow) (p=0.001).
  • Thick fiber distribution was similar in polymorphous low-grade adenocarcinoma and adenoid cystic carcinoma (p>0.05).
  • We conclude that with picrosirius red staining and polarizing microscopy, stromal collagen fibers differ significantly in pleomorphic adenoma from those in polymorphous low-grade adenocarcinoma and adenoid cystic carcinoma, but not from mucous extravasation phenomenon.
  • Similarity between polymorphous low-grade adenocarcinoma and adenoid cystic carcinoma may indicate that these tumor types represent a single entity with a broad spectrum of biological behavior.
  • [MeSH-major] Adenocarcinoma / pathology. Adenoma, Pleomorphic / pathology. Azo Compounds. Carcinoma, Adenoid Cystic / pathology. Salivary Gland Neoplasms / pathology. Stromal Cells / pathology

  • MedlinePlus Health Information. consumer health - Salivary Gland Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16899283.001).
  • [ISSN] 0065-1281
  • [Journal-full-title] Acta histochemica
  • [ISO-abbreviation] Acta Histochem.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Azo Compounds; 0 / Coloring Agents; 0 / Fibrillar Collagens; 1294D5G72N / C.I. direct red 80
  •  go-up   go-down


16. Ohno E, Hirooka Y, Itoh A, Ishigami M, Katano Y, Ohmiya N, Niwa Y, Goto H: Intraductal papillary mucinous neoplasms of the pancreas: differentiation of malignant and benign tumors by endoscopic ultrasound findings of mural nodules. Ann Surg; 2009 Apr;249(4):628-34
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Twelve clinicopathological variables and CE-EUS morphologic findings were assessed.Mural nodules defined as blood flow supplied protrusions were classified into 4 types: type I: low papillary nodule, type II: polypoid nodule, type III:papillary nodule, and type IV: invasive nodule.
  • RESULTS: Forty-two, 26, 16, and 3 were pathologically diagnosed as adenoma,noninvasive carcinoma, invasive IPMNs, and coexistent invasive ductal cancer, respectively.
  • CONCLUSIONS: In conclusion, new morphologic criteria were useful to identify the malignant potentials of IPMNs.
  • [MeSH-minor] Adenocarcinoma, Mucinous / diagnosis. Adenocarcinoma, Mucinous / pathology. Adenocarcinoma, Mucinous / ultrasonography. Aged. Aged, 80 and over. Analysis of Variance. Biopsy, Fine-Needle. Cohort Studies. Confidence Intervals. Contrast Media. Diagnosis, Differential. Female. Humans. Immunohistochemistry. Logistic Models. Male. Mucous Membrane / pathology. Mucous Membrane / ultrasonography. Multivariate Analysis. Neoplasm Staging. Odds Ratio. Probability. Sensitivity and Specificity

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19300203.001).
  • [ISSN] 1528-1140
  • [Journal-full-title] Annals of surgery
  • [ISO-abbreviation] Ann. Surg.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Contrast Media
  •  go-up   go-down


17. Mulder SA, Van Leerdam ME, Ouwendijk RJ, Bac DJ, Giard RW, Kuipers EJ: Attendance at surveillance endoscopy of patients with adenoma or colorectal cancer. Scand J Gastroenterol; 2007 Jan;42(1):66-71
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Attendance at surveillance endoscopy of patients with adenoma or colorectal cancer.
  • OBJECTIVE: Surveillance of patients treated for adenoma or colorectal cancer (CRC) is intended to reduce the incidence of CRC.
  • MATERIAL AND METHODS: The study comprised a cohort follow-up of patients under 75 years of age with adenomas or CRC at index endoscopy in the period 1997-99.
  • Polyps were classified as adenomas in 167/280 (61%) patients.
  • Forty-five (27%) of the adenoma patients underwent surveillance endoscopy within the guideline interval, 63 (38%) underwent delayed endoscopy, and 59 (35%) did not have any follow-up at all.
  • [MeSH-major] Adenocarcinoma / diagnosis. Adenoma / diagnosis. Colonic Polyps / diagnosis. Colonoscopy. Colorectal Neoplasms / diagnosis


18. Maeshima AM, Tochigi N, Yoshida A, Asamura H, Tsuta K, Tsuda H: Clinicopathologic analysis of multiple (five or more) atypical adenomatous hyperplasias (AAHs) of the lung: evidence for the AAH-adenocarcinoma sequence. J Thorac Oncol; 2010 Apr;5(4):466-71
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clinicopathologic analysis of multiple (five or more) atypical adenomatous hyperplasias (AAHs) of the lung: evidence for the AAH-adenocarcinoma sequence.
  • The clinicopathologic features of the AAHs in the lung background and the main tumors were examined with regard to the number and the size of the AAHs, the incidence and histology of adenocarcinomas (ADs), and the outcome.
  • [MeSH-major] Adenocarcinoma / pathology. Adenoma / pathology. Carcinoma, Large Cell / pathology. Carcinoma, Squamous Cell / pathology. Lung Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20357616.001).
  • [ISSN] 1556-1380
  • [Journal-full-title] Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer
  • [ISO-abbreviation] J Thorac Oncol
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


19. Wang W, Zhou ZW, Wan DS, Lu ZH, Chen G, Pan ZZ, Li LR, Wu XJ, Ding PR: [Clinical analyses of 70 cases of multiple primary colorectal carcinoma]. Ai Zheng; 2008 May;27(5):505-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Thirty-three patients had colorectal carcinoma accompanying with adenoma and multiple polyps.
  • CONCLUSIONS: The occurrence of MPCC is largely related with adenomas and polyps.
  • The patients accompanying with adenoma and multiple polyps should be followed up intensively.
  • [MeSH-minor] Adenocarcinoma, Mucinous / diagnosis. Adenocarcinoma, Mucinous / pathology. Adenocarcinoma, Mucinous / surgery. Adenocarcinoma, Papillary / diagnosis. Adenocarcinoma, Papillary / pathology. Adenocarcinoma, Papillary / surgery. Adult. Aged. Female. Follow-Up Studies. Humans. Male. Middle Aged. Neoplasm Staging. Rectum / surgery. Retrospective Studies. Survival Rate

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18479600.001).
  • [Journal-full-title] Ai zheng = Aizheng = Chinese journal of cancer
  • [ISO-abbreviation] Ai Zheng
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  •  go-up   go-down


20. Pauzar B, Staklenac B, Loncar B: Fine needle aspiration biopsy of follicular thyroid tumors. Coll Antropol; 2010 Mar;34(1):87-91
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [MeSH-major] Adenocarcinoma, Follicular / pathology. Adenoma / pathology. Biopsy, Fine-Needle / standards. Thyroid Neoplasms / pathology. Thyroid Nodule / pathology

  • MedlinePlus Health Information. consumer health - Thyroid Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20432738.001).
  • [ISSN] 0350-6134
  • [Journal-full-title] Collegium antropologicum
  • [ISO-abbreviation] Coll Antropol
  • [Language] eng
  • [Publication-type] Journal Article; Validation Studies
  • [Publication-country] Croatia
  •  go-up   go-down


21. Zheng HC, Xu XY, Yu M, Takahashi H, Masuda S, Takano Y: The role of Reg IV gene and its encoding product in gastric carcinogenesis. Hum Pathol; 2010 Jan;41(1):59-69
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • To clarify the role of Reg IV in gastric carcinogenesis and subsequent progression, we examined its expression by immunohistochemistry and in situ hybridization on tissue microarray containing gastric carcinoma, adjacent nonneoplastic mucosa, adenoma, intestinal metaplasia, or gastritis.
  • The Reg IV protein expression was gradually decreased from intestinal metaplasia, adenoma, and carcinoma to gastritis (P < .05).
  • Our study indicated that Reg IV expression experienced up-regulation in gastric intestinal metaplasia and adenoma and then down-regulation with malignant transformation of gastric epithelial cells.
  • [MeSH-major] Adenocarcinoma / genetics. Gene Expression Regulation, Neoplastic. Lectins, C-Type / genetics. Stomach Neoplasms / genetics
  • [MeSH-minor] Adenoma / genetics. Adenoma / metabolism. Adenoma / pathology. Aged. Biomarkers, Tumor / metabolism. Blotting, Western. Carcinoma, Signet Ring Cell / genetics. Carcinoma, Signet Ring Cell / metabolism. Carcinoma, Signet Ring Cell / secondary. Cell Line, Tumor. Cell Transformation, Neoplastic. DNA, Neoplasm / analysis. Female. Gastric Mucosa / metabolism. Gastritis / genetics. Gastritis / metabolism. Gastritis / pathology. Humans. In Situ Hybridization. Male. Middle Aged. Neoplasm Staging. Precancerous Conditions. Sequence Analysis, DNA. Tissue Array Analysis


22. Sells DM, Brix AE, Nyska A, Jokinen MP, Orzech DP, Walker NJ: Respiratory tract lesions in noninhalation studies. Toxicol Pathol; 2007 Jan;35(1):170-7
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Changes included respiratory epithelial hyperplasia, degeneration and necrosis of olfactory epithelium, olfactory epithelial metaplasia, adenoma, adenocarcinoma, squamous cell carcinoma, and neuroblastoma.
  • In the lung, compound-related lesions included alveolar histiocytosis, alveolar epithelial hyperplasia, bronchiolar metaplasia of the alveolar epithelium, squamous metaplasia, alveolar/bronchial adenoma and carcinoma, and squamous tumors.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Gan. 1979 Feb;70(1):29-36 [446975.001]
  • [Cites] Toxicol Pathol. 2005;33(3):371-7 [15805076.001]
  • [Cites] Anticancer Res. 1981;1(5):279-86 [7345971.001]
  • [Cites] Cancer Res. 1982 Oct;42(10):4236-40 [7105017.001]
  • [Cites] Environ Health Perspect. 1990 Apr;85:177-86 [2200661.001]
  • [Cites] Environ Health Perspect. 1990 Apr;85:275-89 [2200667.001]
  • [Cites] Arch Toxicol. 1991;65(1):1-9 [2043044.001]
  • [Cites] Toxicol Pathol. 1991;19(4 Pt 1):321-36 [1813979.001]
  • [Cites] J Toxicol Environ Health A. 2002 Apr 12;65(7):523-37 [11939710.001]
  • [Cites] Toxicol Pathol. 2002 Mar-Apr;30(2):178-87 [11950161.001]
  • [Cites] Arch Toxicol. 2003 Apr;77(4):233-42 [12698239.001]
  • [Cites] Toxicol Pathol. 2004 May-Jun;32(3):333-7 [15204975.001]
  • [Cites] Toxicol Pathol. 1991;19(4 Pt 1):358-72 [1813982.001]
  • [Cites] Drug Metab Dispos. 1992 Sep-Oct;20(5):643-52 [1358567.001]
  • [Cites] Drug Metab Rev. 1993;25(1-2):173-205 [8449146.001]
  • [Cites] J Histochem Cytochem. 1993 Jun;41(6):877-85 [8315279.001]
  • [Cites] Biochem Pharmacol. 1995 May 17;49(10):1387-94 [7763281.001]
  • [Cites] Toxicol Pathol. 1996 Sep-Oct;24(5):564-72 [8923677.001]
  • [Cites] Cancer Res. 1980 Feb;40(2):298-302 [7356512.001]
  • (PMID = 17325986.001).
  • [ISSN] 0192-6233
  • [Journal-full-title] Toxicologic pathology
  • [ISO-abbreviation] Toxicol Pathol
  • [Language] eng
  • [Grant] United States / Intramural NIH HHS / / Z99 ES999999
  • [Publication-type] Journal Article; Research Support, N.I.H., Intramural; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Xenobiotics
  • [Number-of-references] 24
  • [Other-IDs] NLM/ NIHMS33525; NLM/ PMC3433271
  •  go-up   go-down


23. Shaco-Levy R, Bean SM, Bentley RC, Robboy SJ: Natural history of biologically malignant struma ovarii: analysis of 27 cases with extraovarian spread. Int J Gynecol Pathol; 2010 May;29(3):212-27
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The microscopic diagnosis of the thyroid tissue was follicular adenoma in 17 cases (63%), papillary carcinoma in 7 (26%), unremarkable in 2 (7%), and follicular carcinoma in 1 case (4%).
  • [MeSH-major] Adenocarcinoma, Follicular / pathology. Ovarian Neoplasms / pathology. Struma Ovarii / pathology

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20407319.001).
  • [ISSN] 1538-7151
  • [Journal-full-title] International journal of gynecological pathology : official journal of the International Society of Gynecological Pathologists
  • [ISO-abbreviation] Int. J. Gynecol. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


24. Mazal PR, Stichenwirth M, Koller A, Blach S, Haitel A, Susani M: Expression of aquaporins and PAX-2 compared to CD10 and cytokeratin 7 in renal neoplasms: a tissue microarray study. Mod Pathol; 2005 Apr;18(4):535-40
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [MeSH-minor] Adenocarcinoma, Clear Cell / metabolism. Adenocarcinoma, Clear Cell / pathology. Adenoma, Oxyphilic / metabolism. Adenoma, Oxyphilic / pathology. Aquaporin 1. Aquaporin 2. Aquaporins / biosynthesis. Blood Group Antigens. Carcinoma, Papillary / metabolism. Carcinoma, Papillary / pathology. Carcinoma, Renal Cell / metabolism. Carcinoma, Renal Cell / pathology. DNA-Binding Proteins / biosynthesis. Humans. Immunohistochemistry. Keratin-7. Keratins / biosynthesis. Kidney / chemistry. Kidney / pathology. Neoplasm Staging. Neprilysin / biosynthesis. PAX2 Transcription Factor. Tissue Array Analysis / methods. Transcription Factors / biosynthesis

  • MedlinePlus Health Information. consumer health - Kidney Cancer.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15502805.001).
  • [ISSN] 0893-3952
  • [Journal-full-title] Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc
  • [ISO-abbreviation] Mod. Pathol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / AQP1 protein, human; 0 / AQP2 protein, human; 0 / Aquaporin 2; 0 / Aquaporins; 0 / Biomarkers, Tumor; 0 / Blood Group Antigens; 0 / DNA-Binding Proteins; 0 / KRT7 protein, human; 0 / Keratin-7; 0 / PAX2 Transcription Factor; 0 / PAX2 protein, human; 0 / Transcription Factors; 146410-94-8 / Aquaporin 1; 68238-35-7 / Keratins; EC 3.4.24.11 / Neprilysin
  •  go-up   go-down


25. Kusaba T, Nakayama T, Yamazumi K, Yakata Y, Yoshizaki A, Nagayasu T, Sekine I: Expression of p-STAT3 in human colorectal adenocarcinoma and adenoma; correlation with clinicopathological factors. J Clin Pathol; 2005 Aug;58(8):833-8
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Expression of p-STAT3 in human colorectal adenocarcinoma and adenoma; correlation with clinicopathological factors.
  • AIMS: To examine the relation between p-STAT3 (activated form of STAT3) expression and clinicopathological factors in human colorectal adenocarcinoma and adenoma.
  • METHODS: Immunohistochemical analyses were carried out on tissues from 44 colorectal adenomas and 95 colorectal adenocarcinomas, comprising 18 intramucosal carcinomas and 77 invasive carcinomas.
  • Only eight of the 44 adenomas showed immunopositivity for p-STAT3, resulting in a significant difference between total adenocarcinomas and adenomas (p < 0.001).
  • Among the 95 cases of colorectal adenocarcinoma, p-STAT3 immunoreactivity was significantly correlated with the depth of tumour invasion (p < 0.05), venous invasion (p < 0.05), lymph node metastasis (p < 0.05), and increasing stages of the Dukes' classification (p < 0.01).
  • These findings suggest that p-STAT3 expression is an important factor related to carcinogenesis and/or tumour invasion of colorectal adenocarcinoma.
  • [MeSH-major] Adenocarcinoma / metabolism. Adenoma / metabolism. Biomarkers, Tumor / metabolism. Colorectal Neoplasms / metabolism. DNA-Binding Proteins / metabolism. Trans-Activators / metabolism

  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer. 1994 Apr 15;73(8):2076-82 [8156513.001]
  • [Cites] Proc Natl Acad Sci U S A. 1994 May 24;91(11):4806-10 [7545930.001]
  • [Cites] Science. 1994 Jun 3;264(5164):1415-21 [8197455.001]
  • [Cites] Am J Pathol. 1994 Dec;145(6):1285-90 [7992833.001]
  • [Cites] Cancer Lett. 2000 Apr 3;151(1):31-8 [10766420.001]
  • [Cites] Oncogene. 2000 May 15;19(21):2474-88 [10851046.001]
  • [Cites] Oncogene. 2000 May 15;19(21):2489-95 [10851047.001]
  • [Cites] Oncogene. 2000 May 15;19(21):2607-11 [10851059.001]
  • [Cites] Gynecol Oncol. 2000 Oct;79(1):67-73 [11006034.001]
  • [Cites] Am J Pathol. 2001 Jan;158(1):25-32 [11141475.001]
  • [Cites] Dig Dis Sci. 2001 Feb;46(2):230-41 [11281168.001]
  • [Cites] Oncogene. 2002 Mar 27;21(13):2000-8 [11960372.001]
  • [Cites] J Clin Invest. 2002 May;109(9):1139-42 [11994401.001]
  • [Cites] Cancer. 2002 May 1;94(9):2393-400 [12015764.001]
  • [Cites] Oncogene. 2002 Oct 10;21(46):7001-10 [12370822.001]
  • [Cites] Oncogene. 2003 Mar 13;22(10):1517-27 [12629515.001]
  • [Cites] Gastroenterology. 2003 Sep;125(3):891-905 [12949733.001]
  • [Cites] Oncogene. 2003 Oct 30;22(49):7809-18 [14586407.001]
  • [Cites] J Cell Physiol. 2004 Feb;198(2):209-22 [14603523.001]
  • [Cites] J Biol Chem. 2004 Apr 9;279(15):15114-23 [14701810.001]
  • [Cites] Oncogene. 2004 Apr 29;23(20):3550-60 [15116091.001]
  • [Cites] World J Gastroenterol. 2004 Jun 1;10(11):1569-73 [15162527.001]
  • [Cites] Br J Surg. 1976 May;63(5):384-8 [1268479.001]
  • [Cites] Histopathology. 1981 Mar;5(2):141-63 [7216178.001]
  • [Cites] Cancer. 1986 Sep 15;58(6):1340-5 [3742458.001]
  • [Cites] Science. 1994 Apr 1;264(5155):95-8 [8140422.001]
  • [Cites] Cytokine. 1995 Feb;7(2):118-29 [7780031.001]
  • [Cites] Nature. 1995 Oct 19;377(6550):591-4 [7566171.001]
  • [Cites] EMBO J. 1996 Jul 15;15(14):3651-8 [8670868.001]
  • [Cites] Proc Natl Acad Sci U S A. 1997 Apr 15;94(8):3801-4 [9108058.001]
  • [Cites] Jpn J Cancer Res. 1997 Jun;88(6):600-4 [9263538.001]
  • [Cites] Science. 1997 Sep 12;277(5332):1630-5 [9287210.001]
  • [Cites] Leuk Lymphoma. 1998 Aug;30(5-6):433-42 [9711905.001]
  • [Cites] Int J Cancer. 1998 Oct 29;78(3):326-30 [9766567.001]
  • [Cites] J Leukoc Biol. 1998 Nov;64(5):675-80 [9823774.001]
  • [Cites] Immunity. 1999 Jan;10(1):105-15 [10023775.001]
  • [Cites] Jpn J Cancer Res. 1998 Dec;89(12):1267-75 [10081487.001]
  • [Cites] Cell. 1999 Aug 6;98(3):295-303 [10458605.001]
  • [Cites] J Clin Pathol. 1949 May;2(2):95-8 [16810849.001]
  • (PMID = 16049285.001).
  • [ISSN] 0021-9746
  • [Journal-full-title] Journal of clinical pathology
  • [ISO-abbreviation] J. Clin. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / DNA-Binding Proteins; 0 / Neoplasm Proteins; 0 / STAT3 Transcription Factor; 0 / STAT3 protein, human; 0 / Trans-Activators
  • [Other-IDs] NLM/ PMC1770863
  •  go-up   go-down


26. Rouillier P, Senesse P, Cottet V, Valléau A, Faivre J, Boutron-Ruault MC: Dietary patterns and the adenomacarcinoma sequence of colorectal cancer. Eur J Nutr; 2005 Aug;44(5):311-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • AIM: The aim of this study was to determine dietary patterns associated with the colorectal adenoma-carcinoma pathway.
  • Patients with hyperplastic polyps (n = 103), adenomas < 10 mm, (n = 154) or larger adenomas (n = 208) were then compared with polyp-free controls (n = 426), and colorectal cancer cases (n = 171) compared with population controls (n = 309) using unconditional logistic regression adjusted on age and gender.
  • Logistic regression identified cluster 2 [corrected] as significantly associated with risk of small adenomas (OR = 1.7; 95% confidence interval 1.0-2.7), large adenomas (OR = 1.9; 1.2-3.0) and cancers (OR = 1.7; 1.1-2.8) compared with cluster 1 [corrected] Cluster 4 diet was inversely associated with risk of small adenomas (OR = 0.4; 0.2-1.0).
  • Multiple adjustment decreased the strength of the relationships with cluster 2 [corrected] which remained significantly associated with adenomas, but not cancer.
  • CONCLUSION: A lowenergy diet appeared as protective all along the adenoma-carcinoma sequence, contrary to a high-energy, high-processed meat and -animal fat diet.
  • [MeSH-major] Adenocarcinoma / epidemiology. Colorectal Neoplasms / epidemiology. Energy Intake / physiology. Feeding Behavior

  • Genetic Alliance. consumer health - Colorectal Cancer.
  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [ErratumIn] Eur J Nutr. 2005 Aug;44(5):318
  • [Cites] Nutr Cancer. 2002;44(1):7-15 [12672636.001]
  • [Cites] N Engl J Med. 1999 Jan 21;340(3):169-76 [9895396.001]
  • [Cites] Public Health Nutr. 2001 Jun;4(3):787-95 [11415486.001]
  • [Cites] Arch Intern Med. 2003 Feb 10;163(3):309-14 [12578511.001]
  • [Cites] Am J Clin Nutr. 2003 May;77(5):1156-63 [12716666.001]
  • [Cites] J Natl Cancer Inst. 2000 Nov 1;92 (21):1740-52 [11058617.001]
  • [Cites] J Nutr. 2001 Nov;131(11 Suppl):3109S-20S [11694656.001]
  • [Cites] Am J Epidemiol. 1998 Jul 1 ;148(1):4-16 [9663397.001]
  • [Cites] Int J Cancer. 2002 Mar 10;98(2):241-56 [11857415.001]
  • [Cites] Eur J Clin Nutr. 2003 Jan;57(1):1-17 [12548291.001]
  • [Cites] Eur J Cancer Prev. 2000 Aug;9(4):241-56 [10958327.001]
  • [Cites] Public Health Nutr. 2002 Feb;5(1):89-90 [12001983.001]
  • [Cites] J Natl Cancer Inst. 2001 Apr 4;93(7):525-33 [11287446.001]
  • [Cites] Clin Gastroenterol. 1976 Sep;5(3):505-25 [1022372.001]
  • [Cites] Br J Cancer. 1999 Mar;79(7-8):1283-7 [10098773.001]
  • [Cites] Nutr Cancer. 1989;12(1):83-91 [2710650.001]
  • [Cites] Am J Clin Nutr. 2001 Jan;73(1):61-7 [11124751.001]
  • [Cites] Gut. 2000 Feb;46(2):191-9 [10644312.001]
  • [Cites] Am J Epidemiol. 2001 Dec 15;154(12 ):1143-9 [11744520.001]
  • [Cites] Gut. 2001 Jul;49(1):87-90 [11413115.001]
  • [Cites] Gut. 2002 May;50(5):642-6 [11950809.001]
  • [Cites] N Engl J Med. 2003 Jun 26;348(26):2599-608 [12826634.001]
  • [Cites] Nutr Cancer. 2001;39(1):50-7 [11588902.001]
  • (PMID = 15316829.001).
  • [ISSN] 1436-6207
  • [Journal-full-title] European journal of nutrition
  • [ISO-abbreviation] Eur J Nutr
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Germany
  •  go-up   go-down


27. Ghidirim G, Mişin I, Istrate V, Cazacu S: Endoscopic papillectomy into the treatment of neoplastic lesions of vater papilla. Curr Health Sci J; 2009 Apr;35(2):92-7
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Adenomas of the duodenal papilla are rare.
  • The frequency of malignant adenomas is 15-30%.
  • Villous adenoma is a premalignant lesion with the highest rate of transformation.
  • AIM: Evaluation of the efficacy and safety of endoscopic papillectomy for ampullary adenomas.
  • MATERIAL AND METHOD: 12 patients were selected (F:M, 5:7, age range 37 - 68 years) with ampullary adenoma, treated by endoscopic papillectomy.
  • Pathology examination has show: tubulo-villous adenoma (5 patients); villous adenoma (4 patients), tubular adenoma (2 cases), adenocarcinoma (one case).
  • CONCLUSION: Endoscopic papillectomy is a safe and well-tolerated alternative to surgical treatment of ampullary adenoma.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 24778815.001).
  • [ISSN] 2067-0656
  • [Journal-full-title] Current health sciences journal
  • [ISO-abbreviation] Curr Health Sci J
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Romania
  • [Other-IDs] NLM/ PMC3945241
  • [Keywords] NOTNLM ; Vater papilla / ampullary adenoma / bleeding / endoscopic papillectomy / pancreatitis / sphyncterotomy
  •  go-up   go-down


28. Tsuboi S, Taketa K, Nouso K, Fujikawa T, Manabe K, Ohmori H, Higashi T, Shiratori Y: High level of expression of alpha-fetoprotein receptor in gastric cancers. Tumour Biol; 2006;27(6):283-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • However, no statistically significant difference in staining intensity was found among the groups of well-differentiated, moderately differentiated and poorly differentiated adenocarcinomas.
  • On the other hand, the staining intensity of signet ring cell carcinoma was significantly weaker than that of the three adenocarcinoma groups.
  • [MeSH-minor] Adenoma / metabolism. Adenoma / pathology. Gastritis / metabolism. Gastritis / pathology. Humans. Immunohistochemistry. Kinetics. Polyps / metabolism. Polyps / pathology. Stomach Ulcer / metabolism. Stomach Ulcer / pathology. alpha-Fetoproteins / metabolism

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright (c) 2006 S. Karger AG, Basel.
  • (PMID = 17028464.001).
  • [ISSN] 1010-4283
  • [Journal-full-title] Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine
  • [ISO-abbreviation] Tumour Biol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Receptors, Peptide; 0 / alpha-Fetoproteins; 0 / alpha-fetoprotein receptor, human
  •  go-up   go-down


29. Papadogeorgakis N, Petsinis V, Goutzanis L, Kostakis G, Alexandridis C: Parapharyngeal space tumors: surgical approaches in a series of 13 cases. Int J Oral Maxillofac Surg; 2010 Mar;39(3):243-50
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The aim of this study is to present the surgical procedures used for the treatment of 13 patients with parapharyngeal space tumors; 11 of them were suffering from benign tumors (the most frequent being pleomorphic adenoma; 8 cases) and 2 from malignant lesions.
  • [MeSH-minor] Adenocarcinoma / surgery. Adenoma, Pleomorphic / surgery. Adult. Aged. Biopsy, Fine-Needle. Deglutition Disorders / diagnosis. Disease-Free Survival. Female. Follow-Up Studies. Humans. Lip / surgery. Magnetic Resonance Imaging. Male. Mandible / surgery. Middle Aged. Mouth / surgery. Neck / surgery. Osteotomy / classification. Osteotomy / methods. Postoperative Complications. Radiotherapy, Adjuvant. Sarcoma, Synovial / surgery. Tomography, X-Ray Computed. Young Adult

  • MedlinePlus Health Information. consumer health - Head and Neck Cancer.
  • MedlinePlus Health Information. consumer health - Throat Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20005672.001).
  • [ISSN] 1399-0020
  • [Journal-full-title] International journal of oral and maxillofacial surgery
  • [ISO-abbreviation] Int J Oral Maxillofac Surg
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Denmark
  •  go-up   go-down


30. Boissan M, De Wever O, Lizarraga F, Wendum D, Poincloux R, Chignard N, Desbois-Mouthon C, Dufour S, Nawrocki-Raby B, Birembaut P, Bracke M, Chavrier P, Gespach C, Lacombe ML: Implication of metastasis suppressor NM23-H1 in maintaining adherens junctions and limiting the invasive potential of human cancer cells. Cancer Res; 2010 Oct 1;70(19):7710-22
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Analysis of NM23-H1 expression in clinical specimens revealed high expression in premalignant lesions (liver cirrhosis and colon adenoma) and the central body of primary liver or colon tumors, but downregulation at the invasive front of tumors.
  • [MeSH-minor] Actins / metabolism. Adenocarcinoma / genetics. Adenocarcinoma / metabolism. Adenocarcinoma / pathology. Breast Neoplasms / genetics. Breast Neoplasms / metabolism. Breast Neoplasms / pathology. Carcinoma, Hepatocellular / genetics. Carcinoma, Hepatocellular / metabolism. Carcinoma, Hepatocellular / pathology. Cell Line, Tumor. Cell Movement / genetics. Colonic Neoplasms / genetics. Colonic Neoplasms / metabolism. Colonic Neoplasms / pathology. Cytoskeleton / metabolism. Cytoskeleton / pathology. Gene Silencing. Humans. Liver Neoplasms / genetics. Liver Neoplasms / metabolism. Liver Neoplasms / pathology. Matrix Metalloproteinase 14 / metabolism. Neoplasm Invasiveness. Wnt Proteins / metabolism


31. Wente MN, Schmied BM, Schmidt J, Büchler MW: [Differentiated therapy for intraductal papillary mucinous neoplasms]. Chirurg; 2009 Jan;80(1):7-13
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The decision for surgical or conservative management is based on the adenoma-carcinoma sequence and the differentiation into main-duct or branch-duct IPMN.
  • Invasive IPMN forms (carcinoma in situ and invasive carcinoma) and in particular noninvasive IPMNs (adenoma and borderline tumors) reveal significantly better survival rates than ductal adenocarcinoma of the pancreas.
  • [MeSH-major] Adenocarcinoma, Mucinous / surgery. Carcinoma, Pancreatic Ductal / surgery. Carcinoma, Papillary / surgery. Pancreatectomy / methods. Pancreatic Neoplasms / surgery
  • [MeSH-minor] Adenocarcinoma / diagnosis. Adenocarcinoma / mortality. Adenocarcinoma / pathology. Adenocarcinoma / surgery. Carcinoma in Situ / diagnosis. Carcinoma in Situ / mortality. Carcinoma in Situ / pathology. Carcinoma in Situ / surgery. Humans. Magnetic Resonance Imaging. Neoplasm Invasiveness. Neoplasm Staging. Pancreas / pathology. Prognosis. Radiography, Dual-Energy Scanned Projection. Survival Rate. Tomography, Spiral Computed

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Minerva Chir. 2004 Apr;59(2):185-207 [15238892.001]
  • [Cites] Radiology. 2008 Sep;248(3):876-86 [18632526.001]
  • [Cites] Gastroenterology. 2002 Nov;123(5):1500-7 [12404225.001]
  • [Cites] Am J Surg. 1999 Oct;178(4):344-7 [10587197.001]
  • [Cites] Gut. 2002 Nov;51(5):717-22 [12377813.001]
  • [Cites] Am J Surg Pathol. 2004 Aug;28(8):977-87 [15252303.001]
  • [Cites] Ann Surg. 2004 Jun;239(6):788-97; discussion 797-9 [15166958.001]
  • [Cites] Gut. 2008 Mar;57(3):287-9 [18268051.001]
  • [Cites] World J Surg. 2008 Oct;32(10):2253-60 [18668283.001]
  • [Cites] Arch Surg. 2008 Jul;143(7):639-46; discussion 646 [18645105.001]
  • [Cites] J Clin Gastroenterol. 2008 Mar;42(3):284-94 [18223495.001]
  • [Cites] Pancreatology. 2006;6(1-2):17-32 [16327281.001]
  • [Cites] Eur J Surg Oncol. 2007 Aug;33(6):678-84 [17207960.001]
  • [Cites] Am J Surg Pathol. 2001 May;25(5):579-86 [11342768.001]
  • [Cites] Am J Surg. 2005 May;189(5):632-6; discussion 637 [15862510.001]
  • [Cites] Gastroenterology. 2007 Jul;133(1):72-9; quiz 309-10 [17631133.001]
  • [Cites] Ann Surg Oncol. 2006 Apr;13(4):582-94 [16523362.001]
  • [Cites] Gut. 2007 Aug;56(8):1086-90 [17127707.001]
  • [Cites] Arch Surg. 1999 Oct;134(10 ):1131-6 [10522860.001]
  • [Cites] Ann Surg. 1997 Oct;226(4):491-8; discussion 498-500 [9351717.001]
  • [Cites] J Clin Gastroenterol. 2006 Oct;40(9):856-62 [17016145.001]
  • [Cites] Pancreas. 2004 Apr;28(3):241-6 [15084964.001]
  • [Cites] J Gastrointest Surg. 2003 Jan;7(1):12-8; discussion 18-9 [12559180.001]
  • [Cites] J Clin Gastroenterol. 2003 Mar;36(3):261-5 [12590239.001]
  • [Cites] Lancet. 2005 Jan 8-14;365(9454):153-65 [15639298.001]
  • [Cites] Ann Surg. 2007 Dec;246(6):966-74; discussion 974-5 [18043098.001]
  • [Cites] Am J Surg Pathol. 2000 Oct;24(10):1372-7 [11023098.001]
  • [Cites] Am J Surg Pathol. 1999 Jan;23 (1):1-16 [9888699.001]
  • [Cites] World J Surg. 2008 Feb;32(2):271-8; discussion 279-80 [18027021.001]
  • [Cites] Gut. 2008 Mar;57(3):339-43 [17660227.001]
  • [Cites] Ann Surg. 2001 Sep;234(3):313-21; discussion 321-2 [11524584.001]
  • [Cites] Cancer Control. 2008 Oct;15(4):322-33 [18813200.001]
  • [Cites] Ann Surg Oncol. 2008 Jan;15(1):199-205 [17909912.001]
  • [Cites] Gut. 2008 Nov;57(11):1490-1 [18941002.001]
  • [Cites] Am J Gastroenterol. 2008 Nov;103(11):2871-7 [18775021.001]
  • [Cites] J Gastrointest Surg. 2008 Mar;12(3):414-6 [17968632.001]
  • [Cites] Ann Surg. 2004 May;239(5):678-85; discussion 685-7 [15082972.001]
  • [Cites] Korean J Radiol. 2003 Jul-Sep;4(3):157-62 [14530644.001]
  • [Cites] J Clin Pathol. 2008 Dec;61(12):1303-13 [18703569.001]
  • [Cites] Gut. 2008 Nov;57(11):1561-5 [18477671.001]
  • [Cites] Nihon Shokakibyo Gakkai Zasshi. 2007 Sep;104(9):1338-43 [17827904.001]
  • [Cites] Ann Surg. 2004 Mar;239(3):400-8 [15075659.001]
  • [Cites] Gut. 2002 Jun;50(6):861-8 [12010891.001]
  • [Cites] Ann Surg. 2007 Oct;246(4):644-51; discussion 651-4 [17893501.001]
  • [Cites] J Gastrointest Surg. 2008 Mar;12(3):401-4 [17957438.001]
  • [Cites] J Gastrointest Surg. 2008 Jan;12(1):101-9 [17917784.001]
  • (PMID = 19082569.001).
  • [ISSN] 1433-0385
  • [Journal-full-title] Der Chirurg; Zeitschrift fur alle Gebiete der operativen Medizen
  • [ISO-abbreviation] Chirurg
  • [Language] ger
  • [Publication-type] Comparative Study; English Abstract; Journal Article; Review
  • [Publication-country] Germany
  • [Number-of-references] 50
  •  go-up   go-down


32. Jang JY, Kim SW, Lee SE, Yang SH, Lee KU, Lee YJ, Kim SC, Han DJ, Choi DW, Choi SH, Heo JS, Cho BH, Yu HC, Yoon DS, Lee WJ, Lee HE, Kang GH, Lee JM: Treatment guidelines for branch duct type intraductal papillary mucinous neoplasms of the pancreas: when can we operate or observe? Ann Surg Oncol; 2008 Jan;15(1):199-205
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • There were 112 benign cases: 47 adenoma, 63 borderline cases, and 26 malignant cases, with 9 of these being noninvasive and 17 invasive.
  • [MeSH-major] Adenocarcinoma, Mucinous / surgery. Adenoma / surgery. Carcinoma, Pancreatic Ductal / surgery. Pancreatectomy. Pancreatic Neoplasms / surgery. Pancreaticoduodenectomy

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17909912.001).
  • [ISSN] 1534-4681
  • [Journal-full-title] Annals of surgical oncology
  • [ISO-abbreviation] Ann. Surg. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Multicenter Study; Practice Guideline; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


33. Nguyen H, Loustaunau C, Facista A, Ramsey L, Hassounah N, Taylor H, Krouse R, Payne CM, Tsikitis VL, Goldschmid S, Banerjee B, Perini RF, Bernstein C: Deficient Pms2, ERCC1, Ku86, CcOI in field defects during progression to colon cancer. J Vis Exp; 2010;(41)
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The molecular abnormalities that are responsible for a field defect in the colon should be detectable at high frequency in the histologically normal tissue surrounding a colonic adenocarcinoma or surrounding an adenoma with advanced neoplasia (well on the way to a colon cancer), but at low frequency in the colonic mucosa from patients without colonic neoplasia.
  • Using immunohistochemistry, entire crypts within 10 cm on each side of colonic adenocarcinomas or advanced colonic neoplasias were found to be frequently reduced or absent in expression for two DNA repair proteins, Pms2 and/or ERCC1.

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer Res. 2001 Jan 1;61(1):50-2 [11196196.001]
  • [Cites] Lancet Oncol. 2000 Sep;1(1):15-6 [11905680.001]
  • [Cites] Oncogene. 2002 Aug 12;21(35):5441-9 [12154406.001]
  • [Cites] Am J Pathol. 2004 Apr;164(4):1447-53 [15039232.001]
  • [Cites] Cancer. 1953 Sep;6(5):963-8 [13094644.001]
  • [Cites] Cancer Res. 2009 Apr 15;69(8):3382-9 [19336570.001]
  • [Cites] Proc Natl Acad Sci U S A. 2006 Jan 17;103(3):714-9 [16407113.001]
  • [Cites] Appl Immunohistochem Mol Morphol. 2006 Jun;14(2):166-72 [16785784.001]
  • [Cites] Carcinogenesis. 2007 Jan;28(1):215-22 [16887864.001]
  • [Cites] Cancer Lett. 2008 Feb 18;260(1-2):1-10 [18164807.001]
  • [Cites] Gastroenterology. 2008 Dec;135(6):2128-40, 2140.e1-8 [18801366.001]
  • [Cites] Mutat Res. 2005 Jan;589(1):47-65 [15652226.001]
  • (PMID = 20689513.001).
  • [ISSN] 1940-087X
  • [Journal-full-title] Journal of visualized experiments : JoVE
  • [ISO-abbreviation] J Vis Exp
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S.; Video-Audio Media
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, Nuclear; 0 / DNA-Binding Proteins; 0 / Ku autoantigen; EC 1.9.3.1 / Electron Transport Complex IV; EC 3.1.- / ERCC1 protein, human; EC 3.1.- / Endonucleases; EC 3.6.1.- / Adenosine Triphosphatases; EC 3.6.1.- / PMS2 protein, human; EC 6.5.1.- / DNA Repair Enzymes
  • [Other-IDs] NLM/ PMC3149991
  •  go-up   go-down


34. Roggin KK, Yeh JJ, Ferrone CR, Riedel E, Gerdes H, Klimstra DS, Jaques DP, Brennan MF: Limitations of ampullectomy in the treatment of nonfamilial ampullary neoplasms. Ann Surg Oncol; 2005 Dec;12(12):971-80
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Conversion to PD should be considered when intraoperative or final pathology identifies invasive adenocarcinoma.
  • [MeSH-minor] Adenocarcinoma / surgery. Adenoma / surgery. Adult. Aged. Aged, 80 and over. Algorithms. Disease-Free Survival. Female. Frozen Sections. Humans. Lymphatic Metastasis. Male. Middle Aged. Neoplasm Staging. Pancreaticoduodenectomy. Retrospective Studies. Sensitivity and Specificity. Survival Analysis

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Ann Surg Oncol. 2005 Dec;12(12):955-6 [16228813.001]
  • (PMID = 16244798.001).
  • [ISSN] 1068-9265
  • [Journal-full-title] Annals of surgical oncology
  • [ISO-abbreviation] Ann. Surg. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


35. Iizuka H, Okamura S, Onozato Y, Ishihara H, Kakizaki S, Mori M: Endoscopic submucosal dissection for colorectal tumors. Gastroenterol Clin Biol; 2009 Oct-Nov;33(10-11):1004-11
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • EMR was used in the majority of adenomas, and showed high rates of both one-piece resection (OPR) and complete resection (CR) for adenomas less than 20 mm.
  • However, for adenomas and cancers greater or equal to 20 mm, the CR rate for EMR was significantly lower than that for ESD because of the incidence of OPR with a positive lateral margin (16% vs 0% with ESD vs EMR).
  • [MeSH-minor] Adenocarcinoma / pathology. Adenocarcinoma / surgery. Adenoma / pathology. Adenoma / surgery. Adult. Aged. Aged, 80 and over. Female. Humans. Intestinal Perforation / etiology. Male. Middle Aged. Outcome Assessment (Health Care). Retrospective Studies. Risk Factors. Time Factors

  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19762190.001).
  • [ISSN] 0399-8320
  • [Journal-full-title] Gastroentérologie clinique et biologique
  • [ISO-abbreviation] Gastroenterol. Clin. Biol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] France
  •  go-up   go-down


36. Valladares Ayerbes M, Aparicio Gallego G, Díaz Prado S, Jiménez Fonseca P, García Campelo R, Antón Aparicio LM: Origin of renal cell carcinomas. Clin Transl Oncol; 2008 Nov;10(11):697-712
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Cancer is a heritable disorder of somatic cells: environment and heredity are both important in the carcinogenic process.
  • [MeSH-minor] Adenocarcinoma, Clear Cell / genetics. Adenocarcinoma, Clear Cell / pathology. Adenoma, Chromophobe / genetics. Adenoma, Chromophobe / pathology. Adenoma, Oxyphilic / genetics. Adenoma, Oxyphilic / pathology. Carcinoma, Papillary / genetics. Carcinoma, Papillary / pathology. Cell Lineage. Cell Transdifferentiation. Genes, Tumor Suppressor. Hematopoietic Stem Cells / pathology. Humans. Kidney Glomerulus / pathology. Mutation. Neoplasm Proteins / genetics. Neoplasm Proteins / physiology. Oncogenes

  • MedlinePlus Health Information. consumer health - Kidney Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Urol. 1997 Sep;158(3 Pt 1):724-8 [9258068.001]
  • [Cites] Proc Natl Acad Sci U S A. 1971 Apr;68(4):820-3 [5279523.001]
  • [Cites] Radiology. 2003 Jan;226(1):33-46 [12511666.001]
  • [Cites] Nature. 1991 Jun 6;351(6326):453-6 [2046748.001]
  • [Cites] Cancer Res. 1994 Jul 15;54(14):3710-3 [8033088.001]
  • [Cites] Kidney Int. 2002 Feb;61(2):387-95 [11849378.001]
  • [Cites] J Pathol. 1999 Sep;189(1):105-11 [10451496.001]
  • [Cites] Hum Mutat. 1996;8(4):348-57 [8956040.001]
  • [Cites] Mayo Clin Proc. 2000 Mar;75(3):265-72 [10725953.001]
  • [Cites] Int J Cancer. 1989 Mar 15;43(3):422-7 [2925273.001]
  • [Cites] J Med Genet. 1991 Jul;28(7):443-7 [1895313.001]
  • [Cites] Nat Genet. 1997 May;16(1):68-73 [9140397.001]
  • [Cites] J Natl Cancer Inst. 1989 Jul 19;81(14):1097-101 [2738940.001]
  • [Cites] Oncogene. 1997 Mar 6;14(9):1093-8 [9070658.001]
  • [Cites] Am J Pathol. 2001 Sep;159(3):825-9 [11549574.001]
  • [Cites] Cancer Genet Cytogenet. 1984 Apr;11(4):479-81 [6704944.001]
  • [Cites] Semin Oncol. 2000 Apr;27(2):138-49 [10768593.001]
  • [Cites] Lab Invest. 1987 Jun;56(6):642-53 [2439772.001]
  • [Cites] Am J Hum Genet. 1998 Jun;62(6):1475-83 [9585616.001]
  • [Cites] Arch Dermatol. 1977 Dec;113(12):1674-7 [596896.001]
  • [Cites] Urology. 2002 Dec;60(6):941-6 [12475646.001]
  • [Cites] J Urol. 1998 Aug;160(2):335-40 [9679872.001]
  • [Cites] Nat Rev Cancer. 2004 May;4(5):381-93 [15122209.001]
  • [Cites] J Urol. 1989 Nov;142(5):1364-8 [2810532.001]
  • [Cites] Hum Pathol. 1988 Aug;19(8):980-7 [2456980.001]
  • [Cites] Histopathology. 2001 Nov;39(5):455-62 [11737302.001]
  • [Cites] Hum Mutat. 1995;5(1):66-75 [7728151.001]
  • [Cites] J Urol. 1995 Jan;153(1):22-6 [7966777.001]
  • [Cites] Cancer Cell. 2005 Aug;8(2):143-53 [16098467.001]
  • [Cites] Development. 1998 Sep;125(17):3313-22 [9693135.001]
  • [Cites] Cancer Genet Cytogenet. 1995 May;81(1):72-5 [7773963.001]
  • [Cites] Anticancer Res. 1996 Nov-Dec;16(6B):3807-11 [9042262.001]
  • [Cites] Int J Biochem Cell Biol. 1997 Jan;29(1):55-62 [9076941.001]
  • [Cites] Cancer Cell. 2002 Aug;2(2):157-64 [12204536.001]
  • [Cites] Cancer. 1988 Nov 1;62(9):1946-51 [2458824.001]
  • [Cites] J Med Genet. 1993 Feb;30(2):104-7 [8445612.001]
  • [Cites] Nat Genet. 1998 Sep;20(1):66-9 [9731534.001]
  • [Cites] Adv Cancer Res. 1993;62:89-124 [8109322.001]
  • [Cites] Cancer Res. 1995 Dec 15;55(24):6189-95 [8521412.001]
  • [Cites] N Engl J Med. 1979 Sep 13;301(11):592-5 [470981.001]
  • [Cites] Nature. 1988 Mar 17;332(6161):268-9 [2894613.001]
  • [Cites] Am J Clin Pathol. 2004 Jun;121(6):878-83 [15198361.001]
  • [Cites] Kidney Int. 1994 Feb;45(2):314-9 [8164414.001]
  • [Cites] Histopathology. 1993 Feb;22(2):135-9 [8454257.001]
  • [Cites] J Pathol. 1994 May;173(1):39-44 [7931836.001]
  • [Cites] J Urol. 1994 Mar;151(3):561-6 [8308957.001]
  • [Cites] J Urol. 1996 Jul;156(1):281-5 [8648824.001]
  • [Cites] Science. 1993 May 28;260(5112):1317-20 [8493574.001]
  • [Cites] J Urol. 1985 Mar;133(3):502-5 [3883008.001]
  • [Cites] Blood. 1991 Dec 1;78(11):2848-53 [1720038.001]
  • [Cites] Br J Cancer. 1994 Feb;69(2):230-4 [8297719.001]
  • [Cites] Histopathology. 1987 Feb;11(2):157-70 [2437002.001]
  • [Cites] Science. 1991 Feb 15;251(4995):802-4 [1846706.001]
  • [Cites] Cancer Res. 1993 Dec 1;53(23):5780-3 [8242636.001]
  • [Cites] Pathol Res Pract. 1997;193(4):299-304 [9258956.001]
  • [Cites] J Urol. 1995 Mar;153(3 Pt 2):907-12 [7853572.001]
  • [Cites] Int J Cancer. 1997 Jul 17;72(2):265-9 [9219831.001]
  • [Cites] Kidney Int. 1999 Oct;56(4):1455-67 [10504497.001]
  • [Cites] Oncogene. 1997 Sep 25;15(13):1583-6 [9380410.001]
  • [Cites] Cancer Res. 1989 Dec 15;49(24 Pt 1):6972-5 [2582439.001]
  • [Cites] JAMA. 1995 Feb 15;273(7):564-70 [7837390.001]
  • [Cites] Cancer Treat Res. 2003;116:3-27 [14650823.001]
  • [Cites] Cancer. 1996 Mar 15;77(6):1154-60 [8635138.001]
  • [Cites] Cancer Genet Cytogenet. 1990 Apr;45(2):197-205 [2317768.001]
  • [Cites] J Am Soc Nephrol. 1992 Apr;2(10 Suppl):S190-7 [1600136.001]
  • [Cites] Am J Surg Pathol. 2001 Dec;25(12):1485-92 [11717537.001]
  • [Cites] Cancer Res. 1995 Feb 1;55(3):658-62 [7834636.001]
  • [Cites] Int J Cancer. 1996 Jun 21;69(3):212-7 [8682590.001]
  • [Cites] Cancer Res. 1998 Jan 15;58(2):226-31 [9443397.001]
  • [Cites] Curr Opin Nephrol Hypertens. 2001 May;10(3):315-20 [11342792.001]
  • [Cites] Am J Surg Pathol. 2002 Dec;26(12):1542-52 [12459621.001]
  • [Cites] EMBO J. 1990 May;9(5):1595-602 [1691710.001]
  • [Cites] Cancer Res. 1989 Jul 1;49(13):3627-30 [2659164.001]
  • [Cites] J Natl Cancer Inst. 1972 Feb;48(2):313-24 [4347033.001]
  • [Cites] Cancer Res. 1990 Aug 1;50(15):4504-9 [1973362.001]
  • [Cites] Arch Pathol Lab Med. 1986 Sep;110(9):825-32 [3530188.001]
  • [Cites] Am J Pathol. 1996 Dec;149(6):2089-94 [8952541.001]
  • [Cites] J Urol. 1999 Oct;162(4):1246-58 [10492174.001]
  • [Cites] Am J Clin Pathol. 1986 Jun;85(6):724-31 [2422924.001]
  • [Cites] Am J Surg Pathol. 2004 May;28(5):676-8 [15105658.001]
  • [Cites] Genomics. 1990 Dec;8(4):634-40 [2276737.001]
  • [Cites] Am J Hum Genet. 2001 Oct;69(4):876-82 [11533913.001]
  • [Cites] Nephrol Dial Transplant. 1999 Dec;14(12):2860-72 [10570089.001]
  • [Cites] Eur Urol. 2003 Jun;43(6):680-5 [12767370.001]
  • [Cites] Int J Cancer. 1987 Aug 15;40(2):171-8 [3610386.001]
  • [Cites] Cytogenet Cell Genet. 1996;75(2-3):180-5 [9040788.001]
  • [Cites] J Pathol. 1997 Oct;183(2):151-5 [9390026.001]
  • (PMID = 19015066.001).
  • [ISSN] 1699-048X
  • [Journal-full-title] Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico
  • [ISO-abbreviation] Clin Transl Oncol
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] Italy
  • [Chemical-registry-number] 0 / Neoplasm Proteins
  • [Number-of-references] 94
  •  go-up   go-down


37. Yagi K, Aruga Y, Nakamura A, Sekine A, Umezu H: The study of dynamic chemical magnifying endoscopy in gastric neoplasia. Gastrointest Endosc; 2005 Dec;62(6):963-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • METHODS: Forty-five patients (27 men, 18 women; median age 61.6 years) with gastric carcinoma or adenoma were enrolled in a prospective trial of enhanced magnifying endoscopy after instillation of 1.5% acetic acid.
  • Acetic acid-enhanced magnified views of carcinoma or adenoma and the surrounding non-neoplastic mucosa were observed, and the duration of whitening time of each lesion was recorded.
  • The mean duration of whitening differed with each histologic type: low-grade adenoma, 94 seconds; high-grade adenoma, 24.3 seconds; noninvasive carcinoma, 20.1 seconds; invasive intramucosal carcinoma, 3.5 seconds; and submucosal carcinoma or beyond, 2.5 seconds.
  • CONCLUSIONS: Acetic acid-enhanced magnifying endoscopy was useful for the diagnosis of gastric adenocarcinoma.
  • [MeSH-minor] Adenoma / diagnosis. Adenoma / pathology. Carcinoma / diagnosis. Carcinoma / pathology. Female. Humans. Indicators and Reagents. Male

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • Hazardous Substances Data Bank. ACETIC ACID .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16301045.001).
  • [ISSN] 0016-5107
  • [Journal-full-title] Gastrointestinal endoscopy
  • [ISO-abbreviation] Gastrointest. Endosc.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Indicators and Reagents; Q40Q9N063P / Acetic Acid
  •  go-up   go-down


38. Gambarotti M, Medicina D, Baronchelli C, Bercich L, Bonetti F, Facchetti F: Alpha-1-antitrypsin-positive "signet-ring" bile duct adenoma in a patient with M(MALTON) mutation. Int J Surg Pathol; 2008 Apr;16(2):218-21
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Alpha-1-antitrypsin-positive "signet-ring" bile duct adenoma in a patient with M(MALTON) mutation.
  • A 65-year-old man with a colonic adenocarcinoma and a single small liver nodule underwent surgery.
  • The nodule showed the histological features of a bile duct adenoma.
  • [MeSH-major] Adenoma / genetics. Bile Duct Neoplasms / genetics. Bile Ducts, Intrahepatic. Mutation. alpha 1-Antitrypsin / genetics

  • MedlinePlus Health Information. consumer health - Bile Duct Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18417685.001).
  • [ISSN] 1066-8969
  • [Journal-full-title] International journal of surgical pathology
  • [ISO-abbreviation] Int. J. Surg. Pathol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / alpha 1-Antitrypsin
  •  go-up   go-down


39. Pokala N, Delaney CP, Kiran RP, Brady K, Senagore AJ: Outcome of laparoscopic colectomy for polyps not suitable for endoscopic resection. Surg Endosc; 2007 Mar;21(3):400-3
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Mean polyp size was 3.1 cm, and pathology revealed tubular (n = 14), tubulovillous (n = 33) and villous adenoma (n = 2), pseudopolyp (n = 1), and prolapse of the appendix into the cecum mimicking an adenoma (n = 1).
  • High-grade dysplasia was seen in four tubular (33%) and five tubulovillous adenomas (15.5%).
  • Adenocarcinoma not identified at colonoscopy was found in 11 polyps (20%), 9 tubulovillous (27.8%) and both villous adenomas (100%).

  • MedlinePlus Health Information. consumer health - Colonic Polyps.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Dis Colon Rectum. 2003 Mar;46(3):340-8 [12626909.001]
  • [Cites] Lancet Oncol. 2005 Jul;6(7):477-84 [15992696.001]
  • [Cites] Arch Surg. 2004 Jan;139(1):39-42 [14718273.001]
  • [Cites] N Engl J Med. 2004 May 13;350(20):2050-9 [15141043.001]
  • [Cites] Gastrointest Endosc. 1996 Mar;43(3):256-7 [8857147.001]
  • [Cites] Surg Endosc. 1994 Jan;8(1):12-7; discussion 18 [8153858.001]
  • [Cites] Surg Laparosc Endosc. 1991 Sep;1(3):144-50 [1688289.001]
  • [Cites] J Am Coll Surg. 2003 Aug;197(2):177-81 [12892794.001]
  • [Cites] Dis Colon Rectum. 1991 Apr;34(4):323-8 [1848810.001]
  • [Cites] Gastroenterol Clin Biol. 1998 Apr;22(4):425-30 [9762273.001]
  • [Cites] Ann Surg. 2003 Jul;238(1):67-72 [12832967.001]
  • [Cites] World J Surg. 2002 Mar;26(3):377-83 [11865378.001]
  • [Cites] Surg Endosc. 1997 Jun;11(6):643-4 [9171124.001]
  • [Cites] Surg Endosc. 1998 Nov;12(11):1341-4 [9788858.001]
  • [Cites] Dis Colon Rectum. 2003 Apr;46(4):503-9 [12682545.001]
  • [Cites] Lancet. 2004 Apr 10;363(9416):1187-92 [15081650.001]
  • [Cites] Ann Surg. 1992 Dec;216(6):703-7 [1466626.001]
  • [Cites] Surg Endosc. 1997 Feb;11(2):119-22 [9069140.001]
  • [Cites] AORN J. 1992 Dec;56(6):1068-73 [1463326.001]
  • [Cites] Dis Colon Rectum. 2000 Sep;43(9):1246-9 [11005491.001]
  • [Cites] Lancet. 2002 Jun 29;359(9325):2224-9 [12103285.001]
  • [Cites] Dis Colon Rectum. 2001 May;44(5):746-8 [11357040.001]
  • [Cites] Cochrane Database Syst Rev. 2005 Jul 20;(3):CD003145 [16034888.001]
  • [Cites] Mayo Clin Proc. 2000 Apr;75(4):344-8 [10761487.001]
  • [Cites] Br J Surg. 2002 Aug;89(8):1020-4 [12153628.001]
  • [Cites] Mayo Clin Proc. 1994 Sep;69(9):834-40 [8065184.001]
  • [Cites] Surg Endosc. 1999 Mar;13(3):231-2 [10064752.001]
  • [Cites] Hepatogastroenterology. 1997 Jan-Feb;44(13):40-4 [9058116.001]
  • [Cites] Gastrointest Endosc. 1996 Mar;43(3):183-8 [8857131.001]
  • [Cites] Br J Surg. 1999 Apr;86(4):505-8 [10215825.001]
  • [Cites] Ann Chir. 1997;51(9):986-9 [10868040.001]
  • [Cites] ANZ J Surg. 2003 Dec;73(12):988-95 [14632888.001]
  • [Cites] Am J Surg. 2006 Mar;191(3):377-80 [16490550.001]
  • (PMID = 17180271.001).
  • [ISSN] 1432-2218
  • [Journal-full-title] Surgical endoscopy
  • [ISO-abbreviation] Surg Endosc
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


40. A-Cienfuegos J, Rotellar F, Martí-Cruchaga P, Valentí V, Zozaya G, Bueno A, Pedano N, Lozano MD, Sola JJ, Pardo F: Intraductal papillary mucinous neoplasms (IPMN) of the pancreas: clinico-pathologic results. Rev Esp Enferm Dig; 2010 May;102(5):314-20
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: intraductal papillary mucinous neoplasm (IPMN) shows a series of lesions which evolve from benign lesions -adenoma- to invasive carcinoma.
  • A patient without invasive carcinoma died at 66 months of follow-up for pancreas adenocarcinoma.

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20524759.001).
  • [ISSN] 1130-0108
  • [Journal-full-title] Revista española de enfermedades digestivas : organo oficial de la Sociedad Española de Patología Digestiva
  • [ISO-abbreviation] Rev Esp Enferm Dig
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Spain
  •  go-up   go-down


41. Kikuchi Y, Kashima TG, Nishiyama T, Shimazu K, Morishita Y, Shimazaki M, Kii I, Horie H, Nagai H, Kudo A, Fukayama M: Periostin is expressed in pericryptal fibroblasts and cancer-associated fibroblasts in the colon. J Histochem Cytochem; 2008 Aug;56(8):753-64
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The pericryptal pattern of periostin deposition was decreased in adenoma and adenocarcinoma, preceding the decrease of the number of pericryptal fibroblasts.
  • [MeSH-major] Adenocarcinoma / metabolism. Adenoma / metabolism. Cell Adhesion Molecules / biosynthesis. Colon / metabolism. Colonic Neoplasms / metabolism. Fibroblasts / metabolism

  • COS Scholar Universe. author profiles.
  • KOMP Repository. gene/protein/disease-specific - KOMP Repository (subscription/membership/fee required).
  • Mouse Genome Informatics (MGI). Mouse Genome Informatics (MGI) .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer. 2001 Aug 15;92(4):843-8 [11550156.001]
  • [Cites] Mech Dev. 2001 May;103(1-2):183-8 [11335131.001]
  • [Cites] Nature. 2001 Nov 1;414(6859):98-104 [11689954.001]
  • [Cites] Cancer Res. 2002 Sep 15;62(18):5358-64 [12235007.001]
  • [Cites] Breast Cancer Res Treat. 2003 Feb;77(3):245-52 [12602924.001]
  • [Cites] Gastroenterology. 2004 Jan;126(1):111-21 [14699493.001]
  • [Cites] Dev Dyn. 2004 Apr;229(4):857-68 [15042709.001]
  • [Cites] Mol Cell Biol. 2004 May;24(9):3992-4003 [15082792.001]
  • [Cites] Cancer Cell. 2004 Apr;5(4):329-39 [15093540.001]
  • [Cites] Hum Pathol. 1993 May;24(5):525-33 [8491492.001]
  • [Cites] Biochem J. 1993 Aug 15;294 ( Pt 1):271-8 [8363580.001]
  • [Cites] Annu Rev Cell Biol. 1993;9:511-40 [8280470.001]
  • [Cites] Cancer Res. 1997 May 1;57(9):1644-9 [9135000.001]
  • [Cites] J Physiol. 1999 Jan 1;514 ( Pt 1):211-27 [9831728.001]
  • [Cites] J Gastroenterol. 1999 Apr;34(2):215-20 [10213121.001]
  • [Cites] J Bone Miner Res. 1999 Jul;14(7):1239-49 [10404027.001]
  • [Cites] Pathol Int. 1999 May;49(5):426-34 [10417686.001]
  • [Cites] Am J Physiol. 1999 Aug;277(2 Pt 1):C183-201 [10444394.001]
  • [Cites] Anat Rec A Discov Mol Cell Evol Biol. 2004 Dec;281(2):1264-75 [15386274.001]
  • [Cites] Carcinogenesis. 2005 May;26(5):908-15 [15731169.001]
  • [Cites] Cell. 2005 May 6;121(3):335-48 [15882617.001]
  • [Cites] Biochem Biophys Res Commun. 2006 Apr 14;342(3):766-72 [16497272.001]
  • [Cites] J Allergy Clin Immunol. 2006 Jul;118(1):98-104 [16815144.001]
  • [Cites] J Biol Chem. 2006 Jul 14;281(28):19700-8 [16702213.001]
  • [Cites] Cancer Res. 2006 Jul 15;66(14):6928-35 [16849536.001]
  • [Cites] Breast Cancer Res. 2006;8(5):R56 [17014703.001]
  • [Cites] Oncogene. 2007 Mar 29;26(14):2082-94 [17043657.001]
  • [Cites] Gastroenterology. 2007 Apr;132(4):1447-64 [17408641.001]
  • [Cites] J Cell Biochem. 2007 Jun 1;101(3):695-711 [17226767.001]
  • [Cites] J Exp Med. 2008 Feb 18;205(2):295-303 [18208976.001]
  • [Cites] Mod Pathol. 2008 Aug;21(8):1044-53 [18487994.001]
  • [Cites] J Bone Miner Metab. 2000;18(3):132-9 [10783846.001]
  • [Cites] J Lab Clin Med. 2000 Sep;136(3):201-8 [10985498.001]
  • [Cites] J Gastroenterol Hepatol. 2001 Sep;16(9):991-1000 [11595063.001]
  • (PMID = 18443362.001).
  • [ISSN] 0022-1554
  • [Journal-full-title] The journal of histochemistry and cytochemistry : official journal of the Histochemistry Society
  • [ISO-abbreviation] J. Histochem. Cytochem.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Cell Adhesion Molecules; 0 / Collagen Type I; 0 / Gels; 0 / POSTN protein, human; 0 / Postn protein, mouse
  • [Other-IDs] NLM/ PMC2443605
  •  go-up   go-down


42. Pequin P, Manfredi S, Quentin V, Heresbach D, Boyer J, Siproudhis L, Bretagne JF: Patients with sporadic duodenal adenoma are a high-risk group for advanced colorectal neoplasia: results of a case-control study. Aliment Pharmacol Ther; 2007 Jul 15;26(2):277-82
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Patients with sporadic duodenal adenoma are a high-risk group for advanced colorectal neoplasia: results of a case-control study.
  • METHODS: Cases were 35 patients referred for the management of sporadic duodenal adenoma and who underwent colonoscopy.
  • Colonoscopy findings among cases were compared with those from a control group matched for age and sex (two controls per case) without duodenal adenoma.
  • Colonoscopy findings were categorized as adenoma, advanced adenoma, cancer or advanced neoplasia.
  • RESULTS: Colorectal adenoma was present in 31% of cases vs. 24% of controls, advanced neoplasia in 29% vs. 4%, advanced adenoma in 23% vs. 3% and adenocarcinoma in 6% vs. 1%.
  • The relative risks of advanced colorectal adenoma and advanced colorectal neoplasia in cases were 10.1 (95% CI: 1.8-100.1, P = 0.003) and 8.9 (95% CI: 2.1-53.3, P = 0.001), respectively.
  • CONCLUSIONS: The relative risk of advanced colorectal adenoma and advanced neoplasia in cases was nine- to 10-fold that among controls.
  • Patients with sporadic duodenal adenoma represent a high-risk group for advanced colorectal neoplasia and should therefore undergo complete colonoscopy.
  • [MeSH-major] Adenoma / pathology. Colonoscopy. Colorectal Neoplasms / diagnosis. Duodenal Neoplasms / pathology. Precancerous Conditions / pathology

  • MedlinePlus Health Information. consumer health - Colonoscopy.
  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • MedlinePlus Health Information. consumer health - Intestinal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17593073.001).
  • [ISSN] 0269-2813
  • [Journal-full-title] Alimentary pharmacology & therapeutics
  • [ISO-abbreviation] Aliment. Pharmacol. Ther.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down


43. Gimeno-García AZ, Ramírez F, Gonzalo V, Balaguer F, Petit A, Pellisé M, Llach J, Bordas JM, Piqué JM, Castells A: [High-grade dysplasia as a risk factor of metachronous advanced colorectal neoplasms in patients with advanced adenomas]. Gastroenterol Hepatol; 2007 Apr;30(4):207-11
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [High-grade dysplasia as a risk factor of metachronous advanced colorectal neoplasms in patients with advanced adenomas].
  • [Transliterated title] Displasia de alto grado como factor de riesgo de neoplasia colorrectal avanzada metacrónica, en pacientes con adenomas avanzados.
  • BACKGROUND: Patients with advanced adenomas (AA) have a high risk of developing advanced colorectal neoplasms.
  • However, its predictive value for developing advanced neoplams in patients with advanced adenoma is unknown.
  • The number of metachronic polyps (p = 0.67), adenomas (p = 0.73), AA (p = 0.93) and AA with HGD (p = 0.88) was also similar.
  • [MeSH-major] Adenocarcinoma / pathology. Adenoma / pathology. Colonic Polyps / pathology. Colonoscopy / methods. Colorectal Neoplasms / pathology. Neoplasms, Multiple Primary / pathology. Precancerous Conditions / pathology


44. Tarakji B, Kujan O, Nassani MZ: Immunohistochemical Expression of p53 in Pleomorphic Adenoma and Carcinoma Ex Pleomorphic Adenoma. J Cancer Epidemiol; 2010;2010:250606
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Immunohistochemical Expression of p53 in Pleomorphic Adenoma and Carcinoma Ex Pleomorphic Adenoma.
  • This marker may be useful in differentiating pleomorphic adenoma (PA) from carcinoma ex pleomorphic adenoma (CPA), as these tumors are often difficult to distinguish on the basis of morphology alone.
  • Design. Paraffin blocks of 29 cases of PA, which were surrounded by normal parotid gland, and 27 cases of carcinoma ex pleomorphic adenoma were retrieved and validated.
  • In all cases of carcinoma ex pleomorphic adenoma, a PA "ghost" was identified, and the malignant element was either undifferentiated carcinoma or adenocarcinoma.
  • Nuclear P53 was expressed strongly in 6/29 (20.7%) pleomorphic salivary adenoma and 10/27 (37%) carcinoma ex pleomorphic adenoma.
  • Conclusion. Our data suggest that inactivation of p53 may play an important role in the evolution of pleomorphic salivary adenoma and carcinoma ex pleomorphic adenoma.

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Pathol. 1997 Jun;182(2):180-4 [9274528.001]
  • [Cites] Pathol Int. 1998 Apr;48(4):265-72 [9648154.001]
  • [Cites] Int J Oncol. 2000 Mar;16(3):477-83 [10675478.001]
  • [Cites] Cancer Lett. 1992 Jul 31;65(1):61-71 [1324786.001]
  • [Cites] J Immunol Methods. 1992 Jul 6;151(1-2):237-44 [1378473.001]
  • [Cites] J Pathol. 1992 Apr;166(4):389-94 [1381431.001]
  • [Cites] Eur Rev Med Pharmacol Sci. 2008 Sep-Oct;12(5):321-5 [19024217.001]
  • [Cites] Nature. 1989 Dec 7;342(6250):705-8 [2531845.001]
  • [Cites] Acta Pathol Jpn. 1993 Jul-Aug;43(7-8):413-22 [8396843.001]
  • [Cites] Br J Cancer. 1996 Mar;73(6):728-34 [8611372.001]
  • [Cites] Diagn Mol Pathol. 1998 Aug;7(4):224-31 [9917133.001]
  • [Cites] Hum Pathol. 2009 Mar;40(3):390-7 [18992915.001]
  • [Cites] Cancer. 1981 Jul 1;48(1):113-21 [6263450.001]
  • [Cites] Cancer. 1995 Apr 15;75(8):2037-44 [7697591.001]
  • [Cites] Hum Pathol. 1996 Aug;27(8):782-6 [8760010.001]
  • [Cites] J Oral Pathol Med. 1997 May;26(5):217-23 [9178173.001]
  • [Cites] Cancer. 1997 Jun 15;79(12):2314-9 [9191518.001]
  • [Cites] Oncol Rep. 1999 May-Jun;6(3):539-45 [10203588.001]
  • [Cites] Anal Quant Cytol Histol. 1999 Aug;21(4):336-42 [10560511.001]
  • (PMID = 21253477.001).
  • [ISSN] 1687-8566
  • [Journal-full-title] Journal of cancer epidemiology
  • [ISO-abbreviation] J Cancer Epidemiol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Egypt
  • [Other-IDs] NLM/ PMC3022193
  •  go-up   go-down


45. Jeong HK, Park CH, Jun CH, Lee GH, Kim HI, Kim HS, Choi SK, Rew JS: A prospective randomized trial of either famotidine or pantoprazole for the prevention of bleeding after endoscopic submucosal dissection. J Korean Med Sci; 2007 Dec;22(6):1055-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • In a prospective trial, patients undergoing ESD due to gastric adenoma or adenocarcinoma were randomly assigned to pantoprazole or famotidine.

  • MedlinePlus Health Information. consumer health - Gastrointestinal Bleeding.
  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • Hazardous Substances Data Bank. PANTOPRAZOLE .
  • Hazardous Substances Data Bank. FAMOTIDINE .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] N Engl J Med. 2000 Aug 3;343(5):310-6 [10922420.001]
  • [Cites] Gastrointest Endosc. 2006 Dec;64(6):877-83 [17140890.001]
  • [Cites] Gastrointest Endosc. 2002 Mar;55(3):390-6 [11868015.001]
  • [Cites] Gastrointest Endosc. 2002 Apr;55(4):576-81 [11923778.001]
  • [Cites] Gastrointest Endosc. 2002 Oct;56(4):507-12 [12297765.001]
  • [Cites] Gastrointest Endosc. 2003 Apr;57(4):567-79 [12665775.001]
  • [Cites] Gastrointest Endosc. 2003 May;57(6):687-90 [12709698.001]
  • [Cites] Endoscopy. 2003 Jul;35(7):611-2 [12822098.001]
  • [Cites] Endoscopy. 2003 Aug;35(8):690-4 [12929067.001]
  • [Cites] Am J Gastroenterol. 2003 Dec;98(12):2635-41 [14687809.001]
  • [Cites] Endoscopy. 2004 Sep;36(9):788-801 [15326574.001]
  • [Cites] Endoscopy. 2004 Sep;36(9):808-10 [15326576.001]
  • [Cites] Gastroenterology. 1978 Jan;74(1):38-43 [21830.001]
  • [Cites] Scand J Gastroenterol Suppl. 1987;134:55-60 [2889260.001]
  • [Cites] Arch Intern Med. 1998 Jan 12;158(1):54-8 [9437379.001]
  • [Cites] Endoscopy. 1999 Jan;31(1):47-55 [10082409.001]
  • [Cites] Gastrointest Endosc. 1999 Aug;50(2):251-6 [10425422.001]
  • [Cites] Aliment Pharmacol Ther. 1999 Aug;13 Suppl 3:18-26 [10491725.001]
  • [Cites] Intern Med. 2004 Dec;43(12):1120-5 [15645644.001]
  • [Cites] Aliment Pharmacol Ther. 2005 Jun;21 Suppl 2:111-5 [15943857.001]
  • [Cites] Dig Dis Sci. 2006 Jan;51(1):123-31 [16416224.001]
  • [Cites] Gastrointest Endosc. 2006 Feb;63(2):243-9 [16427929.001]
  • [Cites] World J Gastroenterol. 2005 Dec 14;11(46):7335-9 [16437638.001]
  • [Cites] Aliment Pharmacol Ther. 2006 Sep 1;24(5):837-43 [16918888.001]
  • [Cites] Endoscopy. 2001 Mar;33(3):221-6 [11293753.001]
  • (PMID = 18162722.001).
  • [ISSN] 1011-8934
  • [Journal-full-title] Journal of Korean medical science
  • [ISO-abbreviation] J. Korean Med. Sci.
  • [Language] eng
  • [Publication-type] Journal Article; Randomized Controlled Trial
  • [Publication-country] Korea (South)
  • [Chemical-registry-number] 0 / 2-Pyridinylmethylsulfinylbenzimidazoles; 0 / Anti-Ulcer Agents; 5QZO15J2Z8 / Famotidine; D8TST4O562 / pantoprazole
  • [Other-IDs] NLM/ PMC2694634
  •  go-up   go-down


46. Kazakov DV, Requena L, Kutzner H, Fernandez-Figueras MT, Kacerovska D, Mentzel T, Schwabbauer P, Michal M: Morphologic diversity of syringocystadenocarcinoma papilliferum based on a clinicopathologic study of 6 cases and review of the literature. Am J Dermatopathol; 2010 Jun;32(4):340-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Morphologic diversity of syringocystadenocarcinoma papilliferum based on a clinicopathologic study of 6 cases and review of the literature.
  • The purpose of our investigation was to study a series of syringocystadenocarcinoma papilliferum to document morphologic variations of the neoplasm.
  • Syringocystadenocarcinoma papilliferum invariably occurred in association with syringocystadenoma papilliferum and presented as an in situ adenocarcinoma and/or invasive adenocarcinoma.
  • It is concluded that morphologic diversity of syringocystadenocarcinoma papilliferum is substantial.
  • Its association with the benign counterpart and ductal changes suggests a transformation that may involve usual ductal hyperplasia-atypical ductal hyperplasia-(ductal) adenocarcinoma in situ-invasive adenocarcinoma pathway.
  • [MeSH-minor] Adenoma, Sweat Gland / pathology. Aged. Aged, 80 and over. Carcinoma in Situ / pathology. Carcinoma, Ductal / pathology. Carcinoma, Squamous Cell / pathology. Female. Humans. Male. Middle Aged

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20216201.001).
  • [ISSN] 1533-0311
  • [Journal-full-title] The American Journal of dermatopathology
  • [ISO-abbreviation] Am J Dermatopathol
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 25
  •  go-up   go-down


47. Okabayashi T, Kobayashi M, Nishimori I, Sugimoto T, Namikawa T, Okamoto K, Okamoto N, Kosaki T, Onishi S, Araki K: Clinicopathological features and medical management of intraductal papillary mucinous neoplasms. J Gastroenterol Hepatol; 2006 Feb;21(2):462-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • RESULTS: Among the 23 patients, 12 had IPMN adenoma, three had borderline IPMN, four had IPMN with carcinoma in situ, and four had IPMN with invasive carcinoma.
  • [MeSH-major] Adenocarcinoma, Mucinous / diagnosis. Adenocarcinoma, Mucinous / surgery. Pancreatectomy. Pancreatic Neoplasms / diagnosis. Pancreatic Neoplasms / surgery

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16509876.001).
  • [ISSN] 0815-9319
  • [Journal-full-title] Journal of gastroenterology and hepatology
  • [ISO-abbreviation] J. Gastroenterol. Hepatol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] Australia
  •  go-up   go-down


48. Nakata K, Nagai E, Ohuchida K, Aishima S, Hayashi A, Miyasaka Y, Yu J, Mizumoto K, Tanaka M, Tsuneyoshi M: REG4 is associated with carcinogenesis in the 'intestinal' pathway of intraductal papillary mucinous neoplasms. Mod Pathol; 2009 Mar;22(3):460-8
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Regenerating islet-derived family, member 4 (REG4) is associated with the adenoma-carcinoma sequence in colon cancer and it is also associated with intestinal phenotype.
  • To investigate the expressions of REG4 and CDX2 in IPMNs and in invasive ductal adenocarcinoma derived from IPMN, we used immunohistochemical staining and microdissection-based quantitative real-time reverse transcription-polymerase chain reaction.
  • REG4 expression was observed more frequently in borderline lesions (14/28) and carcinoma (21/45) compared to adenoma (8/52).
  • [MeSH-minor] Adenocarcinoma, Mucinous / metabolism. Adenocarcinoma, Mucinous / pathology. Adenocarcinoma, Papillary / metabolism. Adenocarcinoma, Papillary / pathology. Biomarkers, Tumor / analysis. Gene Expression. Homeodomain Proteins / biosynthesis. Homeodomain Proteins / genetics. Humans. Immunohistochemistry. Ki-67 Antigen / metabolism. Microdissection. Mucin-2 / biosynthesis. RNA, Messenger / analysis. Reverse Transcriptase Polymerase Chain Reaction

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19136934.001).
  • [ISSN] 1530-0285
  • [Journal-full-title] Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc
  • [ISO-abbreviation] Mod. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / CDX2 protein, human; 0 / Homeodomain Proteins; 0 / Ki-67 Antigen; 0 / Lectins, C-Type; 0 / MUC2 protein, human; 0 / Mucin-2; 0 / REG4 protein, human; 0 / RNA, Messenger
  •  go-up   go-down


49. Lerma E, Mora J: Telomerase activity in "suspicious" thyroid cytology. Cancer; 2005 Dec 25;105(6):492-7
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The histopathologic diagnoses were nodular hyperplasia in 5 patients, follicular adenoma in 3 patients, papillary carcinoma in 11 patients, follicular carcinoma in 1 patient, medullary carcinoma in 2 patients, and lymphoma in 1 patient.
  • TA was detected in 6 of 18 histologically confirmed thyroid neoplasms (1 of 3 follicular adenomas, 3 of 11 papillary carcinomas, 0 of 1 follicular carcinoma, 1 of 2 medullary carcinomas, and 1 of 1 lymphoma), including 1 neoplasm with scanty atypical cells.
  • [MeSH-minor] Adenocarcinoma, Follicular / diagnosis. Adenocarcinoma, Follicular / enzymology. Adenocarcinoma, Follicular / pathology. Biopsy, Fine-Needle. Carcinoma, Medullary / diagnosis. Carcinoma, Medullary / enzymology. Carcinoma, Medullary / pathology. Carcinoma, Papillary / diagnosis. Carcinoma, Papillary / enzymology. Carcinoma, Papillary / pathology. Humans

  • MedlinePlus Health Information. consumer health - Lymphoma.
  • MedlinePlus Health Information. consumer health - Thyroid Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16104043.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; EC 2.7.7.49 / Telomerase
  •  go-up   go-down


50. Lash RH, Genta RM, Schuler CM: Sessile serrated adenomas: prevalence of dysplasia and carcinoma in 2139 patients. J Clin Pathol; 2010 Aug;63(8):681-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Sessile serrated adenomas: prevalence of dysplasia and carcinoma in 2139 patients.
  • BACKGROUND AND AIMS: Sessile serrated adenomas (SSAs) are recognised as precursors to microsatellite unstable adenocarcinomas.
  • There were 1816 (85%) patients without dysplasia (SSA-), 257 (12%) with low-grade dysplasia (SSA-LD), 45 (2%) with high-grade dysplasia (SSA-HD) and 21 (1%) with adenocarcinoma (SSA-CA).
  • Women comprised 53% of the SSA- group (968/1816), 57% of the SSA-LD group (147/257), 69% of the SSA-HD group (31/45) and 76% of the SSA-CA group (16/21), being more likely to have high-grade dysplasia (OR 1.94, 95% CI 1.03 to 3.67) and adenocarcinoma (OR 2.80, 95% CI 1.02 to 7.68).
  • Based on significant age differences between groups, there appears to be a stepwise progression of dysplasia and carcinoma in SSAs over 10 to 15 years, a period two to three times longer than that for conventional adenomas.
  • [MeSH-major] Adenoma / epidemiology. Colorectal Neoplasms / epidemiology
  • [MeSH-minor] Adenocarcinoma / epidemiology. Adenocarcinoma / pathology. Adult. Age Distribution. Aged. Aged, 80 and over. Biopsy. Colonoscopy. Disease Progression. Female. Humans. Intestinal Polyps / epidemiology. Intestinal Polyps / pathology. Male. Middle Aged. Prevalence. United States / epidemiology. Young Adult


51. Hardisty JF, Willson GA, Brown WR, McConnell EE, Frame SR, Gaylor DW, Kennedy GL, Butenhoff JL: Pathology Working Group review and evaluation of proliferative lesions of mammary gland tissues in female rats fed ammonium perfluorooctanoate (APFO) in the diet for 2 years. Drug Chem Toxicol; 2010 Apr;33(2):131-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [MeSH-major] Adenocarcinoma / chemically induced. Adenoma / chemically induced. Caprylates / toxicity. Environmental Pollutants / toxicity. Fibroadenoma / chemically induced. Fluorocarbons / toxicity. Mammary Glands, Animal / drug effects. Mammary Neoplasms, Animal / chemically induced. Neoplasms, Multiple Primary / chemically induced

  • Hazardous Substances Data Bank. Perfluorooctanoic acid .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20307141.001).
  • [ISSN] 1525-6014
  • [Journal-full-title] Drug and chemical toxicology
  • [ISO-abbreviation] Drug Chem Toxicol
  • [Language] eng
  • [Publication-type] Consensus Development Conference; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Caprylates; 0 / Environmental Pollutants; 0 / Fluorocarbons; 947VD76D3L / perfluorooctanoic acid
  • [Number-of-references] 46
  •  go-up   go-down


52. Manenti G, Galbiati F, Pettinicchio A, Spinola M, Piconese S, Leoni VP, Conti B, Ravagnani F, Incarbone M, Pastorino U, Dragani TA: A V141L polymorphism of the human LRMP gene is associated with survival of lung cancer patients. Carcinogenesis; 2006 Jul;27(7):1386-90
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Mouse Lrmp and Casc1 genes are candidates for the pulmonary adenoma susceptibility 1 (Pas1) locus, the major determinant of strain variation in lung tumor susceptibility.
  • Analysis of LRMP and CASC1 gene SNPs in 361 lung adenocarcinoma (ADCA) patients and 327 healthy controls revealed common SNPs in LRMP (V141L and S197C) and CASC1 (R33S and three intronic variations), and none showed a significant association with lung ADCA risk.
  • [MeSH-major] Adenocarcinoma / genetics. Adenocarcinoma / mortality. Lung Neoplasms / genetics. Lung Neoplasms / mortality. Membrane Proteins / genetics

  • Genetic Alliance. consumer health - Lung Cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16410263.001).
  • [ISSN] 0143-3334
  • [Journal-full-title] Carcinogenesis
  • [ISO-abbreviation] Carcinogenesis
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / LRMP protein, human; 0 / Membrane Proteins
  •  go-up   go-down


53. Westhoff CC, Hoffmann S, Barth PJ: Clear cell follicular adenoma of the thyroid--a challenge in intra-operative diagnostics. Exp Clin Endocrinol Diabetes; 2010 Jan;118(1):19-21
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clear cell follicular adenoma of the thyroid--a challenge in intra-operative diagnostics.
  • We report the case of a 61-year-old man with a clear cell adenoma of the thyroid.
  • Based on the light microscopic findings and the immunohistochemical profile, the lesion was diagnosed as clear cell follicular adenoma of the thyroid.
  • [MeSH-major] Adenocarcinoma, Clear Cell / diagnosis. Adenoma / diagnosis. Thyroid Neoplasms / diagnosis. Thyroid Nodule / diagnosis

  • MedlinePlus Health Information. consumer health - Thyroid Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] J. A. Barth Verlag in Georg Thieme Verlag KG Stuttgart, New York.
  • (PMID = 19235130.001).
  • [ISSN] 1439-3646
  • [Journal-full-title] Experimental and clinical endocrinology & diabetes : official journal, German Society of Endocrinology [and] German Diabetes Association
  • [ISO-abbreviation] Exp. Clin. Endocrinol. Diabetes
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


54. de Araújo VC, Furuse C, Cury PR, Altemani A, Alves VA, de Araújo NS: Desmoplasia in different degrees of invasion of carcinoma ex-pleomorphic adenoma. Head Neck Pathol; 2007 Dec;1(2):112-7
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Desmoplasia in different degrees of invasion of carcinoma ex-pleomorphic adenoma.
  • Stroma desmoplasia was studied by immunohistochemistry for alpha-smooth muscle actin (alpha-SMA) in 17 instances of carcinoma ex-pleomorphic adenoma (CXPA) classified according to the presence of epithelial and myoepithelial cells and the degree of invasion: intracapsular, minimally and frankly invasive carcinoma.
  • In "resident" pleomorphic adenoma, no desmoplasia was detected.
  • [MeSH-major] Adenocarcinoma / pathology. Adenoma, Pleomorphic / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Oncogene. 2000 Nov 30;19(51):5898-905 [11127821.001]
  • [Cites] Cancer Res. 2001 Jan 15;61(2):550-5 [11212248.001]
  • [Cites] Cancer Res. 2001 Feb 1;61(3):926-30 [11221884.001]
  • [Cites] Cancer Res. 2001 Mar 1;61(5):1833-8 [11280733.001]
  • [Cites] Nature. 2001 May 17;411(6835):375-9 [11357145.001]
  • [Cites] J Biol Chem. 2001 May 18;276(20):17058-62 [11279127.001]
  • [Cites] Cancer Res. 2001 Oct 15;61(20):7435-43 [11606377.001]
  • [Cites] Cancer Res. 2002 Sep 15;62(18):5351-7 [12235006.001]
  • [Cites] J Pathol. 2003 Jul;200(4):429-47 [12845611.001]
  • [Cites] J Oral Pathol Med. 2004 Jul;33(6):335-9 [15200481.001]
  • [Cites] Arch Pathol Lab Med. 1978 Apr;102(4):185-8 [580712.001]
  • [Cites] Virchows Arch A Pathol Anat Histopathol. 1984;403(4):323-36 [6429937.001]
  • [Cites] Pathol Res Pract. 1996 Jul;192(7):712-7 [8880872.001]
  • [Cites] Med Hypotheses. 1997 Jan;48(1):37-46 [9049988.001]
  • [Cites] Hepatology. 1997 Dec;26(6):1458-66 [9397985.001]
  • [Cites] Am J Surg Pathol. 1998 Feb;22(2):141-7 [9500214.001]
  • [Cites] Jpn J Clin Oncol. 1998 Oct;28(10):615-20 [9839502.001]
  • [Cites] Int J Cancer. 1999 May 17;81(4):629-36 [10225455.001]
  • [Cites] Nat Med. 1999 Jun;5(6):662-8 [10371505.001]
  • [Cites] Cancer Metastasis Rev. 1998-1999;17(4):411-9 [10453285.001]
  • [Cites] Clin Gastroenterol Hepatol. 2005 Apr;3(4):370-5 [15822042.001]
  • [Cites] Histopathology. 2005 Jun;46(6):635-41 [15910594.001]
  • [Cites] J Clin Pathol. 2005 Dec;58(12):1311-4 [16311353.001]
  • [Cites] Oral Oncol. 2006 Nov;42(10):1011-6 [16757205.001]
  • [Cites] Appl Immunohistochem Mol Morphol. 2008 Jan;16(1):48-53 [18091320.001]
  • [Cites] Mol Endocrinol. 1992 Jan;6(1):15-25 [1738367.001]
  • [Cites] Proc Natl Acad Sci U S A. 1993 Feb 1;90(3):999-1003 [8430113.001]
  • [Cites] J Surg Oncol. 1993 May;53(1):36-42 [8479195.001]
  • [Cites] Lab Invest. 1993 Jun;68(6):696-707 [8515656.001]
  • [Cites] J Cell Biol. 1993 Jul;122(1):103-11 [8314838.001]
  • [Cites] J Clin Invest. 1993 Dec;92(6):2569-76 [7504687.001]
  • [Cites] Cell. 1996 Aug 23;86(4):531-42 [8752208.001]
  • [Cites] Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 1996 Jun;81(6):655-64 [8784897.001]
  • [Cites] J Clin Invest. 1995 Feb;95(2):859-73 [7532191.001]
  • [Cites] Gastroenterology. 1996 Feb;110(2):375-82 [8566583.001]
  • [Cites] Lab Invest. 1996 Apr;74(4):781-96 [8606488.001]
  • [Cites] J Cell Biol. 1996 Jul;134(2):401-11 [8707825.001]
  • (PMID = 20614261.001).
  • [ISSN] 1936-0568
  • [Journal-full-title] Head and neck pathology
  • [ISO-abbreviation] Head Neck Pathol
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Actins; 0 / Biomarkers, Tumor
  • [Other-IDs] NLM/ PMC2807519
  • [Keywords] NOTNLM ; Carcinoma ex-pleomorphic adenoma / Desmoplasia / Front of invasion / Immunohistochemistry / Intracapsular carcinoma ex-pleomorphic adenoma / Invasive carcinoma ex-pleomorphic adenoma / Malignant transformation of pleomorphic adenoma / Myofibroblast / α-Smooth muscle actin
  •  go-up   go-down


55. Rivera M, Tuttle RM, Patel S, Shaha A, Shah JP, Ghossein RA: Encapsulated papillary thyroid carcinoma: a clinico-pathologic study of 106 cases with emphasis on its morphologic subtypes (histologic growth pattern). Thyroid; 2009 Feb;19(2):119-27
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Encapsulated papillary thyroid carcinoma: a clinico-pathologic study of 106 cases with emphasis on its morphologic subtypes (histologic growth pattern).
  • CONCLUSION: E-CPTC resembles classical PTC in its propensity to metastasize to lymph nodes and its vascular/capsular invasive pattern while E-FVPTC behaves more like follicular carcinoma/adenoma group of tumors.
  • [MeSH-minor] Adenocarcinoma, Follicular / pathology. Adenocarcinoma, Papillary / pathology. Adult. Aged, 80 and over. Carcinoma, Papillary / pathology. Female. Humans. Lymphatic Metastasis / pathology. Male. Middle Aged. Neoplasm Invasiveness / pathology. Retrospective Studies. Treatment Outcome


56. Götz R: Inter-cellular adhesion disruption and the RAS/RAF and beta-catenin signalling in lung cancer progression. Cancer Cell Int; 2008;8:7
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Mutational activation of protein kinases and loss of cell adhesion occur together in human lung adenocarcinoma but how these two pathways interconnect is only poorly understood.
  • Mouse models of human lung adenocarcinoma with oncogene expression targeted to subtypes of lung epithelial cells led to formation of adenomas or adenocarcinomas that lacked metastatic potential.
  • Conditional genetic abrogation of epithelial tumour cell adhesion in mice with benign lung tumours induced by oncogenic RAF kinase has been demonstrated to induce intratumourous vascularization (angiogenic switch), progression to invasive adenocarcinoma and micrometastasis.

  • Mouse Genome Informatics (MGI). Mouse Genome Informatics (MGI) .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Mol Cell Biol. 1994 Sep;14(9):5671-81 [8065304.001]
  • [Cites] Proc Natl Acad Sci U S A. 1994 Mar 1;91(5):1858-62 [8127895.001]
  • [Cites] J Cell Biol. 1993 Feb;120(3):757-66 [8425900.001]
  • [Cites] Dev Biol. 1993 Apr;156(2):426-43 [8462742.001]
  • [Cites] Nature. 1995 Dec 21-28;378(6559):785-9 [8524413.001]
  • [Cites] Curr Opin Cell Biol. 1995 Oct;7(5):619-27 [8573335.001]
  • [Cites] Oncogene. 1996 Sep 5;13(5):883-9 [8806677.001]
  • [Cites] Histol Histopathol. 1996 Apr;11(2):463-83 [8861769.001]
  • [Cites] Science. 1997 Mar 21;275(5307):1787-90 [9065402.001]
  • [Cites] Science. 1997 Mar 21;275(5307):1790-2 [9065403.001]
  • [Cites] Cancer. 1997 Apr 15;79(8):1521-6 [9118033.001]
  • [Cites] Cell. 1997 Sep 5;90(5):871-82 [9298899.001]
  • [Cites] J Biol Chem. 1998 Mar 13;273(11):6166-70 [9497337.001]
  • [Cites] Cancer Res. 1998 Mar 1;58(5):1021-6 [9500465.001]
  • [Cites] Cancer Res. 1998 Mar 15;58(6):1130-4 [9515795.001]
  • [Cites] Mol Cell Biol. 1998 Oct;18(10):5762-70 [9742093.001]
  • [Cites] J Cell Biol. 1999 Feb 22;144(4):687-99 [10037790.001]
  • [Cites] J Cell Sci. 1999 Apr;112 ( Pt 8):1237-45 [10085258.001]
  • [Cites] Dev Biol. 1999 May 1;209(1):60-71 [10208743.001]
  • [Cites] Biochem Biophys Res Commun. 1999 Aug 2;261(2):406-11 [10425198.001]
  • [Cites] Mol Cell. 1999 Aug;4(2):199-207 [10488335.001]
  • [Cites] EMBO J. 1999 Nov 1;18(21):5931-42 [10545105.001]
  • [Cites] J Biol Chem. 1999 Dec 17;274(51):36734-40 [10593980.001]
  • [Cites] Nature. 2000 Jan 6;403(6765):41-5 [10638745.001]
  • [Cites] J Biol Chem. 2000 Apr 21;275(16):11858-64 [10766812.001]
  • [Cites] Cell Growth Differ. 2000 Apr;11(4):185-90 [10775035.001]
  • [Cites] Science. 2000 Aug 18;289(5482):1197-202 [10947988.001]
  • [Cites] Genes Dev. 2000 Oct 1;14(19):2501-14 [11018017.001]
  • [Cites] Genes Chromosomes Cancer. 2001 Mar;30(3):316-21 [11170292.001]
  • [Cites] Cancer Res. 2001 Jan 1;61(1):249-55 [11196170.001]
  • [Cites] Br J Cancer. 2001 Mar 23;84(6):813-8 [11259097.001]
  • [Cites] J Biol Chem. 2001 Jun 8;276(23):20436-43 [11279024.001]
  • [Cites] Cell. 2001 May 4;105(3):391-402 [11348595.001]
  • [Cites] Cell. 2005 Jun 17;121(6):823-35 [15960971.001]
  • [Cites] Cancer Res. 2005 Jul 1;65(13):5561-70 [15994928.001]
  • [Cites] Nature. 2005 Aug 4;436(7051):642 [16079833.001]
  • [Cites] Hum Pathol. 2005 Jul;36(7):768-76 [16084946.001]
  • [Cites] PLoS Med. 2005 Nov;2(11):e313 [16187797.001]
  • [Cites] Curr Biol. 2005 Nov 22;15(22):1989-97 [16303557.001]
  • [Cites] Cell. 2005 Dec 2;123(5):889-901 [16325582.001]
  • [Cites] Carcinogenesis. 2006 Apr;27(4):729-39 [16332724.001]
  • [Cites] Immunity. 2005 Dec;23(6):599-609 [16356858.001]
  • [Cites] Nat Rev Cancer. 2006 Mar;6(3):184-92 [16453012.001]
  • [Cites] Cancer Res. 2006 Feb 15;66(4):2279-86 [16489032.001]
  • [Cites] CA Cancer J Clin. 2006 Mar-Apr;56(2):106-30 [16514137.001]
  • [Cites] Genome Res. 2006 May;16(5):595-605 [16606705.001]
  • [Cites] Am J Surg Pathol. 2006 May;30(5):606-13 [16699315.001]
  • [Cites] Cancer Cell. 2006 Jun;9(6):485-95 [16730237.001]
  • [Cites] Development. 2006 Jul;133(13):2455-65 [16735479.001]
  • [Cites] Int J Cancer. 2006 Nov 15;119(10):2261-71 [16894562.001]
  • [Cites] Semin Cancer Biol. 2006 Aug;16(4):253-64 [16904903.001]
  • [Cites] Nat Immunol. 2006 Oct;7(10):1048-56 [16951689.001]
  • [Cites] Gastroenterology. 2006 Oct;131(4):1096-109 [17030180.001]
  • [Cites] Nat Rev Cancer. 2006 Nov;6(11):846-56 [17060944.001]
  • [Cites] Methods Enzymol. 2006;419:285-321 [17141060.001]
  • [Cites] Genes Dev. 2007 Feb 15;21(4):379-84 [17299132.001]
  • [Cites] Cell. 2007 Feb 23;128(4):735-45 [17320510.001]
  • [Cites] Nat Rev Mol Cell Biol. 2007 May;8(5):369-78 [17377526.001]
  • [Cites] Nat Rev Genet. 2007 May;8(5):341-52 [17440531.001]
  • [Cites] Cancer Sci. 2007 Jul;98(7):1006-13 [17459054.001]
  • [Cites] Cancer Res. 2007 May 15;67(10):4933-9 [17510423.001]
  • [Cites] Cell. 2007 Jun 1;129(5):957-68 [17540175.001]
  • [Cites] Nature. 2007 Jul 19;448(7151):318-24 [17554336.001]
  • [Cites] Nature. 2007 Jul 26;448(7152):445-51 [17597761.001]
  • [Cites] Nature. 2007 Jul 19;448(7151):260-2 [17637646.001]
  • [Cites] Chest. 2007 Sep;132(3 Suppl):29S-55S [17873159.001]
  • [Cites] Arch Toxicol. 1991;65(2):81-94 [1711838.001]
  • [Cites] Exp Cell Res. 1967 Apr;46(1):144-54 [6025276.001]
  • [Cites] J Cell Biol. 1995 Jul;130(2):461-71 [7542250.001]
  • [Cites] Mol Cell Biol. 1995 Aug;15(8):4553-61 [7623846.001]
  • [Cites] Biochem Biophys Res Commun. 1995 Mar 28;208(3):1067-72 [7702605.001]
  • [Cites] Cell Adhes Commun. 1994 Aug;2(4):319-27 [7820535.001]
  • [Cites] J Cell Biol. 1994 Dec;127(5):1375-80 [7962096.001]
  • [Cites] Biochem Biophys Res Commun. 1994 Nov 30;205(1):73-8 [7999105.001]
  • [Cites] Oncogene. 2007 Jul 26;26(34):5023-7 [17311002.001]
  • [Cites] Cell Biol Int. 2007 Apr;31(4):366-73 [17336101.001]
  • [Cites] Nature. 2007 Apr 5;446(7136):676-9 [17377531.001]
  • [Cites] Oncogene. 2007 May 14;26(22):3113-21 [17496910.001]
  • [Cites] J Pathol. 2007 Jul;212(3):287-94 [17534846.001]
  • [Cites] Nature. 2007 Jul 19;448(7151):313-7 [17554338.001]
  • [Cites] Cell. 2007 Jun 29;129(7):1261-74 [17604717.001]
  • [Cites] Cancer Cell. 2007 Aug;12(2):145-59 [17692806.001]
  • [Cites] Nature. 2007 Oct 11;449(7163):682-8 [17898713.001]
  • [Cites] Nat Biotechnol. 2008 Jan;26(1):101-6 [18059259.001]
  • [Cites] Cancer Metastasis Rev. 2008 Jun;27(2):147-58 [18246411.001]
  • [Cites] Cancer Res. 2001 May 15;61(10):3986-97 [11358816.001]
  • [Cites] Langenbecks Arch Surg. 2001 Jul;386(4):293-301 [11466572.001]
  • [Cites] Oncogene. 2001 Oct 4;20(45):6551-8 [11641780.001]
  • [Cites] Ann Epidemiol. 2001 Nov;11(8):547-53 [11709274.001]
  • [Cites] Cancer Res. 2002 Apr 1;62(7):2064-71 [11929826.001]
  • [Cites] Mech Dev. 2002 Jul;115(1-2):53-62 [12049767.001]
  • [Cites] Nature. 2002 Jun 27;417(6892):949-54 [12068308.001]
  • [Cites] J Clin Oncol. 2002 Jul 1;20(13):2930-6 [12089221.001]
  • [Cites] Am J Pathol. 2002 Jul;161(1):173-82 [12107102.001]
  • [Cites] Cancer Res. 2002 Nov 1;62(21):6297-303 [12414660.001]
  • [Cites] Exp Hematol. 2002 Nov;30(11):1333-8 [12423687.001]
  • [Cites] Nat Rev Cancer. 2003 Jan;3(1):11-22 [12509763.001]
  • [Cites] Chest. 2003 Jan;123(1 Suppl):97S-104S [12527569.001]
  • [Cites] Mol Cell Biol. 2003 Apr;23(7):2287-97 [12640114.001]
  • [Cites] Nature. 2003 May 22;423(6938):409-14 [12717450.001]
  • [Cites] Cancer Res. 2003 May 1;63(9):2268-77 [12727849.001]
  • [Cites] Nat Rev Cancer. 2003 Jun;3(6):459-65 [12778136.001]
  • [Cites] Cancer Cell. 2003 Aug;4(2):111-20 [12957286.001]
  • [Cites] Nat Rev Cancer. 2004 Feb;4(2):118-32 [14964308.001]
  • [Cites] Nat Rev Cancer. 2004 Mar;4(3):177-83 [14993899.001]
  • [Cites] N Engl J Med. 2004 May 20;350(21):2129-39 [15118073.001]
  • [Cites] Science. 2004 Jun 4;304(5676):1497-500 [15118125.001]
  • [Cites] Br J Cancer. 2004 Jul 19;91(2):355-8 [15188009.001]
  • [Cites] J Cell Sci. 2004 Jul 1;117(Pt 15):3207-19 [15226396.001]
  • [Cites] Nat Cell Biol. 2004 Oct;6(10):931-40 [15448698.001]
  • [Cites] Nature. 2004 Sep 30;431(7008):525-6 [15457249.001]
  • [Cites] J Cell Biol. 2004 Oct 25;167(2):339-49 [15492040.001]
  • [Cites] Nat Rev Mol Cell Biol. 2004 Nov;5(11):875-85 [15520807.001]
  • [Cites] APMIS. 2005 Jan;113(1):54-7 [15676015.001]
  • [Cites] Development. 2005 Mar;132(6):1363-74 [15716345.001]
  • [Cites] Cancer Lett. 2005 May 10;222(1):1-10 [15837535.001]
  • [Cites] Nat Rev Cancer. 2007 Oct;7(10):778-90 [17882278.001]
  • [Cites] Nature. 2007 Dec 6;450(7171):893-8 [17982442.001]
  • [Cites] Cell Cycle. 2008 Jan 1;7(1):45-51 [18196970.001]
  • [Cites] Oncogene. 2008 Jun 5;27(25):3635-40 [18212743.001]
  • [Cites] Cell Stem Cell. 2007 Jun 7;1(1):55-70 [18371336.001]
  • [Cites] Nat Rev Cancer. 2003 Jun;3(6):401-10 [12778130.001]
  • [Cites] Biochim Biophys Acta. 2003 Jun 5;1653(1):1-24 [12781368.001]
  • [Cites] Annu Rev Physiol. 2004;66:601-23 [14977415.001]
  • [Cites] Science. 2004 Mar 5;303(5663):1483-7 [15001769.001]
  • [Cites] J Biol. 2004;3(3):11 [15186480.001]
  • [Cites] Cell. 2004 Jun 25;117(7):927-39 [15210113.001]
  • [Cites] Genes Dev. 2004 Sep 15;18(18):2225-30 [15371335.001]
  • [Cites] Nature. 2004 Oct 28;431(7012):1112-7 [15475948.001]
  • [Cites] Trends Cell Biol. 2004 Nov;14(11):639-47 [15519853.001]
  • [Cites] Cell Res. 2005 Jan;15(1):28-32 [15686623.001]
  • [Cites] EMBO J. 2005 Apr 20;24(8):1571-83 [15791206.001]
  • [Cites] Nat Rev Mol Cell Biol. 2005 Aug;6(8):635-45 [16064138.001]
  • [Cites] Trends Cell Biol. 2005 Sep;15(9):494-501 [16084092.001]
  • [Cites] Cancer Res. 2005 Nov 1;65(21):9719-26 [16266992.001]
  • [Cites] Lung Cancer. 2006 Feb;51(2):181-91 [16324768.001]
  • [Cites] Cell. 2005 Dec 2;123(5):903-15 [16325583.001]
  • [Cites] Cancer Res. 2006 Jan 1;66(1):283-9 [16397241.001]
  • [Cites] Genes Dev. 2006 Feb 15;20(4):399-410 [16481469.001]
  • [Cites] Cell. 2006 Mar 24;124(6):1111-5 [16564000.001]
  • [Cites] Development. 2006 May;133(9):1611-24 [16613830.001]
  • [Cites] Genes Dev. 2006 Jun 1;20(11):1496-510 [16705038.001]
  • [Cites] Genes Dev. 2006 Jun 1;20(11):1394-404 [16751178.001]
  • [Cites] Cell. 2006 Aug 25;126(4):663-76 [16904174.001]
  • [Cites] Nat Immunol. 2006 Oct;7(10):1037-47 [16951686.001]
  • [Cites] Biochem Soc Trans. 2006 Nov;34(Pt 5):647-62 [17052169.001]
  • [Cites] Cancer Cell. 2006 Nov;10(5):437-49 [17097565.001]
  • (PMID = 18492263.001).
  • [ISSN] 1475-2867
  • [Journal-full-title] Cancer cell international
  • [ISO-abbreviation] Cancer Cell Int.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC2427011
  •  go-up   go-down


57. Chen JM, Li WH, Wang JD, Feng YD, Wu JH, Gong JP: [Cell balance between apoptosis and proliferation in colon cancer and its correlation with prognosis]. Ai Zheng; 2005 May;24(5):554-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • RESULTS: AI/PI ratio of cells was significantly higher in normal colon tissue than in colon adenoma tissue, Dukes' A colon cancer, Dukes' B colon cancer, and Dukes' C and D colon cancer (0.45+/-0.19 vs. 0.30+/-0.07, 0.29+/-0.11, 0.28+/-0.10, and 0.26+/-0.07, respectively, P < 0.01).
  • The expression of Ki-67 was observed in normal colon tissue, colon adenoma, and colon cancer under confocal microscope.
  • [MeSH-minor] Adenocarcinoma / metabolism. Adenocarcinoma / pathology. Adenoma / metabolism. Adenoma / pathology. Adult. Aged. Cell Proliferation. Female. Follow-Up Studies. Homeostasis. Humans. Ki-67 Antigen / metabolism. Male. Middle Aged. Neoplasm Staging. Prognosis

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15890096.001).
  • [Journal-full-title] Ai zheng = Aizheng = Chinese journal of cancer
  • [ISO-abbreviation] Ai Zheng
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Ki-67 Antigen
  •  go-up   go-down


58. Russo P: Partial nephrectomy achieves local tumor control and prevents chronic kidney disease. Expert Rev Anticancer Ther; 2006 Dec;6(12):1745-51
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [MeSH-minor] Adenocarcinoma, Clear Cell / pathology. Adenocarcinoma, Clear Cell / surgery. Adenoma, Oxyphilic / pathology. Adenoma, Oxyphilic / surgery. Carcinoma, Papillary / pathology. Carcinoma, Papillary / surgery. Carcinoma, Renal Cell / pathology. Carcinoma, Renal Cell / surgery. Cardiovascular Diseases / etiology. Cardiovascular Diseases / mortality. Chronic Disease. Humans. Kidney Cortex / surgery. Kidney Diseases / etiology. Kidney Diseases / prevention & control. Kidney Function Tests. Kidney Transplantation. Postoperative Complications / etiology. Postoperative Complications / prevention & control. Tissue Donors. Treatment Outcome

  • Genetic Alliance. consumer health - Kidney Disease.
  • MedlinePlus Health Information. consumer health - Kidney Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17181488.001).
  • [ISSN] 1744-8328
  • [Journal-full-title] Expert review of anticancer therapy
  • [ISO-abbreviation] Expert Rev Anticancer Ther
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Number-of-references] 42
  •  go-up   go-down


59. Barrier F, de La Guerenne A, Semjen E, Wierre L, Horrent S, Decaudin B, Resibois JP, Weillaert MP, Azar R, Odou P: [Spontaneously acquired haemophilia: report of a patient with prostatic adenoma]. Ann Biol Clin (Paris); 2006 Jul-Aug;64(4):347-52
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Spontaneously acquired haemophilia: report of a patient with prostatic adenoma].
  • A prostatic adenocarcinoma was suspected: a 5 cm prostatic tumour was found and the PSA level was 113 ng/mL.
  • The patient's disease was identified as a spontaneously acquired haemophilia A associated with prostatic adenocarcinoma.
  • [MeSH-major] Adenoma / complications. Hemophilia A / etiology. Prostatic Neoplasms / blood. Prostatic Neoplasms / complications

  • MedlinePlus Health Information. consumer health - Hemophilia.
  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16829479.001).
  • [ISSN] 0003-3898
  • [Journal-full-title] Annales de biologie clinique
  • [ISO-abbreviation] Ann. Biol. Clin. (Paris)
  • [Language] fre
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] France
  • [Chemical-registry-number] 0 / Triazines; 55824-91-4 / 4-azido-7-phenylpyrazolo-(1,5a)-1,3,5-triazine; 9001-27-8 / Factor VIII; EC 3.4.21.77 / Prostate-Specific Antigen
  •  go-up   go-down


60. Winter JM, Cameron JL, Olino K, Herman JM, de Jong MC, Hruban RH, Wolfgang CL, Eckhauser F, Edil BH, Choti MA, Schulick RD, Pawlik TM: Clinicopathologic analysis of ampullary neoplasms in 450 patients: implications for surgical strategy and long-term prognosis. J Gastrointest Surg; 2010 Feb;14(2):379-87
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • METHODS: Between 1970 and 2007, 450 patients who underwent surgical resection of ampullary adenoma or adenocarcinoma were identified from a prospective, single-institution database.
  • Final diagnosis was invasive adenocarcinoma (77.1%) or adenoma (22.9%).
  • Median tumor size was similar for adenomas associated with an adenocarcinoma (2.5 cm) versus adenomas without invasive cancer (2.9 cm; P=0.71).
  • Metastatic disease to regional lymph nodes was present in 54.5% patients with adenocarcinoma.
  • CONCLUSION: When surgery is indicated, radical resection is required for early invasive adenocarcinoma of the ampulla of Vater, as lymph node metastases are present in nearly 30% of patients with T1 disease.
  • [MeSH-major] Adenocarcinoma / surgery. Adenoma / surgery. Ampulla of Vater / surgery. Common Bile Duct Neoplasms / surgery

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Arch Surg. 1996 Apr;131(4):366-71 [8615720.001]
  • [Cites] Ann Surg. 1997 May;225(5):590-9; discussion 599-600 [9193186.001]
  • [Cites] J Gastrointest Surg. 2006 Nov;10(9):1280-90; discussion 1290 [17114014.001]
  • [Cites] World J Surg. 1999 Sep;23(9):901-6 [10449818.001]
  • [Cites] Surg Endosc. 2006 Apr;20(4):608-13 [16508819.001]
  • [Cites] Ann Surg. 1998 Jul;228(1):87-94 [9671071.001]
  • [Cites] Ann Surg. 1996 Nov;224(5):621-7 [8916877.001]
  • [Cites] J BUON. 2008 Oct-Dec;13(4):569-72 [19145682.001]
  • [Cites] World J Surg. 1996 Jul-Aug;20(6):707-12 [8662157.001]
  • [Cites] J Gastrointest Surg. 2005 Dec;9(9):1191-204; discussion 1204-6 [16332474.001]
  • [Cites] J Gastrointest Surg. 2006 Nov;10(9):1199-210; discussion 1210-1 [17114007.001]
  • [Cites] World J Surg. 1997 May;21(4):379-83 [9143568.001]
  • [Cites] Am Surg. 1995 Jul;61(7):607-11 [7793742.001]
  • [Cites] ANZ J Surg. 2001 Sep;71(9):529-33 [11527262.001]
  • [Cites] Adv Surg. 1996;30:293-310 [8960341.001]
  • [Cites] Aust N Z J Surg. 1999 Mar;69(3):195-8 [10075358.001]
  • [Cites] Ann Surg. 1995 Jan;221(1):43-9 [7826160.001]
  • [Cites] World J Surg. 2007 Jan;31(1):137-43; discussion 144-6 [17171495.001]
  • [Cites] Hepatogastroenterology. 2008 Jul-Aug;55(85):1463-9 [18795713.001]
  • [Cites] Ann Surg. 1997 Sep;226(3):248-57; discussion 257-60 [9339931.001]
  • [Cites] Ann Surg. 1935 Oct;102(4):763-79 [17856666.001]
  • [Cites] Gastrointest Endosc. 2004 Feb;59(2):225-32 [14745396.001]
  • [Cites] Arch Surg. 2005 Jun;140(6):529-32; discussion 532-3 [15967899.001]
  • [Cites] J Hepatobiliary Pancreat Surg. 2008;15(4):423-8 [18670845.001]
  • [Cites] Ann Surg. 2000 Sep;232(3):419-29 [10973392.001]
  • [Cites] Arch Surg. 1991 Mar;126(3):353-7 [1998478.001]
  • [Cites] World J Surg Oncol. 2006 Mar 08;4:14 [16524478.001]
  • [Cites] Ann Surg Oncol. 2007 Jan;14(1):50-60 [17054003.001]
  • [Cites] Ann Surg. 1993 Sep;218(3):229-37; discussion 237-8 [8103982.001]
  • [Cites] J Surg Oncol. 1991 Jul;47(3):148-54 [2072697.001]
  • [Cites] World J Surg. 2005 Apr;29(4):513-8 [15776300.001]
  • [Cites] Int Semin Surg Oncol. 2005 Aug 30;2:16 [16131399.001]
  • [Cites] Gastrointest Endosc Clin N Am. 1997 Jul;7(3):387-99 [9177141.001]
  • [Cites] Br J Surg. 1994 May;81(5):668-71 [7913860.001]
  • [Cites] Eur J Gastroenterol Hepatol. 2000 Jan;12(1):75-9 [10656214.001]
  • [Cites] Arch Surg. 1999 May;134(5):526-32 [10323425.001]
  • [Cites] Br J Surg. 1995 Dec;82(12):1693-6 [8548244.001]
  • [Cites] Ann Surg. 2005 Jul;242(1):92-100 [15973106.001]
  • [Cites] World J Surg. 2005 May;29(5):649-52 [15827855.001]
  • [Cites] Am J Surg. 1983 Nov;146(5):539-50 [6356946.001]
  • [Cites] Virchows Arch. 2002 Jul;441(1):19-24 [12111196.001]
  • [Cites] Ann Surg. 1998 Sep;228(3):429-38 [9742926.001]
  • [Cites] Mod Pathol. 2003 Mar;16(3):272-8 [12640108.001]
  • (PMID = 19911239.001).
  • [ISSN] 1873-4626
  • [Journal-full-title] Journal of gastrointestinal surgery : official journal of the Society for Surgery of the Alimentary Tract
  • [ISO-abbreviation] J. Gastrointest. Surg.
  • [Language] eng
  • [Grant] United States / NCRR NIH HHS / RR / 1KL2RR025006-01
  • [Publication-type] Comparative Study; Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  •  go-up   go-down


61. Chetty R, Serra S: Intraductal tubular adenoma (pyloric gland-type) of the pancreas: a reappraisal and possible relationship with gastric-type intraductal papillary mucinous neoplasm. Histopathology; 2009 Sep;55(3):270-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Intraductal tubular adenoma (pyloric gland-type) of the pancreas: a reappraisal and possible relationship with gastric-type intraductal papillary mucinous neoplasm.
  • AIMS: Intraductal tubular adenoma (ITA) is an uncommon intraluminal polypoid lesion that occurs in the main pancreatic duct and involves the main pancreatic duct in the region of head or body.
  • [MeSH-major] Adenocarcinoma, Mucinous / pathology. Adenocarcinoma, Papillary / pathology. Adenoma / pathology. Carcinoma in Situ / pathology. Pancreatic Ducts / pathology. Pancreatic Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Histopathology. 2010 Jun;56(7):968-9; author reply 969 [20636797.001]
  • (PMID = 19723141.001).
  • [ISSN] 1365-2559
  • [Journal-full-title] Histopathology
  • [ISO-abbreviation] Histopathology
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  •  go-up   go-down


62. Kim KM, Lee EJ, Kim YH, Chang DK, Odze RD: KRAS mutations in traditional serrated adenomas from Korea herald an aggressive phenotype. Am J Surg Pathol; 2010 May;34(5):667-75
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] KRAS mutations in traditional serrated adenomas from Korea herald an aggressive phenotype.
  • The pathogenesis and risk of malignancy of traditional serrated adenomas (TSAs) are unclear.
  • In North America, TSAs are relatively uncommon, occur mainly in the left colon, and in some studies, have not been shown to have a strong association with hyperplastic polyp (HPP) or sessile polyp adenoma (SSA) precursor lesions.
  • One hundred and twelve TSAs were evaluated pathologically and categorized according to the grade of dysplasia (either low or high grade) and the presence or absence of adenocarcinoma.
  • As controls 35 conventional adenomas were evaluated, 14 of which had adenocarcinoma.
  • TSAs with high-grade dysplasia and intramucosal adenocarcinoma showed a significantly higher frequency of KRAS mutation and MGMT methylation, and a significantly lower frequency of BRAF mutations, compared with TSAs with low-grade dysplasia (P<0.05).
  • [MeSH-major] Adenoma / pathology. Colonic Neoplasms / pathology. Mutation. Precancerous Conditions / pathology. Proto-Oncogene Proteins / genetics. ras Proteins / genetics

  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20305537.001).
  • [ISSN] 1532-0979
  • [Journal-full-title] The American journal of surgical pathology
  • [ISO-abbreviation] Am. J. Surg. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / DNA, Neoplasm; 0 / KRAS protein, human; 0 / Proto-Oncogene Proteins; 0 / Tumor Suppressor Proteins; EC 2.1.1.- / DNA Modification Methylases; EC 2.1.1.63 / MGMT protein, human; EC 2.7.11.1 / BRAF protein, human; EC 2.7.11.1 / Proto-Oncogene Proteins B-raf; EC 3.6.5.2 / ras Proteins; EC 6.5.1.- / DNA Repair Enzymes
  •  go-up   go-down


63. Wang IC, Meliton L, Tretiakova M, Costa RH, Kalinichenko VV, Kalin TV: Transgenic expression of the forkhead box M1 transcription factor induces formation of lung tumors. Oncogene; 2008 Jul 10;27(30):4137-49
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Cell culture experiments with A549 human lung adenocarcinoma cells demonstrated that depletion of Foxm1 by either short interfering RNA transfection or treatment with Foxm1-inhibiting ARF 26-44 peptide significantly reduced Cox-2 expression.
  • [MeSH-major] Adenoma / genetics. Forkhead Transcription Factors / genetics. Lung Neoplasms / genetics

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. 2,6-DI-T-BUTYL-P-CRESOL .
  • Hazardous Substances Data Bank. 3-Methylcholanthrene .
  • Mouse Genome Informatics (MGI). Mouse Genome Informatics (MGI) .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18345025.001).
  • [ISSN] 1476-5594
  • [Journal-full-title] Oncogene
  • [ISO-abbreviation] Oncogene
  • [Language] eng
  • [Grant] United States / NIDDK NIH HHS / DK / DK 54687-06
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Forkhead Transcription Factors; 0 / Foxm1 protein, mouse; 1P9D0Z171K / Butylated Hydroxytoluene; 56-49-5 / Methylcholanthrene; EC 1.14.99.- / Ptgs2 protein, mouse; EC 1.14.99.1 / Cyclooxygenase 2
  •  go-up   go-down


64. Gourgiotis S, Ridolfini MP, Germanos S: Intraductal papillary mucinous neoplasms of the pancreas. Eur J Surg Oncol; 2007 Aug;33(6):678-84
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Presence of a large branch type IPMN and marked dilatation of the main duct indicate the existence of adenoma at least.
  • [MeSH-minor] Adenocarcinoma, Mucinous / diagnosis. Carcinoma, Pancreatic Ductal / diagnosis. Carcinoma, Papillary / diagnosis. Dilatation, Pathologic / pathology. Humans. Prognosis

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17207960.001).
  • [ISSN] 0748-7983
  • [Journal-full-title] European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology
  • [ISO-abbreviation] Eur J Surg Oncol
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Number-of-references] 76
  •  go-up   go-down


65. Yokohira M, Matsuda Y, Suzuki S, Hosokawa K, Yamakawa K, Hashimoto N, Saoo K, Nabae K, Doi Y, Kuno T, Imaida K: Equivocal colonic carcinogenicity of Aloe arborescens Miller var. natalensis berger at high-dose level in a Wistar Hannover rat 2-y study. J Food Sci; 2009 Mar;74(2):T24-30
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Adenomas or adenocarcinomas in the cecum, colon, and rectum were observed in 4% males but not in the 0.8% and control male groups.
  • Similarly, in females, adenomas in the colon were also observed in the 4% but not 0.8% and control groups.

  • Hazardous Substances Data Bank. EMODIN .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19323775.001).
  • [ISSN] 1750-3841
  • [Journal-full-title] Journal of food science
  • [ISO-abbreviation] J. Food Sci.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Glucosides; 0 / Plant Extracts; 38412-46-3 / aloenin; KA46RNI6HN / Emodin; W41H6S09F4 / alloin
  •  go-up   go-down


66. Chu PG, Lau SK, Weiss LM, Jiang Z: Intestinal type of mucinous borderline tumor arising from mixed epithelial and stromal tumor of kidney. Virchows Arch; 2009 Oct;455(4):389-94
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • In areas, the mucinous epithelium showed complex proliferation with stratification, papillae formation, and nuclear atypia, resembling that of an ovarian mucinous borderline tumor, a colorectal tubular adenoma, or a low-grade appendiceal mucinous carcinoma.
  • [MeSH-major] Adenocarcinoma, Mucinous / pathology. Kidney Neoplasms / pathology. Neoplasms, Glandular and Epithelial / pathology

  • MedlinePlus Health Information. consumer health - Kidney Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Urol. 2001 Oct;166(4):1381-2 [11547080.001]
  • [Cites] Am J Surg Pathol. 2007 Apr;31(4):489-500 [17414095.001]
  • [Cites] Arch Pathol Lab Med. 2006 Jan;130(1):80-5 [16390243.001]
  • [Cites] Virchows Arch. 2004 Oct;445(4):359-67 [15322873.001]
  • [Cites] Am J Surg Pathol. 2008 Jun;32(6):884-90 [18425046.001]
  • [Cites] Am J Surg Pathol. 2009 Jan;33(1):72-80 [18971776.001]
  • [Cites] Hum Pathol. 2007 Sep;38(9):1432-7 [17707262.001]
  • [Cites] APMIS. 2008 Nov;116(11):1013-5 [19133001.001]
  • [Cites] Hum Pathol. 2008 Mar;39(3):463-8 [18261632.001]
  • [Cites] Histopathology. 2004 Mar;44(3):302-4 [14987239.001]
  • [Cites] Am J Surg Pathol. 1993 Nov;17(11):1169-75 [8214262.001]
  • [Cites] Virchows Arch. 2005 Sep;447(3):669-71 [16025280.001]
  • [Cites] Am J Surg Pathol. 2006 Sep;30(9):1130-9 [16931958.001]
  • [Cites] Virchows Arch. 2001 Nov;439(5):700-2 [11764393.001]
  • [Cites] Int J Gynecol Pathol. 2002 Oct;21(4):391-400 [12352188.001]
  • [Cites] Pathol Res Pract. 1998;194(6):445-8 [9689654.001]
  • [Cites] Am J Surg Pathol. 2000 Jul;24(7):958-70 [10895818.001]
  • (PMID = 19756727.001).
  • [ISSN] 1432-2307
  • [Journal-full-title] Virchows Archiv : an international journal of pathology
  • [ISO-abbreviation] Virchows Arch.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


67. Pu RT, Yang J, Wasserman PG, Bhuiya T, Griffith KA, Michael CW: Does Hurthle cell lesion/neoplasm predict malignancy more than follicular lesion/neoplasm on thyroid fine-needle aspiration? Diagn Cytopathol; 2006 May;34(5):330-4
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Upon excision, the FNA diagnosis of HLN group had 14 cases of goiter/nodular hyperplasia (16%), 46 cases of adenoma (12 follicular adenoma (14%) and 34 cases of Hurthle cell adenoma (39%)), and 27 cases of carcinoma (31%, 12 papillary carcinoma and 15 Hurthle cell carcinoma).
  • The FLN group had 74 cases of goiter/nodular hyperplasia (34.3%), 8 cases of Hashimoto thyroiditis (3.7%), 73 cases of follicular adenoma (33.8%), one case of granular cell tumor, and 60 cases of carcinoma (27.8%, 46 papillary carcinoma, 12 follicular carcinoma, and 1 Hurthle cell carcinoma and 1 parathyroid carcinoma) upon excision.
  • [MeSH-major] Adenocarcinoma, Follicular / pathology. Adenoma / pathology. Adenoma, Oxyphilic / pathology. Biopsy, Fine-Needle / methods. Oxyphil Cells / pathology. Thyroid Neoplasms / pathology
  • [MeSH-minor] Adenocarcinoma, Papillary / pathology. Adenocarcinoma, Papillary / surgery. Adolescent. Adult. Aged. Aged, 80 and over. Cohort Studies. Female. Goiter, Nodular / pathology. Goiter, Nodular / surgery. Humans. Hyperplasia / pathology. Hyperplasia / surgery. Male. Middle Aged. Prognosis. Thyroid Nodule / pathology. Thyroid Nodule / surgery. Thyroidectomy

  • MedlinePlus Health Information. consumer health - Thyroid Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16604553.001).
  • [ISSN] 8755-1039
  • [Journal-full-title] Diagnostic cytopathology
  • [ISO-abbreviation] Diagn. Cytopathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


68. Menon MP, Khan A: Micro-RNAs in thyroid neoplasms: molecular, diagnostic and therapeutic implications. J Clin Pathol; 2009 Nov;62(11):978-85
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [MeSH-minor] Adenocarcinoma, Follicular / diagnosis. Adenocarcinoma, Follicular / genetics. Adenocarcinoma, Papillary / diagnosis. Adenocarcinoma, Papillary / genetics. Adenoma / diagnosis. Adenoma / genetics. Carcinoma / diagnosis. Carcinoma / genetics. Cell Differentiation / genetics. Diagnosis, Differential. Disease Progression. Gene Expression Regulation, Neoplastic / genetics. Humans. Prognosis

  • MedlinePlus Health Information. consumer health - Thyroid Cancer.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19625289.001).
  • [ISSN] 1472-4146
  • [Journal-full-title] Journal of clinical pathology
  • [ISO-abbreviation] J. Clin. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / MicroRNAs; 0 / RNA, Neoplasm
  • [Number-of-references] 93
  •  go-up   go-down


69. Loddenkemper C: Diagnostic standards in the pathology of inflammatory bowel disease. Dig Dis; 2009;27(4):576-83
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • IBD is associated with an increased risk for the development of colorectal adenocarcinoma.
  • Furthermore, distinction between dysplasia-associated lesions or masses (DALM) and sporadic adenoma-like masses (ALM) is crucial as prophylactic colectomy is usually recommended for DALM and polypectomy may be sufficient for ALM.

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19897978.001).
  • [ISSN] 1421-9875
  • [Journal-full-title] Digestive diseases (Basel, Switzerland)
  • [ISO-abbreviation] Dig Dis
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Switzerland
  • [Number-of-references] 16
  •  go-up   go-down


70. Kamisawa T, Tu Y, Egawa N, Nakajima H, Tsuruta K, Okamoto A: Malignancies associated with intraductal papillary mucinous neoplasm of the pancreas. World J Gastroenterol; 2005 Sep 28;11(36):5688-90
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Histological diagnosis was confirmed in 30 cases (adenoma (n = 19) and adenocarcinoma (n = 11).
  • [MeSH-major] Adenocarcinoma, Mucinous / complications. Carcinoma, Pancreatic Ductal / complications. Colonic Neoplasms / complications. Esophageal Neoplasms / complications. Lung Neoplasms / complications. Stomach Neoplasms / complications

  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16237766.001).
  • [ISSN] 1007-9327
  • [Journal-full-title] World journal of gastroenterology
  • [ISO-abbreviation] World J. Gastroenterol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] China
  • [Other-IDs] NLM/ PMC4481489
  •  go-up   go-down


71. Selvindos PB, Ho YH: Multimedia article. Laparoscopic ultralow anterior resection with colonic J-pouch-anal anastomosis. Dis Colon Rectum; 2008 Nov;51(11):1710-1
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Patients with adenocarcinoma underwent preoperative endorectal ultrasound to individualize for neoadjuvant chemoradiotherapy, based on local extent and lymph nodes seen.
  • The indications were adenocarcinoma (n = 51), squamous-cell carcinoma of rectum (n = 1), dermoid tumor of mesorectum (n = 1), large villous adenoma (n = 1), and carcinoid with local lymph node metastases (n = 1).
  • The adenocarcinomas were a median distance of 6 (3-12) cm from the anal verge.
  • The histologic grading or the adenocarcinoma patients were: Stage I, n = 14; Stage II, n = 23; Stage III, n = 11; Stage IV, n = 3.
  • At a median follow-up of 14 (2-33) months, none of the adenocarcinoma patients who had undergone curative resection had recurrences.
  • [MeSH-major] Adenocarcinoma / surgery. Anal Canal / surgery. Colonic Pouches. Laparoscopy / methods. Proctocolectomy, Restorative / methods. Rectal Neoplasms / surgery

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18679748.001).
  • [ISSN] 1530-0358
  • [Journal-full-title] Diseases of the colon and rectum
  • [ISO-abbreviation] Dis. Colon Rectum
  • [Language] eng
  • [Publication-type] Interactive Tutorial
  • [Publication-country] United States
  •  go-up   go-down


72. Goetzl MA, Outman JE, Griebling TL, Holzbeierlein JM, Weigel JW, Thrasher JB: Digital fecal occult blood testing in the ambulatory urology clinic. J Am Coll Surg; 2008 Jan;206(1):144-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Two patients had benign lower gastrointestinal sources of bleeding, including one with hyperplastic polyps and one with a tubular adenoma.
  • One patient was diagnosed with a moderately differentiated adenocarcinoma of the sigmoid colon.

  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • MedlinePlus Health Information. consumer health - Prostate Cancer Screening.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18155580.001).
  • [ISSN] 1879-1190
  • [Journal-full-title] Journal of the American College of Surgeons
  • [ISO-abbreviation] J. Am. Coll. Surg.
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


73. Solon JG, Al-Azawi D, Hill A, Deasy J, McNamara DA: Colonoscopy and computerized tomography scan are not sufficient to localize right-sided colonic lesions accurately. Colorectal Dis; 2010 Oct;12(10 Online):e267-72
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • RESULTS: Out of 101 patients, 73 (73%) were for adenoma or cancer, with a final diagnosis of adenocarcinoma in 59 (58%).
  • [MeSH-minor] Adenocarcinoma / pathology. Adenocarcinoma / radiography. Adenoma / pathology. Adenoma / radiography. Colectomy. Contrast Media. Humans. Logistic Models. Preoperative Care. Retrospective Studies. Sensitivity and Specificity

  • MedlinePlus Health Information. consumer health - Colonoscopy.
  • MedlinePlus Health Information. consumer health - CT Scans.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] © 2010 The Authors. Colorectal Disease © 2010 The Association of Coloproctology of Great Britain and Ireland.
  • (PMID = 19930147.001).
  • [ISSN] 1463-1318
  • [Journal-full-title] Colorectal disease : the official journal of the Association of Coloproctology of Great Britain and Ireland
  • [ISO-abbreviation] Colorectal Dis
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Contrast Media
  •  go-up   go-down


74. Carroll NM, Carty SE: Promising molecular techniques for discriminating among follicular thyroid neoplasms. Surg Oncol; 2006 Aug;15(2):59-64
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • To guide the extent of thyroidectomy for indeterminate follicular neoplasm (FN), clinicians have long sought ways to differentiate follicular adenoma from carcinoma pre- or intraoperatively.
  • [MeSH-major] Adenocarcinoma, Follicular / blood. Adenocarcinoma, Follicular / diagnosis. Adenoma / blood. Adenoma / diagnosis. Thyroid Neoplasms / blood. Thyroid Neoplasms / diagnosis

  • MedlinePlus Health Information. consumer health - Thyroid Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16949814.001).
  • [ISSN] 0960-7404
  • [Journal-full-title] Surgical oncology
  • [ISO-abbreviation] Surg Oncol
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Biomarkers, Tumor
  • [Number-of-references] 59
  •  go-up   go-down


75. Li D, Jin C, McCulloch C, Kakar S, Berger BM, Imperiale TF, Terdiman JP: Association of large serrated polyps with synchronous advanced colorectal neoplasia. Am J Gastroenterol; 2009 Mar;104(3):695-702
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • OBJECTIVES: Serrated polyps of the colorectum are a histologically and genetically heterogeneous group of lesions, which include classic hyperplasic polyps, sessile serrated adenomas (SSAs), and traditional serrated adenomas.
  • METHODS: Among 4,714 asymptomatic subjects who underwent screening colonoscopy, cases of advanced colorectal neoplasia (tubular adenoma > or =1 cm, adenoma with any villous histology, adenoma with carcinoma in situ / high-grade dysplasia, or invasive adenocarcinoma) were compared with controls without advanced neoplasia with respect to candidate predictors, including age, sex, family history of colorectal cancer, body mass index, the presence and number of small tubular adenomas (<1 cm), the presence of multiple small serrated polyps (<1 cm), and the presence of large serrated polyps (> or =1 cm).
  • RESULTS: Among 467 cases and 4,247 controls, independent predictors of advanced colorectal neoplasia were increasing age (odds ratio (OR)=4.51; 95% confidence interval (CI), 1.43-14.3; P=0.01 for subjects > or =80 years vs. 50-54 years of age); non-advanced tubular adenomas (OR=2.33; 95% CI 1.37-3.96, P=0.0017 for 3 or more); and large serrated polyps (OR=3.24; 95% CI 2.05-5.13, P<0.0001).

  • MedlinePlus Health Information. consumer health - Colonic Polyps.
  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19223889.001).
  • [ISSN] 1572-0241
  • [Journal-full-title] The American journal of gastroenterology
  • [ISO-abbreviation] Am. J. Gastroenterol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


76. Bini EJ, Green B, Poles MA: Screening colonoscopy for the detection of neoplastic lesions in asymptomatic HIV-infected subjects. Gut; 2009 Aug;58(8):1129-34
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: Although non-AIDS defining malignancies are rapidly increasing as HIV-infected subjects live longer, little is know about the results of screening for colonic neoplasms (adenomatous polyps and adenocarcinomas) in this population.
  • Advanced neoplasms were defined as adenomas >or=10 mm or any adenoma, regardless of size, with villous histology, high-grade dysplasia, or adenocarcinoma.
  • Among patients with colorectal adenocarcinoma, HIV-infected subjects were significantly younger (52.4 (SD 1.3) vs 60.3 (SD 4.0) years, p = 0.002) and were more likely to have advanced cancers (stage III or IV) than control subjects (60.0% vs 16.7%, p = 0.24).
  • CONCLUSIONS: HIV-infected subjects have a higher prevalence of colonic neoplasms, and adenocarcinomas develop at a younger age and are more advanced than in uninfected subjects.
  • [MeSH-major] Adenocarcinoma / diagnosis. Adenoma / diagnosis. Colonic Neoplasms / diagnosis. HIV Infections / complications

  • Genetic Alliance. consumer health - HIV.
  • MedlinePlus Health Information. consumer health - HIV/AIDS.
  • MedlinePlus Health Information. consumer health - HIV/AIDS in Women.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19293177.001).
  • [ISSN] 1468-3288
  • [Journal-full-title] Gut
  • [ISO-abbreviation] Gut
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, U.S. Gov't, Non-P.H.S.
  • [Publication-country] England
  •  go-up   go-down


77. Rodrigues S, Rodrigue CM, Attoub S, Fléjou JF, Bruyneel E, Bracke M, Emami S, Gespach C: Induction of the adenoma-carcinoma progression and Cdc25A-B phosphatases by the trefoil factor TFF1 in human colon epithelial cells. Oncogene; 2006 Oct 26;25(50):6628-36
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Induction of the adenoma-carcinoma progression and Cdc25A-B phosphatases by the trefoil factor TFF1 in human colon epithelial cells.
  • To examine the transforming potential of TFF1 in human colon epithelial cells, premalignant PC/AA/C1 adenoma cells (PC) derived from a patient with familial adenomatous polyposis (FAP) were transformed by the TFF1 cDNA and used as a model of the adenoma-carcinoma transition.
  • Accordingly, TFF1 expression is absent in normal human colon crypts but is induced in correlation with Cdc25a and b transcript levels and tumor grade in familial and sporadic colon adenomas and carcinomas.
  • We propose that TFF1 and Cdc25A-B cooperate with other dominant oncogenic pathways to induce the adenoma and adenocarcinoma transitions.
  • [MeSH-major] Adenoma / pathology. Carcinoma / pathology. Cell Cycle Proteins / metabolism. Colon / cytology. Colonic Neoplasms / pathology. Intestinal Mucosa / metabolism. Tumor Suppressor Proteins / physiology. cdc25 Phosphatases / metabolism

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16715141.001).
  • [ISSN] 0950-9232
  • [Journal-full-title] Oncogene
  • [ISO-abbreviation] Oncogene
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Cell Cycle Proteins; 0 / TFF1 protein, human; 0 / Tumor Suppressor Proteins; EC 3.1.3.16 / CDC25B protein, human; EC 3.1.3.16 / Cdc25a protein, mouse; EC 3.1.3.48 / CDC25A protein, human; EC 3.1.3.48 / cdc25 Phosphatases
  •  go-up   go-down


78. Wang SL, Chen WT, Wu MT, Chan HM, Yang SF, Chai CY: Expression of human telomerase reverse transcriptase in thyroid follicular neoplasms: an immunohistochemical study. Endocr Pathol; 2005;16(3):211-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Differential diagnosis of follicular adenoma (FA) and follicular carcinoma (FC) of the thyroid can be difficult in the routine practice of surgical pathology because the diagnosis of FC is strictly defined and determined by the presence of capsular and/or vascular invasion by the tumor.
  • [MeSH-major] Adenocarcinoma, Follicular / enzymology. Adenoma / enzymology. DNA-Binding Proteins / metabolism. Telomerase / metabolism. Thyroid Neoplasms / enzymology

  • MedlinePlus Health Information. consumer health - Thyroid Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cell. 1997 Aug 22;90(4):785-95 [9288757.001]
  • [Cites] Endocr J. 2004 Feb;51(1):47-52 [15004408.001]
  • [Cites] Surgery. 1999 Dec;126(6):1195-8; discussion 1198-9 [10598207.001]
  • [Cites] Cancer Lett. 2003 Mar 10;191(2):223-7 [12618337.001]
  • [Cites] Am J Surg Pathol. 2002 Mar;26(3):365-70 [11859209.001]
  • [Cites] Nat Genet. 1998 Jan;18(1):65-8 [9425903.001]
  • [Cites] J Pathol. 2001 Jun;194(2):183-93 [11400147.001]
  • [Cites] Cancer. 2002 Dec 15;95(12):2487-93 [12467061.001]
  • [Cites] Oncogene. 2000 Aug 10;19(34):3888-93 [10951582.001]
  • [Cites] Nature. 1998 Nov 5;396(6706):84-8 [9817205.001]
  • [Cites] Am J Surg. 2003 Jul;186(1):83-8 [12842757.001]
  • [Cites] Clin Cancer Res. 1998 Jan;4(1):229-34 [9516976.001]
  • [Cites] Cancer Res. 1997 Jun 1;57(11):2144-7 [9187112.001]
  • [Cites] Mayo Clin Proc. 1991 Jan;66(1):11-22 [1988751.001]
  • [Cites] Endocr Pathol. 2003 Fall;14(3):213-19 [14586066.001]
  • [Cites] Br J Cancer. 2004 Mar 22;90(6):1222-9 [15026805.001]
  • [Cites] Nature. 1999 Jul 29;400(6743):464-8 [10440377.001]
  • [Cites] Science. 1997 Aug 15;277(5328):955-9 [9252327.001]
  • [Cites] Med Clin (Barc). 2003 Sep 6;121(7):264-9 [12975039.001]
  • [Cites] Histochem Cell Biol. 2004 May;121(5):391-7 [15138842.001]
  • [Cites] Science. 1995 Sep 1;269(5228):1236-41 [7544491.001]
  • [Cites] Am J Surg Pathol. 2002 Nov;26(11):1508-14 [12409728.001]
  • [Cites] Am J Clin Pathol. 1990 Nov;94(5):527-32 [2239819.001]
  • [Cites] Neoplasma. 2004;51(2):90-6 [15190417.001]
  • [Cites] Nat Genet. 1999 Jan;21(1):111-4 [9916802.001]
  • [Cites] Science. 1998 Jan 16;279(5349):349-52 [9454332.001]
  • [Cites] Hum Pathol. 2001 Feb;32(2):188-95 [11230706.001]
  • [Cites] Clin Orthop Relat Res. 2004 Sep;(426):117-24 [15346061.001]
  • [Cites] Surgery. 1995 Dec;118(6):1131-6; discussion 1136-8 [7491533.001]
  • [Cites] Cancer Res. 1998 Feb 15;58(4):622-5 [9485011.001]
  • [Cites] Oncogene. 1999 Feb 25;18(8):1561-7 [10102626.001]
  • (PMID = 16299404.001).
  • [ISSN] 1046-3976
  • [Journal-full-title] Endocrine pathology
  • [ISO-abbreviation] Endocr. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / DNA-Binding Proteins; EC 2.7.7.49 / Telomerase
  •  go-up   go-down


79. Young LE, Sanduja S, Bemis-Standoli K, Pena EA, Price RL, Dixon DA: The mRNA binding proteins HuR and tristetraprolin regulate cyclooxygenase 2 expression during colon carcinogenesis. Gastroenterology; 2009 May;136(5):1669-79
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • By contrast, increased HuR expression and cytoplasmic localization were observed in 76% of adenomas and 94% of adenocarcinomas, and TTP expression was lost in >75% of adenomas and adenocarcinomas.
  • In both adenomas and adenocarcinomas, COX-2 overexpression was associated with increased HuR and decreased TTP (P < .0001); similar associations were observed in colon cancer cells.
  • [MeSH-minor] Adenocarcinoma / genetics. Adenocarcinoma / metabolism. Adenoma / genetics. Adenoma / metabolism. Cell Line, Tumor. Cytoplasm / metabolism. ELAV Proteins. ELAV-Like Protein 1. HeLa Cells. Humans. Immunohistochemistry. RNA, Messenger / analysis. Transfection

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Gastroenterology. 2005 May;128(5):1445-61 [15887126.001]
  • [Cites] Cancer Res. 2005 Mar 15;65(6):2157-61 [15781626.001]
  • [Cites] Clin Cancer Res. 2005 Oct 15;11(20):7362-8 [16243808.001]
  • [Cites] Nucleic Acids Res. 2006 Jan 1;34(Database issue):D111-4 [16381826.001]
  • [Cites] Mod Pathol. 2006 Sep;19(9):1261-9 [16799479.001]
  • [Cites] Mol Cancer. 2006;5:37 [16982006.001]
  • [Cites] Nat Rev Mol Cell Biol. 2007 Feb;8(2):113-26 [17245413.001]
  • [Cites] J Cell Biochem. 2007 Apr 15;100(6):1477-92 [17133347.001]
  • [Cites] Arch Biochem Biophys. 2007 Jun 15;462(2):278-85 [17517366.001]
  • [Cites] Expert Opin Biol Ther. 2007 Oct;7(10):1515-29 [17916044.001]
  • [Cites] Mol Cancer Res. 2008 Jul;6(7):1124-36 [18644977.001]
  • [Cites] Gastroenterology. 2008 Dec;135(6):2030-42, 2042.e1-3 [18824170.001]
  • [Cites] Mol Cell. 2005 Sep 16;19(6):777-89 [16168373.001]
  • [Cites] Gene. 2000 Jan 25;242(1-2):125-31 [10721704.001]
  • [Cites] J Biol Chem. 2000 Apr 21;275(16):11750-7 [10766797.001]
  • [Cites] J Biol Chem. 2000 Jun 9;275(23):17827-37 [10751406.001]
  • [Cites] J Biol Chem. 2000 Oct 27;275(43):33951-6 [10930401.001]
  • [Cites] Cancer Res. 2000 Nov 1;60(21):6045-51 [11085526.001]
  • [Cites] Eur J Cancer. 2001 Aug;37(12):1469-74 [11506952.001]
  • [Cites] J Clin Invest. 2001 Dec;108(11):1657-65 [11733561.001]
  • [Cites] Am J Gastroenterol. 2002 Apr;97(4):1037-41 [12003384.001]
  • [Cites] EMBO Rep. 2003 Apr;4(4):394-9 [12671683.001]
  • [Cites] J Biol Chem. 2003 Apr 18;278(16):13928-35 [12578839.001]
  • [Cites] Oncogene. 2003 Jun 5;22(23):3554-61 [12789264.001]
  • [Cites] Prog Exp Tumor Res. 2003;37:52-71 [12795048.001]
  • [Cites] Cancer Res. 2003 Jul 15;63(14):3891-3 [12873979.001]
  • [Cites] Oncogene. 2003 Oct 16;22(46):7146-54 [14562043.001]
  • [Cites] Cancer Res. 2003 Nov 15;63(22):7591-4 [14633672.001]
  • [Cites] Proc Natl Acad Sci U S A. 2004 Feb 17;101(7):2011-6 [14769925.001]
  • [Cites] J Biol Chem. 2004 Jul 30;279(31):32393-400 [15187092.001]
  • [Cites] Gastroenterology. 1994 Oct;107(4):1183-8 [7926468.001]
  • [Cites] Cancer Res. 1995 Jun 15;55(12):2556-9 [7780968.001]
  • [Cites] EMBO J. 1998 Jun 15;17(12):3448-60 [9628880.001]
  • [CommentIn] Gastroenterology. 2009 May;136(5):1495-8 [19327732.001]
  • (PMID = 19208339.001).
  • [ISSN] 1528-0012
  • [Journal-full-title] Gastroenterology
  • [ISO-abbreviation] Gastroenterology
  • [Language] eng
  • [Grant] United States / NCRR NIH HHS / RR / P20 RR017698; United States / NCRR NIH HHS / RR / P20 RR017698; United States / NCI NIH HHS / CA / R01 CA134609
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, Surface; 0 / ELAV Proteins; 0 / ELAV-Like Protein 1; 0 / ELAVL1 protein, human; 0 / RNA, Messenger; 0 / RNA-Binding Proteins; 0 / Tristetraprolin; EC 1.14.99.1 / Cyclooxygenase 2
  • [Other-IDs] NLM/ NIHMS488861; NLM/ PMC3742387
  •  go-up   go-down


80. Shia J, Klimstra DS, Nafa K, Offit K, Guillem JG, Markowitz AJ, Gerald WL, Ellis NA: Value of immunohistochemical detection of DNA mismatch repair proteins in predicting germline mutation in hereditary colorectal neoplasms. Am J Surg Pathol; 2005 Jan;29(1):96-104
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • In this study, we analyzed the value of IHC versus that of microsatellite instability (MSI) testing in predicting mutation status of the MLH1, MSH2, and MSH6 genes in colorectal carcinomas and adenomas, and explored the frequency and significance of immunohistochemical staining variability.
  • The study samples included 83 carcinomas and 29 adenomas derived from 110 patients who had strong family histories of colorectal cancer.
  • Coexisting adenomas and carcinomas observed in the same slide (n=12) showed a similar or identical staining pattern for all three proteins.
  • No significant difference was detected in the sensitivity of IHC or MSI in detecting a germline mutation between isolated adenomas and carcinomas.
  • 2) adenomas have similar MMR protein expression patterns as carcinomas and may serve as an adequate sample for screening purposes in the identification of patients with MMR mutations;.

  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15613860.001).
  • [ISSN] 0147-5185
  • [Journal-full-title] The American journal of surgical pathology
  • [ISO-abbreviation] Am. J. Surg. Pathol.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / CA103500-02; United States / NCI NIH HHS / CA / R03 CA103500; United States / NCI NIH HHS / CA / R03 CA103500-02
  • [Publication-type] Evaluation Studies; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Adaptor Proteins, Signal Transducing; 0 / Biomarkers, Tumor; 0 / Carrier Proteins; 0 / DNA, Neoplasm; 0 / DNA-Binding Proteins; 0 / G-T mismatch-binding protein; 0 / MLH1 protein, human; 0 / Neoplasm Proteins; 0 / Nuclear Proteins; 0 / Proto-Oncogene Proteins; EC 3.6.1.3 / MSH2 protein, human; EC 3.6.1.3 / MutS Homolog 2 Protein
  •  go-up   go-down


81. Noda H, Kato Y, Yoshikawa H, Arai M, Togashi K, Nagai H, Konishi F, Miki Y: Frequent involvement of ras-signalling pathways in both polypoid-type and flat-type early-stage colorectal cancers. J Exp Clin Cancer Res; 2006 Jun;25(2):235-42
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The development of colorectal neoplasms proceeds mainly via the adenoma-carcinoma sequence.
  • All BRAF mutation-positive tumors were flat-type cancers, not associated with coexisting adenoma or p53 overexpression.
  • Thus, BRAF mutations most likely participate in de novo colorectal carcinogenesis, K-ras mutations in the adenoma-carcinoma sequence of colorectal carcinogenesis, and RASSF1A promoter methylation in both cascades.
  • [MeSH-major] Adenocarcinoma / genetics. Colorectal Neoplasms / genetics. Genes, ras / genetics. Proto-Oncogene Proteins B-raf / genetics. Signal Transduction. Tumor Suppressor Proteins / genetics

  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • antibodies-online. View related products from antibodies-online.com (subscription/membership/fee required).
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16918136.001).
  • [ISSN] 0392-9078
  • [Journal-full-title] Journal of experimental & clinical cancer research : CR
  • [ISO-abbreviation] J. Exp. Clin. Cancer Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Italy
  • [Chemical-registry-number] 0 / RASSF1 protein, human; 0 / Tumor Suppressor Protein p53; 0 / Tumor Suppressor Proteins; EC 2.7.11.1 / BRAF protein, human; EC 2.7.11.1 / Proto-Oncogene Proteins B-raf
  •  go-up   go-down


82. Sohn JW, Jeon SW, Cho CM, Jung MK, Kim SK, Lee DS, Son HS, Chung IK: Endoscopic resection of duodenal neoplasms: a single-center study. Surg Endosc; 2010 Dec;24(12):3195-200
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: Premalignant duodenal lesions such as adenomas are rare.
  • METHODS: Patients with nonampullary duodenal adenomas or duodenal adenocarcinomas without familial polyposis syndrome between August 2002 and February 2009 were retrospectively analyzed.
  • Of these patients, 23 had duodenal adenomas and 1 had an adenocarcinoma confined to the mucosa.
  • Tubular adenomas were the most common type (17/24, 70.8%).
  • During the short-term follow-up evaluation, EMR showed outcomes and complications comparable with prior procedures, including adenocarcinomas confined to the mucosa.
  • [MeSH-major] Adenocarcinoma / surgery. Adenoma / surgery. Duodenal Neoplasms / surgery. Duodenoscopy

  • MedlinePlus Health Information. consumer health - Intestinal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Ann Surg. 1989 May;209(5):593-8; discussion 598-9 [2650645.001]
  • [Cites] Gastrointest Endosc. 2002 Mar;55(3):390-6 [11868015.001]
  • [Cites] Colorectal Dis. 2006 Jul;8(6):497-500 [16784470.001]
  • [Cites] Arch Surg. 1990 Aug;125(8):961-5 [2378560.001]
  • [Cites] Cancer. 1981 Aug 1;48(3):799-819 [7248908.001]
  • [Cites] J Gastrointest Surg. 2003 May-Jun;7(4):536-41 [12763412.001]
  • [Cites] Hepatogastroenterology. 1996 Mar-Apr;43(8):448-55 [8714243.001]
  • [Cites] Endoscopy. 2006 Mar;38(3):231-5 [16528648.001]
  • [Cites] J Gastrointest Surg. 2000 Jan-Feb;4(1):13-21, discussion 22-3 [10631358.001]
  • [Cites] AJR Am J Roentgenol. 1980 May;134(5):933-6 [6768268.001]
  • [Cites] Endoscopy. 2008 Oct;40(10):806-10 [18828076.001]
  • [Cites] Ann Surg. 1988 Mar;207(3):234-9 [3345110.001]
  • [Cites] Br J Surg. 1988 Feb;75(2):150-3 [3349305.001]
  • [Cites] Endoscopy. 2005 May;37(5):444-8 [15844023.001]
  • (PMID = 20490557.001).
  • [ISSN] 1432-2218
  • [Journal-full-title] Surgical endoscopy
  • [ISO-abbreviation] Surg Endosc
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


83. Carneiro FP, Ramalho LN, Britto-Garcia S, Ribeiro-Silva A, Zucoloto S: Immunohistochemical expression of p16, p53, and p63 in colorectal adenomas and adenocarcinomas. Dis Colon Rectum; 2006 May;49(5):588-94
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Immunohistochemical expression of p16, p53, and p63 in colorectal adenomas and adenocarcinomas.
  • PURPOSE: The aim of this study was to investigate the immunohistochemical expression of p16, p53, and p63 proteins according to some pathologic parameters related to colorectal adenomas and adenocarcinomas such as grade of dysplasia and histologic type.
  • METHODS: Immunohistochemistry with the antibodies p16, p53, and p63 was performed in tubular, tubular-villous, and villous adenomas (n = 30) and in well, moderately, and poorly differentiated adenocarcinomas (n = 30).
  • RESULTS: The p16 and p53 labelings were observed in some adenomas and adenocarcinomas but without any association with p63 expression, histologic type, or grade of differentiation of the neoplasm.
  • P63 expression was found mainly in the villous adenomas and in the poorly differentiated adenocarcinomas.
  • The poorly differentiated adenocarcinomas also exhibited coexpression of CK5 and p63.
  • However, p63 expression was closely associated with villous adenomas and poorly differentiated adenocarcinomas.
  • [MeSH-minor] Adenocarcinoma. Adenoma. Biomarkers, Tumor / genetics. Biomarkers, Tumor / metabolism. DNA-Binding Proteins. Genes, Tumor Suppressor. Humans. Immunohistochemistry. Keratins / metabolism. Transcription Factors. Tumor Suppressor Proteins

  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16575619.001).
  • [ISSN] 0012-3706
  • [Journal-full-title] Diseases of the colon and rectum
  • [ISO-abbreviation] Dis. Colon Rectum
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / DNA-Binding Proteins; 0 / Phosphoproteins; 0 / TP63 protein, human; 0 / Trans-Activators; 0 / Transcription Factors; 0 / Tumor Suppressor Proteins; 68238-35-7 / Keratins
  •  go-up   go-down


84. Shanks JH, Iczkowski KA: Divergent differentiation in urothelial carcinoma and other bladder cancer subtypes with selected mimics. Histopathology; 2009 Jun;54(7):885-900
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Pure squamous carcinoma or adenocarcinoma (the latter in particular) can be difficult to distinguish from contiguous or metastatic spread.
  • [MeSH-minor] Adenocarcinoma, Clear Cell / diagnosis. Adenocarcinoma, Clear Cell / pathology. Adenoma / diagnosis. Adenoma / pathology. Carcinoma, Squamous Cell / diagnosis. Carcinoma, Squamous Cell / pathology. Carcinoma, Transitional Cell / diagnosis. Carcinoma, Transitional Cell / pathology. Cell Differentiation. Cystitis / diagnosis. Cystitis / pathology. Diagnosis, Differential. Giant Cell Tumors / diagnosis. Giant Cell Tumors / pathology. Humans. Neoplasm Metastasis / diagnosis. Neoplasm Metastasis / pathology. Neoplasms, Squamous Cell / diagnosis. Neoplasms, Squamous Cell / pathology. Neuroendocrine Tumors / diagnosis. Neuroendocrine Tumors / pathology. Radiation Injuries / diagnosis. Radiation Injuries / pathology. Urothelium / pathology

  • Genetic Alliance. consumer health - Bladder cancer.
  • MedlinePlus Health Information. consumer health - Bladder Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19178589.001).
  • [ISSN] 1365-2559
  • [Journal-full-title] Histopathology
  • [ISO-abbreviation] Histopathology
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Number-of-references] 152
  •  go-up   go-down


85. Yen AM, Chen TH, Duffy SW, Chen CD: Incorporating frailty in a multi-state model: application to disease natural history modelling of adenoma-carcinoma in the large bowel. Stat Methods Med Res; 2010 Oct;19(5):529-46
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Incorporating frailty in a multi-state model: application to disease natural history modelling of adenoma-carcinoma in the large bowel.
  • We applied these to the example of progression of adenoma to colorectal cancer in a three-state model and to a five-state model including consideration of adenoma size.
  • Results were compared with those of purely homogeneous models in a previous study in terms of cumulative risk of malignant transformation from adenoma to invasive colorectal cancer.
  • [MeSH-major] Adenocarcinoma / pathology. Colonic Neoplasms / pathology. Frail Elderly. Models, Statistical

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20488838.001).
  • [ISSN] 1477-0334
  • [Journal-full-title] Statistical methods in medical research
  • [ISO-abbreviation] Stat Methods Med Res
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down


86. Werder P, Altermatt HJ, Zbären P, Bornstein MM: Canalicular adenoma of a minor salivary gland on the palate: a case presentation. Quintessence Int; 2009 Sep;40(8):623-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Canalicular adenoma of a minor salivary gland on the palate: a case presentation.
  • Canalicular adenomas are uncommon, benign epithelial neoplasms of the salivary glands that usually involve the upper lip and buccal mucosa of elderly people.
  • Differential diagnosis of the canalicular adenoma versus adenocarcinoma is important, as it may result in unjustified radiotherapy or extensive and aggressive surgery.
  • Despite the benign nature of canalicular adenomas, complete surgical removal and a regular clinical follow-up are recommended.
  • The present article describes the diagnostic procedures, surgical management, and follow-up of a canalicular adenoma involving the palate of a 71-year-old man.
  • [MeSH-major] Adenoma / pathology. Salivary Gland Neoplasms / pathology. Salivary Glands, Minor / pathology
  • [MeSH-minor] Adenocarcinoma / diagnosis. Aged. Diagnosis, Differential. Humans. Laser Therapy. Lasers, Gas / therapeutic use. Male. Palatal Neoplasms / pathology. Palatal Neoplasms / radiography. Palatal Neoplasms / surgery. Palate, Hard / pathology. Palate, Hard / radiography. Palate, Hard / surgery

  • MedlinePlus Health Information. consumer health - Salivary Gland Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19639085.001).
  • [ISSN] 1936-7163
  • [Journal-full-title] Quintessence international (Berlin, Germany : 1985)
  • [ISO-abbreviation] Quintessence Int
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


87. Hinsch N, Frank M, Döring C, Vorländer C, Hansmann ML: QPRT: a potential marker for follicular thyroid carcinoma including minimal invasive variant; a gene expression, RNA and immunohistochemical study. BMC Cancer; 2009;9:93
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: The differential diagnosis between follicular thyroid adenoma and minimal invasive follicular thyroid carcinoma is often difficult for several reasons.
  • METHODS: We performed global gene expression analysis of 12 follicular thyroid tumours (4 follicular adenomas, 4 minimal invasive follicular carcinomas and 4 widely invasive follicular carcinomas), followed by immunohistochemical staining of 149 cases.
  • The specificity of the antibody was validated by western blot analysis RESULTS: In gene expression analysis QPRT was detected as differently expressed between follicular thyroid adenoma and follicular thyroid carcinoma.
  • QPRT protein could be detected by immunohistochemistry in 65% of follicular thyroid carcinomas including minimal invasive variant and only 22% of follicular adenomas.
  • [MeSH-major] Adenocarcinoma, Follicular / diagnosis. Pentosyltransferases / genetics. Pentosyltransferases / metabolism. Thyroid Neoplasms / diagnosis
  • [MeSH-minor] Adenoma / diagnosis. Adenoma / genetics. Adenoma / metabolism. Biomarkers, Tumor / genetics. Biomarkers, Tumor / metabolism. Blotting, Western. Cluster Analysis. Diagnosis, Differential. Gene Expression Profiling. Gene Expression Regulation, Neoplastic. Humans. Immunohistochemistry. RNA, Neoplasm / genetics. RNA, Neoplasm / metabolism. Reverse Transcriptase Polymerase Chain Reaction

  • MedlinePlus Health Information. consumer health - Thyroid Cancer.
  • The Lens. Cited by Patents in .
  • antibodies-online. View related products from antibodies-online.com (subscription/membership/fee required).
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Eur J Nucl Med. 2000 Oct;27(10):1465-72 [11083534.001]
  • [Cites] J Korean Med Sci. 2007 Aug;22(4):621-8 [17728499.001]
  • [Cites] J Biol Chem. 2002 Sep 20;277(38):35162-7 [12140278.001]
  • [Cites] Am J Surg Pathol. 2002 Nov;26(11):1508-14 [12409728.001]
  • [Cites] Bioinformatics. 2003 Jan 22;19(2):185-93 [12538238.001]
  • [Cites] J Clin Endocrinol Metab. 2003 May;88(5):2318-26 [12727991.001]
  • [Cites] Clin Cancer Res. 2003 May;9(5):1792-800 [12738736.001]
  • [Cites] Hum Pathol. 2003 Nov;34(11):1092-100 [14652809.001]
  • [Cites] J Clin Invest. 2004 Apr;113(8):1234-42 [15085203.001]
  • [Cites] Endocr J. 2004 Jun;51(3):361-6 [15256783.001]
  • [Cites] Eur J Endocrinol. 2004 Sep;151(3):367-74 [15362967.001]
  • [Cites] Genome Biol. 2004;5(10):R80 [15461798.001]
  • [Cites] Eur J Pharmacol. 1981 Jul 10;72(4):411-2 [6268428.001]
  • [Cites] J Neurochem. 1985 Jul;45(1):199-205 [2582090.001]
  • [Cites] Brain Res. 1985 Jun 17;336(2):207-14 [3159462.001]
  • [Cites] Proc Natl Acad Sci U S A. 1987 May;84(10):3491-5 [3472219.001]
  • [Cites] J Biochem. 1988 Jun;103(6):1054-9 [3139649.001]
  • [Cites] Acta Crystallogr D Biol Crystallogr. 1998 Jan 1;54(Pt 1):119-20 [9761830.001]
  • [Cites] Hum Reprod. 2005 Apr;20(4):852-63 [15705628.001]
  • [Cites] J Clin Endocrinol Metab. 2005 May;90(5):2512-21 [15713710.001]
  • [Cites] Cell Mol Biol (Noisy-le-grand). 2005 Sep 5;51(2):177-86 [16171553.001]
  • [Cites] Histopathology. 2005 Oct;47(4):391-401 [16178894.001]
  • [Cites] Virchows Arch. 2006 Apr;448(4):385-93 [16506015.001]
  • [Cites] Cancer. 2006 May 1;106(9):1891-900 [16565969.001]
  • [Cites] Tumour Biol. 2006;27(4):211-20 [16675914.001]
  • [Cites] Clin Cancer Res. 2006 Jun 1;12(11 Pt 1):3311-8 [16740752.001]
  • [Cites] Clin Endocrinol (Oxf). 2006 Nov;65(5):660-6 [17054470.001]
  • [Cites] J Clin Endocrinol Metab. 2002 Aug;87(8):3947-52 [12161538.001]
  • (PMID = 19321014.001).
  • [ISSN] 1471-2407
  • [Journal-full-title] BMC cancer
  • [ISO-abbreviation] BMC Cancer
  • [Language] eng
  • [Databank-accession-numbers] GEO/ GSE15045
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / RNA, Neoplasm; EC 2.4.2.- / Pentosyltransferases; EC 2.4.2.19 / nicotinate-nucleotide diphosphorylase (carboxylating)
  • [Other-IDs] NLM/ PMC2667537
  •  go-up   go-down


88. Miyazawa M, Yasuda M, Fujita M, Hirasawa T, Kajiwara H, Hirabayashi K, Ogane N, Shimizu M, Asanuma H, Murakami M, Takekoshi S, Mikami M, Osamura RY: Association of hypoxia-inducible factor-1 expression with histology in epithelial ovarian tumors: a quantitative analysis of HIF-1. Arch Gynecol Obstet; 2009 Jun;279(6):789-96
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • METHOD: HIF-1 level in the nucleus was analyzed using DNA binding assay, and HIF-1alpha level in the cytoplasm was measured by ELISA for a total of 36 epithelial ovarian tumors as follows: 5 serous adenocarcinomas (SEAs), 7 clear cell adenocarcinomas (CLAs), 7 endometrioid adenocarcinomas (ENAs), 4 mucinous adenocarcinomas (MUAs), 2 mucinous borderline tumors (MBTs), and 11 mucinous adenomas.
  • RESULTS: HIF-1 level (mg/ml) in the nucleus and HIF-1alpha level (mg/ml) in the cytoplasm were on average 0.116 and 0.178 for SEAs, 0.328 and 0.306 for CLAs, 0.171 and 0.305 for ENAs, 0.097 and 0.176 for MUAs, 0.224 and 0.180 for mucinous borderline tumors, 0.152 and 0.154 for mucinous adenomas.
  • Mucinous adenomas were higher in HIF-1 than MUAs.
  • [MeSH-major] Adenocarcinoma / metabolism. Adenoma / metabolism. Anoxia / metabolism. Hypoxia-Inducible Factor 1, alpha Subunit / metabolism. Ovarian Neoplasms / metabolism

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18936945.001).
  • [ISSN] 1432-0711
  • [Journal-full-title] Archives of gynecology and obstetrics
  • [ISO-abbreviation] Arch. Gynecol. Obstet.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Hypoxia-Inducible Factor 1, alpha Subunit; 9007-49-2 / DNA
  •  go-up   go-down


89. Spanu A, Solinas ME, Chessa F, Sanna D, Nuvoli S, Madeddu G: 131I SPECT/CT in the follow-up of differentiated thyroid carcinoma: incremental value versus planar imaging. J Nucl Med; 2009 Feb;50(2):184-90
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [MeSH-minor] Adenocarcinoma, Follicular / radiography. Adenocarcinoma, Follicular / radionuclide imaging. Adenocarcinoma, Follicular / secondary. Adenocarcinoma, Follicular / surgery. Adenocarcinoma, Papillary / radiography. Adenocarcinoma, Papillary / radionuclide imaging. Adenocarcinoma, Papillary / secondary. Adenocarcinoma, Papillary / surgery. Adenoma, Oxyphilic / radiography. Adenoma, Oxyphilic / radionuclide imaging. Adenoma, Oxyphilic / secondary. Adenoma, Oxyphilic / surgery. Adult. Aged. Aged, 80 and over. Female. Follow-Up Studies. Humans. Male. Middle Aged. Thyroidectomy. Young Adult

  • MedlinePlus Health Information. consumer health - CT Scans.
  • MedlinePlus Health Information. consumer health - Thyroid Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] J Nucl Med. 2009 Aug;50(8):1386; author reply 1386 [19617337.001]
  • (PMID = 19164225.001).
  • [ISSN] 0161-5505
  • [Journal-full-title] Journal of nuclear medicine : official publication, Society of Nuclear Medicine
  • [ISO-abbreviation] J. Nucl. Med.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Iodine Radioisotopes
  •  go-up   go-down


90. Vernez M, Hutter P, Monnerat C, Halkic N, Gugerli O, Bouzourene H: A case of Muir-Torre syndrome associated with mucinous hepatic cholangiocarcinoma and a novel germline mutation of the MSH2 gene. Fam Cancer; 2007;6(1):141-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Muir-Torre syndrome (MTS) is a rare cancer-predisposing syndrome that is autosomal dominantly inherited and characterized by the development of sebaceous skin lesions (adenomas, epitheliomas, basaliomas and carcinomas).
  • [MeSH-minor] Adenocarcinoma, Mucinous / genetics. Adenocarcinoma, Mucinous / surgery. Adenoma / genetics. Adenoma / surgery. Adult. Brain Neoplasms / genetics. Brain Neoplasms / secondary. Brain Neoplasms / surgery. Carcinoma / genetics. Carcinoma / surgery. Colorectal Neoplasms, Hereditary Nonpolyposis / genetics. Colorectal Neoplasms, Hereditary Nonpolyposis / surgery. DNA Mutational Analysis. DNA Probes. DNA-Binding Proteins. Endometrial Neoplasms / surgery. Female. Humans. Microsatellite Instability. Mutation, Missense. Polyps / surgery. Proline / genetics. Sebaceous Gland Neoplasms / genetics. Sebaceous Gland Neoplasms / surgery. Serine / genetics. Syndrome

  • Genetic Alliance. consumer health - Keratoacanthoma.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. (L)-PROLINE .
  • Hazardous Substances Data Bank. L-SERINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Br J Surg. 1967 Mar;54(3):191-5 [6020987.001]
  • [Cites] Arch Dermatol. 1968 Nov;98(5):549-51 [5684233.001]
  • [Cites] J Med Genet. 2004 Jul;41(7):567-72 [15235030.001]
  • [Cites] Cancer Res. 2001 Feb 1;61(3):896-9 [11221877.001]
  • [Cites] Fam Cancer. 2005;4(3):245-8 [16136385.001]
  • [Cites] Cancer Res. 1994 Mar 1;54(5):1159-63 [8118799.001]
  • [Cites] Cancer Res. 1998 Nov 15;58(22):5248-57 [9823339.001]
  • [Cites] Clin Genet. 2005 Nov;68(5):442-7 [16207212.001]
  • [Cites] Scand J Gastroenterol. 2005 Apr;40(4):455-9 [16028441.001]
  • [Cites] Cancer. 1992 Mar 1;69(5):1112-4 [1310886.001]
  • [Cites] J Am Acad Dermatol. 1999 Nov;41(5 Pt 1):681-6 [10534628.001]
  • [Cites] EMBO J. 1998 May 1;17 (9):2677-86 [9564049.001]
  • [Cites] Lancet. 2005 Oct 8;366(9493):1303-14 [16214602.001]
  • [Cites] J Am Acad Dermatol. 1995 Jul;33(1):90-104 [7601953.001]
  • (PMID = 17051350.001).
  • [ISSN] 1389-9600
  • [Journal-full-title] Familial cancer
  • [ISO-abbreviation] Fam. Cancer
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / DNA Probes; 0 / DNA-Binding Proteins; 452VLY9402 / Serine; 9DLQ4CIU6V / Proline; EC 3.6.1.3 / MutS Homolog 2 Protein
  •  go-up   go-down


91. Oue N, Mitani Y, Aung PP, Sakakura C, Takeshima Y, Kaneko M, Noguchi T, Nakayama H, Yasui W: Expression and localization of Reg IV in human neoplastic and non-neoplastic tissues: Reg IV expression is associated with intestinal and neuroendocrine differentiation in gastric adenocarcinoma. J Pathol; 2005 Oct;207(2):185-98
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Expression and localization of Reg IV in human neoplastic and non-neoplastic tissues: Reg IV expression is associated with intestinal and neuroendocrine differentiation in gastric adenocarcinoma.
  • Among 143 gastric adenocarcinomas, Reg IV expression was detected in 42 (29.4%) and was associated with both the intestinal mucin phenotype and neuroendocrine differentiation.
  • Of 36 colorectal adenocarcinomas, 13 (36.1%) were positive for Reg IV, which was associated with tumour stage (p = 0.0379, Fisher's exact test).
  • Reg IV expression was also detected in 5 (21.7%) of 23 ductal adenocarcinomas of the pancreas.
  • These data suggest that Reg IV is expressed by gastrointestinal and pancreatic tumours, including adenocarcinomas and carcinoid tumours, and that Reg IV is associated with intestinal and neuroendocrine differentiation of the stomach and gastric carcinoma.
  • [MeSH-major] Adenocarcinoma / chemistry. Lectins, C-Type / analysis. Neoplasm Proteins / analysis. Stomach Neoplasms / chemistry
  • [MeSH-minor] Adenoma / chemistry. Biomarkers, Tumor / analysis. Blotting, Western / methods. Breast Neoplasms / chemistry. Carcinoid Tumor / chemistry. Cell Differentiation / physiology. Cell Line, Tumor. Colon / metabolism. Colorectal Neoplasms / chemistry. Female. Humans. Immunohistochemistry / methods. Intestine, Small / metabolism. Lung Neoplasms / chemistry. Pancreas / metabolism. Pancreatic Neoplasms / chemistry. Phenotype. RNA, Messenger / analysis. RNA, Neoplasm / analysis. Reverse Transcriptase Polymerase Chain Reaction / methods. Stomach / metabolism

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright (c) 2005 Pathological Society of Great Britain and Ireland. Published by John Wiley & Sons, Ltd.
  • (PMID = 16086444.001).
  • [ISSN] 0022-3417
  • [Journal-full-title] The Journal of pathology
  • [ISO-abbreviation] J. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Lectins, C-Type; 0 / Neoplasm Proteins; 0 / REG4 protein, human; 0 / RNA, Messenger; 0 / RNA, Neoplasm
  •  go-up   go-down


92. Mikami Y, Kiyokawa T, Moriya T, Sasano H: Immunophenotypic alteration of the stromal component in minimal deviation adenocarcinoma ('adenoma malignum') and endocervical glandular hyperplasia: a study using oestrogen receptor and alpha-smooth muscle actin double immunostaining. Histopathology; 2005 Feb;46(2):130-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Immunophenotypic alteration of the stromal component in minimal deviation adenocarcinoma ('adenoma malignum') and endocervical glandular hyperplasia: a study using oestrogen receptor and alpha-smooth muscle actin double immunostaining.
  • AIMS: To define the phenotypic alteration of the stromal component in association with destructive invasion which is a crucial feature in distinguishing minimal deviation adenocarcinoma (MDA) from benign endocervical glandular lesions.
  • METHODS AND RESULTS: We studied endocervical glandular hyperplasias including non-specific-type (NEGH) (n = 3) and lobular-type (LEGH) (n = 8), and minimal deviation adenocarcinoma (MDA) (n = 11), well-differentiated endocervical adenocarcinoma of usual-type (WDA) (n = 11), and adenocarcinoma in situ (AIS) (n = 6) of the cervix, by double immunostaining for oestrogen receptor (ER) and alpha-smooth muscle actin (alpha-SMA) using peroxidase- and alkaline phosphatase-polymer methods, respectively.
  • [MeSH-major] Actins / analysis. Adenocarcinoma / pathology. Cervix Uteri / pathology. Receptors, Estrogen / analysis. Uterine Cervical Neoplasms / pathology


93. Vlaicu SI, Tegla CA, Cudrici CD, Fosbrink M, Nguyen V, Azimzadeh P, Rus V, Chen H, Mircea PA, Shamsuddin A, Rus H: Epigenetic modifications induced by RGC-32 in colon cancer. Exp Mol Pathol; 2010 Feb;88(1):67-76
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We have now shown that RGC-32 is expressed in precancerous states, and its expression is significantly higher in adenomas than in normal colon tissue.

  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2009 Elsevier Inc. All rights reserved.
  • [Cites] Exp Mol Pathol. 2005 Apr;78(2):116-22 [15713436.001]
  • [Cites] J Clin Pathol. 2005 May;58(5):509-14 [15858123.001]
  • [Cites] Mol Cancer Res. 2005 May;3(5):261-9 [15886297.001]
  • [Cites] J Clin Oncol. 2006 Jan 10;24(2):274-87 [16365179.001]
  • [Cites] Anticancer Res. 1999 Jan-Feb;19(1B):741-8 [10216486.001]
  • [Cites] Gastroenterology. 2006 Aug;131(2):630-9 [16890615.001]
  • [Cites] Blood. 2006 Sep 15;108(6):2020-8 [16728703.001]
  • [Cites] J Pathol. 2006 Oct;210(2):147-54 [16850502.001]
  • [Cites] Cancer. 2006 Aug 15;107(4):668-75 [16826582.001]
  • [Cites] World J Gastroenterol. 2006 Oct 21;12(39):6391-6 [17072968.001]
  • [Cites] Cancer Metastasis Rev. 2006 Sep;25(3):435-57 [16951986.001]
  • [Cites] Oncogene. 2007 Feb 22;26(8):1110-21 [17146433.001]
  • [Cites] Nat Rev Genet. 2007 Apr;8(4):286-98 [17339880.001]
  • [Cites] Proc Natl Acad Sci U S A. 2007 Jul 24;104(30):12371-6 [17640913.001]
  • [Cites] PLoS One. 2008;3(4):e2020 [18414679.001]
  • [Cites] Arch Immunol Ther Exp (Warsz). 2008 Mar-Apr;56(2):115-22 [18373239.001]
  • [Cites] Oncogene. 2008 Oct 2;27(44):5856-66 [18560354.001]
  • [Cites] J Neuroimmunol. 2008 Oct 15;203(1):94-103 [18692252.001]
  • [Cites] J Biol Chem. 2009 Apr 3;284(14):9426-32 [19158077.001]
  • [Cites] J Biol Chem. 1998 Oct 9;273(41):26977-81 [9756947.001]
  • [Cites] Gastroenterology. 1996 Feb;110(2):375-82 [8566583.001]
  • [Cites] Oncogene. 1991 Aug;6(8):1471-6 [1886718.001]
  • [Cites] BMC Gastroenterol. 2004 Sep 23;4:22 [15385053.001]
  • [Cites] Oncogene. 2004 Oct 21;23(49):8065-77 [15361855.001]
  • [Cites] Cell Res. 2004 Jun;14(3):217-26 [15225415.001]
  • [Cites] Int J Colorectal Dis. 2004 Jul;19(4):325-33 [15060836.001]
  • [Cites] Cancer Cell. 2003 Jun;3(6):537-49 [12842083.001]
  • [Cites] J Biol Chem. 2002 Jan 4;277(1):502-8 [11687586.001]
  • [Cites] Nat Genet. 2000 May;25(1):25-9 [10802651.001]
  • [Cites] Virchows Arch. 2000 Mar;436(3):224-8 [10782880.001]
  • [Cites] Exp Mol Pathol. 2009 Apr;86(2):87-94 [19162005.001]
  • [Cites] J Pathol. 1999 Jan;187(1):82-90 [10341708.001]
  • [Cites] Nature. 2004 Nov 18;432(7015):298-306 [15549091.001]
  • [Cites] J Pathol. 2005 Jan;205(1):65-73 [15586362.001]
  • (PMID = 19883641.001).
  • [ISSN] 1096-0945
  • [Journal-full-title] Experimental and molecular pathology
  • [ISO-abbreviation] Exp. Mol. Pathol.
  • [Language] ENG
  • [Grant] United States / NINDS NIH HHS / NS / R01 NS42011; United States / NINDS NIH HHS / NS / R01 NS042011; United States / NIEHS NIH HHS / ES / ES 07263; United States / NIEHS NIH HHS / ES / T32 ES007263; United States / NINDS NIH HHS / NS / NS042011-05; United States / NINDS NIH HHS / NS / R01 NS042011-05
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, U.S. Gov't, Non-P.H.S.
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Cell Cycle Proteins; 0 / Histones; 0 / Muscle Proteins; 0 / Nerve Tissue Proteins; 0 / RGC32 protein, human
  • [Other-IDs] NLM/ NIHMS157642; NLM/ PMC2815209
  •  go-up   go-down


94. Kitamura H, Okudela K: Bronchioloalveolar neoplasia. Int J Clin Exp Pathol; 2010;4(1):97-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [MeSH-major] Adenocarcinoma, Bronchiolo-Alveolar / pathology. Lung Neoplasms / pathology
  • [MeSH-minor] Adenoma / genetics. Adenoma / pathology. Animals. Disease Models, Animal. Hyperplasia / genetics. Hyperplasia / pathology. Mice. Mutation. Precancerous Conditions / genetics. Precancerous Conditions / pathology. Proto-Oncogene Proteins / genetics. Receptor, Epidermal Growth Factor / genetics. ras Proteins / genetics

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Lancet. 2000 Feb 5;355(9202):479-85 [10841143.001]
  • [Cites] Am J Surg Pathol. 2010 Feb;34(2):243-55 [20061937.001]
  • [Cites] Am J Clin Pathol. 2002 Mar;117(3):464-70 [11888087.001]
  • [Cites] Carcinogenesis. 2003 Jun;24(6):1143-8 [12807761.001]
  • [Cites] N Engl J Med. 2004 Jan 22;350(4):379-92 [14736930.001]
  • [Cites] N Engl J Med. 2004 May 20;350(21):2129-39 [15118073.001]
  • [Cites] Toxicology. 1989 Mar;54(3):241-71 [2650016.001]
  • [Cites] Am J Pathol. 1995 Apr;146(4):876-87 [7717455.001]
  • [Cites] Cancer Res. 1996 May 1;56(9):2224-8 [8616876.001]
  • [Cites] Am J Surg Pathol. 1996 May;20(5):553-62 [8619420.001]
  • [Cites] Nat Genet. 1996 Apr;12(4):455-7 [8630506.001]
  • [Cites] Nat Genet. 1996 Dec;14(4):465-7 [8944028.001]
  • [Cites] Mod Pathol. 1997 May;10(5):469-73 [9160312.001]
  • [Cites] Oncogene. 1997 Oct 9;15(15):1833-40 [9362450.001]
  • [Cites] Trends Genet. 1998 Apr;14(4):139-44 [9594661.001]
  • [Cites] Exp Lung Res. 1998 Jul-Aug;24(4):481-97 [9659579.001]
  • [Cites] Am J Clin Pathol. 1999 May;111(5):610-22 [10230351.001]
  • [Cites] Lung Cancer. 2005 Oct;50(1):1-8 [15950315.001]
  • [Cites] Int J Cancer. 2006 Jan 15;118(2):257-62 [16231326.001]
  • [Cites] Carcinogenesis. 2007 Sep;28(9):1851-8 [17693665.001]
  • [Cites] Carcinogenesis. 2008 May;29(5):957-63 [18299280.001]
  • [Cites] Lung Cancer. 2000 Aug;29(2):125-30 [10963842.001]
  • (PMID = 21228931.001).
  • [ISSN] 1936-2625
  • [Journal-full-title] International journal of clinical and experimental pathology
  • [ISO-abbreviation] Int J Clin Exp Pathol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / KRAS protein, human; 0 / Proto-Oncogene Proteins; EC 2.7.10.1 / Receptor, Epidermal Growth Factor; EC 3.6.5.2 / ras Proteins
  • [Other-IDs] NLM/ PMC3016107
  • [Keywords] NOTNLM ; Bronchioloalveolar carcinoma / KRAS gene / atypical adenomatous hyperplasia / epidermal growth factor receptor gene / molecular targeting therapy / murine model
  •  go-up   go-down


95. Gupta N, Kakar AK, Chowdhury V, Gulati P, Shankar LR, Vindal A: Magnetic resonance spectroscopy as a diagnostic modality for carcinoma thyroid. Eur J Radiol; 2007 Dec;64(3):414-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [MeSH-minor] Adenocarcinoma, Follicular / diagnosis. Adenocarcinoma, Follicular / pathology. Adenocarcinoma, Mucinous / diagnosis. Adenocarcinoma, Mucinous / pathology. Adenoma / diagnosis. Adenoma / pathology. Adolescent. Adult. Biopsy, Fine-Needle. Carcinoma, Papillary / diagnosis. Carcinoma, Papillary / pathology. Child. Choline / analysis. Cysts / diagnosis. Cysts / pathology. Female. Humans. Male. Middle Aged. Sensitivity and Specificity. Thyroid Diseases / diagnosis. Thyroid Diseases / pathology. Thyroiditis, Autoimmune / diagnosis. Thyroiditis, Autoimmune / pathology

  • MedlinePlus Health Information. consumer health - Thyroid Cancer.
  • Hazardous Substances Data Bank. CHOLINE CHLORIDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17462842.001).
  • [ISSN] 0720-048X
  • [Journal-full-title] European journal of radiology
  • [ISO-abbreviation] Eur J Radiol
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] Ireland
  • [Chemical-registry-number] N91BDP6H0X / Choline
  •  go-up   go-down


96. Young J, Jass JR: The case for a genetic predisposition to serrated neoplasia in the colorectum: hypothesis and review of the literature. Cancer Epidemiol Biomarkers Prev; 2006 Oct;15(10):1778-84
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • In recent years, an alternative pathway of colorectal cancer development has been described in which serrated polyps replace the traditional adenoma as the precursor lesion.
  • Importantly, serrated polyps and a subset of colorectal cancer show largely nonoverlapping mutation profiles to those found in adenomas and the majority of colorectal cancer.
  • The two most well-characterized syndromes, familial adenomatous polyposis and hereditary nonpolyposis colorectal cancer (Lynch syndrome), both develop via the adenoma-carcinoma pathway and together account for approximately one third of familial colorectal cancer.

  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17035382.001).
  • [ISSN] 1055-9965
  • [Journal-full-title] Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology
  • [ISO-abbreviation] Cancer Epidemiol. Biomarkers Prev.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / U01 CA097735; United States / PHS HHS / / U-01-74778
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Review
  • [Publication-country] United States
  • [Chemical-registry-number] EC 2.7.11.1 / BRAF protein, human; EC 2.7.11.1 / Proto-Oncogene Proteins B-raf
  • [Number-of-references] 93
  •  go-up   go-down


97. Kinoshita H, Yanagisawa A, Watanabe T, Nagawa H, Oya M, Kato Y, Muto T: Increase in the frequency of K-ras codon 12 point mutation in colorectal carcinoma in elderly males in Japan: the 1990s compared with the 1960s. Cancer Sci; 2005 Apr;96(4):218-20
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • In order to determine whether adenoma-carcinoma sequence (ACS) or de novo cancer development, generally considered to be two separate genetic pathways, might be responsible, K-ras codon 12 mutations, good markers for ACS, were examined in 59 and 84 cases of advanced colorectal cancer surgically resected in Cancer Institute Hospital of the Japanese Foundation for Cancer Research in 1960-1969 and in 1990-1999, respectively.
  • [MeSH-major] Adenocarcinoma / genetics. Colorectal Neoplasms / genetics. DNA, Neoplasm / genetics. Genes, ras / genetics. Point Mutation / genetics

  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15819719.001).
  • [ISSN] 1347-9032
  • [Journal-full-title] Cancer science
  • [ISO-abbreviation] Cancer Sci.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Codon; 0 / DNA, Neoplasm
  •  go-up   go-down


98. Wang W, Ozolek JA, Rohde GK: Detection and classification of thyroid follicular lesions based on nuclear structure from histopathology images. Cytometry A; 2010 May;77(5):485-94
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We describe a computerized method to detect and classify follicular adenoma of the thyroid, follicular carcinoma of the thyroid, and normal thyroid based on the nuclear chromatin distribution from digital images of tissue obtained by routine histological methods.
  • We conclude that nuclear structure alone contains enough information to automatically classify the normal thyroid, follicular carcinoma, and follicular adenoma, as long as groups of nuclei (instead of individual ones) are used.
  • We also conclude that the distribution of nuclear size and chromatin concentration (how tightly packed it is) seem to be discriminating features between nuclei of follicular adenoma, follicular carcinoma, and normal thyroid.
  • [MeSH-major] Adenocarcinoma, Follicular / classification. Adenocarcinoma, Follicular / diagnosis. Cell Nucleus / classification. Cell Nucleus / pathology. Diagnostic Imaging / methods. Thyroid Neoplasms / classification. Thyroid Neoplasms / diagnosis

  • MedlinePlus Health Information. consumer health - Diagnostic Imaging.
  • MedlinePlus Health Information. consumer health - Thyroid Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer Invest. 2003;21(6):950-9 [14735698.001]
  • [Cites] Microsc Res Tech. 2003 Aug 1;61(5):457-62 [12845572.001]
  • [Cites] Clin Cancer Res. 2004 Oct 1;10(19):6586-97 [15475448.001]
  • [Cites] J Histochem Cytochem. 1979 Jan;27(1):180-7 [374573.001]
  • [Cites] Cytometry. 1986 Sep;7(5):467-74 [3757694.001]
  • [Cites] Anal Quant Cytol Histol. 1992 Feb;14(1):47-54 [1558615.001]
  • [Cites] Am J Clin Pathol. 1992 Jun;97(6):776-86 [1375804.001]
  • [Cites] Hum Pathol. 1995 Jul;26(7):792-6 [7628853.001]
  • [Cites] Anal Quant Cytol Histol. 1997 Feb;19(1):45-8 [9051185.001]
  • [Cites] J Pathol. 1997 May;182(1):1-8 [9227334.001]
  • [Cites] Anal Cell Pathol. 1997;15(1):1-18 [9373709.001]
  • [Cites] J Surg Oncol. 1998 Aug;68(4):225-30 [9721707.001]
  • [Cites] Obstet Gynecol Surv. 1999 Apr;54(4):253-64 [10198930.001]
  • [Cites] Eur J Endocrinol. 2004 Dec;151(6):779-86 [15588246.001]
  • [Cites] Cytometry B Clin Cytom. 2005 May;65(1):22-8 [15779051.001]
  • [Cites] Biomed Eng Online. 2005;4:31 [15888205.001]
  • [Cites] Biomed Mater Eng. 2006;16(2):119-28 [16477120.001]
  • [Cites] IEEE Trans Image Process. 2006 Aug;15(8):2259-68 [16900681.001]
  • [Cites] IEEE Trans Inf Technol Biomed. 2006 Oct;10(4):782-93 [17044412.001]
  • [Cites] J Digit Imaging. 2007 Sep;20(3):248-55 [17122993.001]
  • [Cites] Oncol Rep. 2008 Feb;19(2):329-37 [18202778.001]
  • [Cites] Cytometry A. 2008 Apr;73(4):341-50 [18163487.001]
  • [Cites] Mod Pathol. 2008 May;21 Suppl 2:S37-43 [18437172.001]
  • [Cites] Expert Rev Mol Diagn. 2008 Nov;8(6):707-25 [18999923.001]
  • [Cites] Comput Med Imaging Graph. 2009 Mar;33(2):91-9 [19111442.001]
  • [Cites] Anal Quant Cytol Histol. 2008 Dec;30(6):323-35 [19160697.001]
  • [Cites] Histopathology. 2009 Feb;54(3):328-36 [19236509.001]
  • [Cites] IEEE Trans Inf Technol Biomed. 2009 May;13(3):291-9 [19171530.001]
  • [Cites] IEEE Trans Med Imaging. 2009 Jul;28(7):1037-50 [19164082.001]
  • [Cites] IEEE Trans Inf Technol Biomed. 2009 Jul;13(4):636-44 [19369162.001]
  • [Cites] Med Image Comput Comput Assist Interv. 2008;11(Pt 2):1083-91 [18982712.001]
  • [Cites] BMC Bioinformatics. 2004 Jun 18;5:78 [15207009.001]
  • [Cites] Pathol Oncol Res. 2001;7(1):46-55 [11349221.001]
  • [Cites] Thyroid. 2001 Oct;11(10):941-6 [11716041.001]
  • [Cites] Bioinformatics. 2001 Dec;17(12):1213-23 [11751230.001]
  • [Cites] Endocr Pathol. 2001 Winter;12(4):417-22 [11914475.001]
  • [Cites] IEEE Trans Inf Technol Biomed. 2002 Mar;6(1):54-8 [11936597.001]
  • [Cites] Cytometry. 2002 Nov 1;49(3):91-5 [12442308.001]
  • [Cites] Int J Med Inform. 2003 Jan;69(1):17-28 [12485701.001]
  • [Cites] Anal Cell Pathol. 2003;25(1):1-36 [12590175.001]
  • [Cites] Clin Cancer Res. 2003 May;9(5):1792-800 [12738736.001]
  • [CommentIn] Cytometry A. 2010 Dec;77(12):1101-2 [20972968.001]
  • (PMID = 20099247.001).
  • [ISSN] 1552-4930
  • [Journal-full-title] Cytometry. Part A : the journal of the International Society for Analytical Cytology
  • [ISO-abbreviation] Cytometry A
  • [Language] eng
  • [Grant] United States / NIGMS NIH HHS / GM / R21 GM088816; United States / NIGMS NIH HHS / GM / R21 GM088816-02
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Other-IDs] NLM/ NIHMS203309; NLM/ PMC3010854
  •  go-up   go-down


99. Mittendorf EA, Khiyami A, McHenry CR: When fine-needle aspiration biopsy cannot exclude papillary thyroid cancer: a therapeutic dilemma. Arch Surg; 2006 Oct;141(10):961-6; discussion 966
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [MeSH-major] Adenocarcinoma / pathology. Adenoma / pathology. Biopsy, Fine-Needle. Thyroid Neoplasms / pathology


100. Sakorafas GH, Sarr MG, van de Velde CJ, Peros G: Intraductal papillary mucinous neoplasms of the pancreas: a surgical perspective. Surg Oncol; 2005 Dec;14(4):155-78
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • IPMNs show a wide spectrum of histologic changes, ranging from adenoma to invasive neoplasm, even within the same neoplasm, suggesting a "field defect" predisposing major segments or even the entire ductal epithelium to the development of IPMN.
  • The extent and type of pancreatectomy remain somewhat controversial but should be based on morphologic changes of the pancreas.
  • However, invasive IPMNs behave quite similar to ductal adenocarcinoma of the pancreas when analyzed stage-by-stage, with a slightly better prognosis; however, even after an R0 resection, recurrence is common.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16517154.001).
  • [ISSN] 0960-7404
  • [Journal-full-title] Surgical oncology
  • [ISO-abbreviation] Surg Oncol
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Netherlands
  • [Number-of-references] 177
  •  go-up   go-down






Advertisement